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The nature and prevalence of hepatitis B, C, D and GB virus infection was 
investigated in 301 "healthy" (control) subjects (including 76 blood donors), 16 patients 
with chronic liver disease (CLD) and 36 patients undergoing haernodialysis (HD) for 
chronic renal failure, from three areas in Libya. Overall, 112 (37.2%) control subjects 
were found to have serological markers of hepatitis B (IIBV) or C (HCV) virus exposure, 
with 35 seropositive for UBsAg and 15 for HCV-RNA by polyrnerase chain reaction 
(PCR). Four HBsAg-positive subjects (including three blood donors) had active viral 
replication (HBV-DNA positive). 32 (88.9%) HD patients had evidence of HBV and/or 
HCV exposure, with 18 having current infections. Ten CLD patients had current infection 
with HCV and four with HBV. Results were correlated with demographic, clinical, and 
serum biochemical parameters and with histologically assessed severity of liver disease. 
Genotyping of HCV in Libyan subjects, by restriction fragment length 
polymorphism, type-specific priming, nucleotide sequencing (of the 5-untTanslated, core 
and NS5 regions of the HCV genome) and phylogenetic analysis, was compared with 
genotypes in 106 patients with chronic hepatitis C from other parts of the world typed 
concurrently. Genotype 4 (with up to six distinct subtypes: a-0 was identified in 84% of 
the HCV-infected Libyans. GB virus infiýction was detected (by PCR using primers 
derived from the GBV-C genome) only in four (all HD patients), compared with 
36 (33.9%) of the non-Libyans (in whom GBV infection correlated strongly with 
intravenous drug use). Overall, the findings indicate: (1) a high background prevalence 
of HBV and HCV infection in Libya (due at least partly to inadequate screening of blood 
donors) but very low prevalence of hepatitis D and GB viruses; (2) HCV genotype 4 
predominates in Libya. Additionally, it is believed for the first time, HCV genotype 5 
was identified in West Africa and the Caribbean. 
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1.1 OiRomc IIVM MSEASE IN DBYA 
Until records of hospital admissions began to become available in 1959, very little was 
kno-%Am about the incidence or causes of liver disease in Libya. Malaria, Entmoeba 
histolytica, and roundworm infections were knoNNu to be prevalent and echinococcosis (hydatid 
disease) was recognized to be endemic and enzootic. Indeed, Casoni [ 1911 ] conducted the 
work leading to development of 1-ýs well knoxAn skin test for Echinococcus in Tripoli, mhile 
Cicogna [1961] recorded that animals in Libya are much infected vvith Echinococcus, Vdth up 
to 60% of dogs, 40% of sheep, 70% of cattle and 20% of pigs examined being found to be 
infected. During 1951-1961,57 patients were documented as having been treated for hepatic 
hydatid disease in the govenunent hospital in Tripoli (Elhamel and Murthy, 1986; Aboundaya, 
1986; Kalani et al. 1984), wbile Dar and Taguri, (1978) reported 180 surgical cases seen in 
Benghazi between 1971-1976. Nonetheless, there is still a paucity of reliable epidemiological 
data. 
Schistosomiasis is also endemic, mainly in southern Libya (Sebha-Fezzan) where, for 
example, a prevalence of 86% has been recorded in the Wadi el Shati (Gebreel et al. 1985). 
Foci of infection also exist in the northern coastal region (Tripolitanio), principally in Tauroga 
(50 km south of Misurata), and in the eastern coastal region (Cyrenaica) mainly in the environs 
of Derna. The schistosome species involved are S. haemcdobium, which is predominant, and 
S. mansoni. 
Although the majority of patients chronically infected vvith S. mansoni or 
S haematobium do not have clinically significant liver disease, about 10% develop 
hepatosplenic schistosomiasis and a proportion of these progress to severe, decompensated 
chronic liver disease (Gilles, 1982; Prata, 1982). The resulting morbidity and mortality has 
major social and economic implications for a country such as Libya Mere such a sizeable 
population are infected with this parasite (Baccush et al. 1993). The variability in outcome of 
the infection has never been satisfactorily explained, but it is not unreasonable to presume that 
factors other than the parasite itself may be involved and that the simultaneous presence of two 
or more agents capable of damaging the liver are likely to lead to greater severity of tissue 
injury. Excessive alcohol consumption is the most obvious candidate but there has been no 
evidence that this accounts for the majority of cases of severe hepatosplenic schistoson-fiasis 
16 
and is highly unlikely in a strict Islamic country such as Libya. Given that viral hepatitis is 
endemic in North Africa, superimposed hepatitis viral infections are more likely to be involved. 
Indeed, studies in Egypt had suggested a correlation between infection with the hepatitis B 
virus and the development of severe hepatic schistosomiasis (Bassily et al. 1983), and recently 
completed studies in the Institute of Liver Studies at Kings College Hospital, London, have 
since shown that almost all such patients in Brazil have chronic hepatitis B or C virus 
infections (Pereira et al. 1994; Pereira et al. 1995) 
In Libya, there has been a steady increase in reported cases of presumed viral hepatitis 
since records began in 1959. However, since 1989, folloving strengthening of the regulations 
relating to notification of viral hepatitis, there has been a dramatic increase in the number of 
cases reported (Fig. 1.1), to the point NNfiere a total of 8562 were notified in 1993, i. e. an 
incidence of about 1: 1000 of the total population and about 1: 500 of urban dwellers ( Secretary 
of Health in Libya, 1993). Details of the ages and sexes of infected individuals are not 
available. 
In 1976, when Christie et al (1976) reported on a severe outbreak of viral hepatitis 
among pregnant women , some information on the nature of the infecting agent(s) began to 
become available. In that study, it had been possible to test only for hepatitis B virus (HBV) 
and, although some cases of UBV infection were identified, this virus could not be implicated 
in the high mortality rate (13%) associated with the epidemic. A similar outbreak in 1970, 
also in Tripoli (reported retrospectively by Wyatt ( 1977), documented a mortality rate of 26% 
but failed to identify the causative agent. In 1983, Gebreel and Christie (1983) reported that 
only 26.2% of Libyan patients with clinically diagnosed chronic viral hepatitis had IIBV, and 
presumed that the remaining 73.8% had non-A, non-B viral infections. This impression was 









1979 1981 1983 1985 1987 1989 1991 1993 
Years 
Figum 1.1 Incidence of notified cases of viral hepatitis in ]Libya. 
Adcptedfrom Libym Secretcay of Hea(th Repoil [1959-1993]. 
Against this background, the present study was originally designed to investigate 
NNhether concomitant chronic infections '"ith the hepatitis B or C viruses might be related to 
the development of severe hepatosplenic schistosomiasis in Libya. As controls for the study, 
sera were collected from a large number of apparently healthy individuals and other subjects 
lAithout evidence of schistosomiasis. This had onlyjust been completedAhen, unfortunately, 
the United Nations imposed sanctions against Libya. Direct travel between Libya and the 
United Kingdom was prohibited and the collection and transportation of ftu-ther frozen samples 
to the U. K. became impracticable. However, as there were no definitive data on the prevalence 
of hepatitis viruses in Libya, it was decided to use the material collected to study hepatitis B, 
D and, particularly, hepatitis C virus infections in this group of subjects representing a cross- 
section of the Libyan population at large. 
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1.2 VRIAL HEPATTM 
That hepatitis can be caused by an infectious agent has been recognized since antiquity 
and, in early times, was known as "epiden-fic jaundice". The oldest viitten record of epidemic 
jaundice is believed to have been made by Flippocrates in the fifth century BC. A description 
ofjaundice has also been found in the ancient Chinese literature around the year 200 AD, and 
NNhat are thought to be references to jaundice have been noted in Egyptian and Indian 
Ayurvedic texts and in the Babylonian Tahnud. In the eighteenth century attempts were 
made to explain jaundice on the basis of common bile duct obstruction and this became 
regarded as the principal cause. This concept proved to be an impediment that hampered 
understanding of the basic pathology underlying the development ofjaundice. Itwasnotuntil 
the late nineteenth century that the concept of jaundice resulting from a generalized infection 
of the liver parenchyma via the blood stream was suggested. It was also recognized at this 
time that j aundice (hepatitis) could occur in both sporadic and epiden-fic form and that it could 
be closely associated with acute and subacute necrosis of the liver (reviewed by Zuckerman, 
1983b). 
Understanding of viral hepatitis received considerable impetus from observations made 
during and immediately after World War 11 in military personnel contracting hepatitic illnesses. 
Clinical observations established that there were probably at least two agents capable of 
causing hepatitis: (1) a short incubation form, hepatitis A, which was variously described as 
infectious hepatitis, campaign jaundice, jaut-iisse de champs, or soldatengelbsucht, which 
appeared to be transmitted by the faccal-oral route and which was responsible for epidemics 
of hepatitis, and (2) a longer incubation form, hepatitis B (also termed serw-n hepatitis or 
homologous serwn j aundice) that appeared to be blood-borne [for review see Krugman. et al. 
(1979)]. The identification of filtrable agents capable of transmitting hepatitis to human 
volunteers established that these fon-ns of hepatitis indeed had a viral aetiology [reviewed by 
Zucken-nan, 1983a) 
The first clues as to the nature of the hepatitis B virus came serendipitously from 
studies by Blumberg and colleagues in the U. S. A. 'Aho were investigating genetic differences 
in circulating low density serum lipoproteins using, as reagents, sera from multiply transfused 
haemophiliacs "ho had developed antibodies to lipoproteins (Blumberg et al. 1962). They 
19 
noted that a serum sample from an Australian aborigine gave a precipitin reaction by 
Ouchterlony immunodiffusion -Aith sera from two haemophiliacs. This did not appear to be 
due to reaction of a lipoprotein NNith its corresponding antibody because the precipitin line 
stained strongly for protein but only weakly for lipid (Blumberg et al. 1965). The antigen in 
this precipitin line was designated "Australia antigen" and was later sho"n to be a protein 
associated výith the hepatitis B virus (Blumberg et al. 1970) 
Following the identification of the hepatitis A virus (HAV) a few years later (Feinstone 
et al. 1973), and with the availability of serological tests for infections with HAV and the 
hepatitis B virus (IIBV), it became clear that there was at least one other major virus capable 
of causing hepatitis. This gave rise to the concept of "non-A, non-B" (NANB) viral hepatitis, 
although the term'NANB hepatitis" was sometimes used during the late 1970s and early 1980s 
as a catch-all category for what was also described as "idiopathic" or "cryptogenic" liver 
disease, often including patients with autoinimune ("lupoid") hepatitis (McFarlane and 
Williams, 1996). 
In 1977 a new viral antigen was identified in the nuclei of hepatocytes of patients 
infected with IJBV (Rizzetto et al. 1977). Subsequent studies revealed that this antigen was 
related to a new virus, later ten-ned hepatitis delta virus (HDV), but it was soon apparent that 
this was not the cause of NANB hepatitis (NANBfý because HDV was always associated with 
I]BV infection (Rizzetto, 1983). It was not until 1989 that Cboo and colleagues at the Chiron 
Corporation in California, in collaboration with Bradley and colleagues at the Center for 
Disease Control in Atlanta, Georgia, identified the hepatitis C virus (HCV) as the major cause 
of blood-borne NANB viral hepatitis (see below). Since then, a number of other hepatitis 
viruses have been identified. One of these, the water-borne hepatitis E virus (HEV), has been 
responsible for large epidemics of hepatitis in India and the Kirghiz republic and for outbreaks 
in Nepal and South East Asia, including Burma, affecting mainly young and middle age adults 
and with a very high mortality (20-39%) in infected pregnant women(Kane et al. 1984). 
Outbreaks of HEV and sporadic infections have also been reported in North Africa, eastern 
Sudan, Somalia, the Ivory Coast, and Mexico, as well as in travellers returning from these 
areas (Centres for Disease Control, 1987a; Centres for Disease Control, 1987b). It has also 
been suggested that there may be a hepatitis F virus, causing sporadic ftilminant hepatic 
failure(Fagan and Williams, 1990), and evidence is accumulating about a hepatitis G virus 
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(designated GB) which seems to be a major cause of "non-A-E" hepatitis (Zuckerman, 1995). 
Nonetheless, epiden-fiologically HAV, HBV and HCV remain the three most important 
hepatitis viruses. From the clinical and socio-economic standpoint, the major difference 
between these three viruses is that chronic infections with HAV are rarely (if ever) seen 
whereas both I1BV and HCV lead to chronic infection in a variable proportion of cases (see 
below). It is estimated that these two viruses each account for some 300 million individuals 
with chronic hepatitis viral infections worldwide (WEO, 1992). There is also increasing 
evidence that I]BV and HCV may have oncogenic potential and may be strongly associated 
with the development of hepatocellular carcinoma, the highest incidence of which is in the 
developing countries where these viruses are endemic (Maupas et al. 1977; Coursaget et al. 
1992; Coursaget et al. 1990b; Goudeau et al. 1979; Kew, 1994; Kew et al. 1990; Bukh et al. 
1993a) 
1.2.1 Clinical featums of viral hepatitis 
The clinical features of acute hepatitis due to infection with the various hepatitis viruses 
are similar in many respects, but are variable and cannot be used to distinguish between the 
different types of viral hepatitis. Following an incubation period of anything from a few days 
to several months, there is a pre-icteric phase lasting for 2-14 days. The initial symptoms are 
usually malaise (variously reported as lethargy or easy fatigueability) and anorexia, followed 
shortly by nausea, vomiting, and abdominal discomfort (often with right upper quadrant pain). 
These symptoms are relatively non-specific and a definitive diagnosis is seldom made during 
this period. Documenting the incubation period is rarely helpful because, although on average 
this is 25 days for HAV and 75 days for UBV and is intermediate (50 days) for NANBH 
(Krugman and Gocke, 1978; Zucken-nan, 1986), much shorter (4 days to 2 weeks) (Craske et 
al. 1975) or longer (up to 33 weeks) (Zucken-nan, 1988) incubations have been reported for 
NANBH. 
About 10-15% of persons with acute viral hepatitis develop a serurn sickness-like 
syndrome during the late incubation period or pre-icteric phase. This is characterized by one, 
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two or all three symptoms of a triad comprising a rash (usually urticarial), low grade fever, and 
polyarthralgia or arthritis. These symptoms are usually short lived and disappear with the 
onset of the icteric phase. The latter begins vvith the appearance of dark urine (and often pale 
stools) and deepening jaundice. These classical symptoms of acute viral hepatitis occur v6th 
similar frequency in all types of hepatitis (Dienstag and Purcell, 1977; Zuckerman, 1988). 
The convalescent period following acute viral hepatitis starts with clearance ofjaundice 
and cessation of the major symptoms, but weakness and easy fatigueability can last for some 
time after apparent recovery. The speed of recovery from an acute illness does not differ 
between the various fon-ns of viral hepatitis (Norkrans, 1978), but can depend on whether the 
patient develops fuhninant hepatitis or chronic infection ensues. About 1% of patients with 
acute HAV or HBV infections develop fialminant hepatic failure, which is associated with a 
high mortality. Fulminant hepatitis due to HCV has been reported in Japan(Muto et al. 1990) 
and Taiwan (Chu et al. 1994), but in other countries it seems to be very rare (Wright et al. 
1991; Sallie et al. 1994). Chronic sequelae to acute HBV and HCV hepatitis occur with 
variable frequency (see below) but chronic HAV infection seems not to occur, although 
protracted or recurrent illnesses have been reported (Dusheiko and Zuckerman, 1994). 
However, it is clear from epiden-fiological studies based on serological markers of 
these infections that very many patients have an anicteric illness which often goes unnoticed. 
This is particularly true of hepatitis C (see below) - the large majority of HCV-infected 
individuals being unable to recall having had a hepatitic illness (Cordoba et al. 1994). This 
may be because, for reasons as yet unknown, HCV infections tend to have a n-filder and 
generally more fluctuating course than acute or chronic infections with the other hepatitis 
viruses (Cordoba et al. 1994). Furthen-nore, the evolution of chronic HCV infection seems to 
be very slow and may often become apparent only incidentally through the fmding of abnormal 
biochemical liver tests during routine health screening (Alter et al. 1989). 
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1.3 DIE HEPATTnS B AND D VIRUSES 
1.3.1 Biology of the hepatitis B vinis 
The hepatitis B virus (HBV) is a double-shelled DNA virus. The complete infectious 
virion is a 42 nm particle that was first identified by Dane and co-workers (Dane et al. 1970) 
and became known as the Dane particle. In 1980, Marion and colleagues described an HBV- 
like virus in Beechy ground squirrels (Spennophilus beecheyi) and proposed the type 
designation Hepadnaviridae (Marion et al. 1980). HBV is the prototype member of this new 
family which now includes several other, non-human, DNA viruses with similar features but 
distinct host specificities (Siddiqui et al. 198 1). These include the Woodchuck hepatitis virus 
(WHV) (Summers et al. 1978) isolated from the eastem Woodchuck (Mcmota monac), the 
ground squirrel hepatitis virus (GSHV) (Marion et al. 1980) that infects Beechy ground 
squirrels, duck hepatitis virus (DHV) (Mason et al. 1980) isolated from Pekin ducks (A nas 
domesticus), tree squirrel hepatitis virus (TSHV) (Feitelson et al. 1986) and a heron hepatitis 
virus (HHV) that has been isolated from grey herons (A rdea cinerea) (Sprengel et al. 1988). 
Other candidate members of the group include kangaroo hepatitis virus (KHV) and stink snake 
hepatitis virus (SSHV) (Bukhari and Tsiquaye, 1990). 
Man is the principal host for HBV but it seems that the virus can infect some other 
higher primates such as chimpanzees, gibbons, orangutans 
(Vaudin 
et al. 1988). The various other mammalian and avian hepatitis viruses each have similarly 
narrow host ranges, but are useful models for the study of HBV. Although marked liver 
tropism is a feature of all hepadnaviruses, HBV is harboured (and replicates) at numerous 
extrahepatic sites, including bone marrow, peripheral blood mononuclear cells, lymph nodes, 
spleen, kidney, colon, and even the skin and testes (Korba et al. 1986; Lieberman et al. 1987; 
Mason et al. 1993). But a very recent report suggests that the tinding of IIBV-DNA in 
peripheral blood mononuclear cells may be explained by adsorption of the virus on the surfaces 
of the cells (Kock et al. 1996). 
During the early studies of Australia antigen a second antigenic specificity, ten-ned Au2, 
was identified with an antiserum produced in rabbits immunized with serum from a patient 
with leukaetnicreticulo-endotheliosis (Le Bouvier, 1971). Shortly afterwards, Le Bouvier and 
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colleagues described a group-specific antigenic specificity which was designated "d', and two 
mutually exclusive determinants, "d' and "y" - all isolates of the virus being either "ad' or "ay" 
(Le Bouvier et al. 1972). This was followed by identification of two additional specificities, 
"w" and "r" by Bancroft et al [1972]. These antigenic subtypes did not appear to have 
relevance of the virulence of the virus but were found to be useful epidemiological markers 
that seemed to correlate with severity of liver disease in different geographical areas (Tiollais 
et al. 1981). 
Extensive studies over the past 25 years have since established the structure and 
genomic organization of I-EBV. The 42 nm particle is composed of an outer protein shell (the 
envelope) surrounding an inner protein shell (the core or capsid) which comprises a core 
protein and an associated HBV-specific DNA polymerase and encloses the viral DNA. The 
latter is a small, partially double-stranded circular DNA of between 3.2 and 3.3 kilobases (kb) 
and an estimated molecular weight of 1.6 x 106 to 2.0 x 10' (Howard, 1986; Ganern and 
Varmus, 1987). The genome consists of a long (L) strand of negative polarity and a short (S) 
strand of positive polarity. Most authorities describe the genornic organization by reference 
to a cleavage site for the restriction enzyme EcoRI (Gerlich, 1993). The L strand is complete 
apart from a nick of one or a few nucleotides at a fixed position about 1800 nucleotides from 
the EcoRI site while the S strand is incomplete (lacking 15-50% of the nucleotides), thereby 
producing a characteristic gap in the genome. The 5' end of the positive strand is located at 
a fixed point approximately 1560 nucleotides from the ECoR1 site (Siddiqui et al. 1979). The 
fixed 5' ends of the two strands overlap by about 250 to 300 base pairs and comprise the so- 
called cohesive end region(Sattler and Robinson, 1979) which maintains the circular shape of 
the genome and prevents the two strands falling apart. The 1HBV genome is remarkably 
compact (Fig. 1.2). There are six overlapping open reading frames (ORFs), four of which are 
known to code for viral polypeptides: S (surface), C (nucleocapsid or core), P (polymerase) 
and X The S ORF codes for three envelope polypeptides, designated "large" (LITBs), 
"medium" (NMs) and "small" (SHBs) according to length (Heermann et al. 1984). The SUBs 
is the most abundant and contains the group "d' and subtype "dly" and "wh, " determinants. 
It is now known that the subtypes arise through single amino acid substitutions in the 
polypeptides (Heermann et al. 1984; Ohnuma et al. 1993). However, these subtypes may occur 
in different strains of HBV, at least six genotypes (A-F) of which have been identified 
(Heen-nann et al. 1984; Norder et al. 1992). 
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Figure 1.2 Schematic organization of the hepatitis B virus genome. 
The MHBs comprises the SHBs with a 55 amino acid N-terminal extension 
containing the pre-S2 region. The importance of the pre-S2 region relates to its capability 
for binding aggregated serum proteins, notably polyaggregated human serum albumin 
(pHSA). It was suggested that., through binding to pHSA receptors on liver cells, this 
might provide a means for HBV to enter hepatocytes (Neurath et al. 1986) but this seems 
unlikely because pHSA is never found circulating in human subjects (Yu et al. 1985). 
Two other possible mechanisms of attachment of HBV to hepatocytes involving the pre-S2 
region have been proposed. Since the SHBs is glycosylated (Heermann & Gerlich, 1991), 
binding via glycan receptors on liver cells might occur. Alternatively, binding may be via 
the amino-terminal portion of pre-S2 to transferrin receptors (Franco et al. 1992). 
However, there is still insufficient concrete evidence to support any of these mechanisms 
as an explanation for the hepatotropism of HBV (Gerlich, 1993). 
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The LI-Ms comprises the complete polypeptide encoded by the S ORF, including the 
pre-SI domain. There is some evidence that pre-SI may be involved in anchoring to cell 
membranes (Persing et al. 1987) and that pre-SI sequences are involved in the binding of 
virions, to the IgA receptor on the surfaces of hepatocytes, which may be the initial step in the 
infectious cycle (Neurath and Strick, 1990; Pontisso et al. 1992). Pre-S I also exerts important 
structural effects on viral particle formation and secretion, in that overproduction of the LHBs 
relative to MHBs and SI]Bs inhibits the secretion of the I]BV surface antigen (HBsAg) 
(Standring et al. 1986; Ou and Rutter, 1987), accumulation of which in hepatocytes probably 
accounts for the characteristic "ground glass" appearance of the cells in liver sections stained 
with haematoxylin and eosin. This accumulation of HBsAg is considered typical of chronic 
hepatitis B, and there is evidence from studies both in humans and in transgenic mouse 
lineages that it may eventually lead to hepatocellular necrosis (Chisari et al. 1987; Chisari, 
1989; Dunsford et al. 1990). 
In cornmon with all hepadnaviruses, viraemia in HBV infections is associated with the 
copious production of incomplete viral particles consisting mainly of the virus coat protein 
(HBsAg), which are shed into the bloodstream. Morphologically these are of two principal 
types: small spheres of about 17-25 ntA which are the most abundant, and tubular or 
filamentous structures of about 20 nm diameter which vary in length. The available evidence 
suggests that the morphology of these particles is determined by the relative proportions of 
SI]Bs, MHBs and LFMs they contain (Marquardt et al. 1987). 
The C ORF encodes two polypeptides (core and pre-core) that are identical except for 
29 amino acids at the N-terminal end of the longer pre-core polypeptide(N4iller et al. 1989). 
The core polypeptide is a nucleic acid binding component which encapsulates the viral nucleic 
acid [(Petit and Pillot, 1985). The pre-core polypeptide is not required for viral replication but 
its proteolytic cleavage products, so-called "e" antigen (Iffle), are secreted into the blood and 
their presence is usually indicative of active viral replication (Standring et al. 1988). The 
ftmction of HBe is unclear but it may act to confuse or suppress host immune responses to 
HBV infected cells. Seroconversion with development of anti-HBe antibodies (see below) and 
disappearance of HBe is usually associated with cessation of active viral replication. 
However, the importance of pre-core in the transport and formation of serw-n HBe has been 
ernphasised by the fmding of an HBV mutant occurring in patients with anti-HBe antibodies 
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who are also seropositive for ITBV-DNA (indicating ongoing viral replication) and have severe 
active liver disease(Carman et al. 1992; Brunetto et al. 1991; Brunetto et al. 1990). This 
mutant has been characterised as having a single point mutation in the pre-core region which 
generates a translational stop codon. As a consequence, HBe production is abrogated and this 
explains the persistence of serum fMV-DNA in the presence of anti-HBe(Akahane et al. 1990; 
Tong et al. 1990). 
The P ORF overlaps all of the other ORFs. The full ftmctions of all of the products 
encoded by the P ORF are not yet known but include the viral polymerase/reverse transcriptase 
activity and primase activity with potential for generatin minus strand synthesis(Mack et al. 9 
1988; Schlicht, 1991). The X ORF comprises a short gene that partially overlaps the core 
gene and codes for a protein of 154 amino acid residues, the in vivo ftmction of which is still 
obscure but which seems to exhibit gene transactivator properties and turnourigenic activity 
(Gerlich, 1993). Evidence that HBxAg with trans-activating properties can be made from a 
viral template integrated into the host genome during chronic infection (Wollersheirn et al. 
1988) supports the hypothesis that HBxAg may play an important role in the pathogenesis of 
chronic infection (Wang et al. 1991). 
By analogy with other hepachiaviruses, it is thought that the HBV genome contains two 
other ORFs: ORF5 and ORF6 (Wang et al. 1991; Miller, 1988; Kaneko and Miller, 1988). 
ORF5 ranges from 70- 100 codons in size and overlaps the P and X ORFs. It is uncertain how 
the gene sequence of ORF5 is translated because it lacks a standard in-phase AUG intiation 
codon. However, its 5' end contains an AUG codon which is believed to initiate protein 
synthesis in a gene of the adenovirus-associated virus (Anderson and Buzash Pollert, 1985). 
Alternatively, it is possible that the ORF5 product might be expressed as a fusion polypeptide 
through ribosornal frame-shifting during translation of the X and/or P ORFs, or that the viral 
mRNA is spliced and an initiation codon is fused in-phase to the 5' end of ORF5. ORF6 is 
believed to be located on the viral plus strand and therefore cannot be expressed from any of 
the knoNNn viral transcripts but may be translated from an antisense mRNA. It may encode a 
2 10 amino acid polypeptide that overlaps the P, Y1, pre-core and ORF5 gene sequences of the 
complementary rninus strand. An in-phase AUG codon is present near the start of the ORF6. 
The status of ORF6 is still hypothetical but it is possible that it may be involved in 
bidirectional transcription of the HBV genome. Bidirectional transcription is a rare event but 
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is known to occur in viruses such as adenovirus, simian virus 40 and herpes virus, and the 
I inf anti-sense or latency-associated transcript is known to be present on y in latently ected 
neurons(Anderson and Buzash Pollert, 1985; Puga and Notkins, 1987; Rock et al. 1987; 
Wagner et al. 1988; Stevens et al. 1987; Spivack and Fraser, 1987). Thus it is possible that 
a latency-associated anti-sense transcript exists during a specific point of HBV replication 
which is translated into the ORF6 gene product, the role of which in the virus' life cycle 
remains obscure. 
Replication begins with conversion of the partially double-stranded HBV-DNA to a 
fully double-stranded circle by HBV-DNA polymerase in the hepatocyte nucleus (Fig. 1.3). 
The L (-) strand is transcribed by host cellular RNA polymerase to give multiple copies of a 
pre-genornic 3.5 kb RNA, which are then transported to the cytoplasm. Here, the core protein 
is made and this encapsulates the pre-genomic RNA together with newly synthesised IIBV- 
DNA polymerase and DNA-linked protein. A new L (-) strand is then synthesised by reverse 
transcription of the pre-genomic RNA, during which the latter is degraded except for a small 
fragment which is thought to provide a primer for the synthesis of a new S (+) strand from the 
newly formed L (-) strand template. The progeny particles are thought to acquire HBsAg- 
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Figum 1.3 Diagrxwuatic mpmsentation of events occuning duting mplication of 
hepatitis B viim in hepatocytes. (1) The virus penetrates the 
hepatocyte, via a specific receptor on the cell membrane which 
recognises a peptide encoded by pre-SI, and uncoats. (2) In the 
nucleus, the partially double-stranded H3V-DNA is converted by DNA 
polymerase into a fully double-stranded circle. (3) L(-) strand is 
transcribed by host cellular RNA polymerase to provide multiple copies 
of a 3.5 kb RNA (pre-genome). (4) The RNAs are transported to the 
cytoplasm where the core protein is made and encapsulates the pre- 
genome RNA and the newly synthesised DNA polymerase and 
DNA-linked protein. (5) L(-) strand is synthesised by reverse 
transcription of the pre-genome, which is concomitantly degraded 
except for a small fragment probably used to prime the synthesis of the 
S(+) strand from the newly-made L(-) strand template. (6) The 
progeny particles obtain HBsAg-containing envelopes, probably by 
budding from the cell's plasma membrane, and become infectious 
virions. Re-cb-awnfrom Bonino, (1992). 
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One other important feature of the HBV genome is the existence of a glucocorticoid- 
responsive element (GRE). A GRE is a segment of DNA that binds a hon-none receptor, 
promoting an increased level of transcription of a given gene(Tur Kaspa et al. 1988) GRES 
are cis-acting elements that function in both orientations and act at variable distances from the 
genes they regulate. In HBV, a GRE has been mapped to an overlapping region between the 
P and S ORFs (Tur Kaspa et al. 1986). There is evidence to suggest that the HBV GRE may 
be involved in regulation of HBsAg gene expression by sex steroids and glucocorticoids (Farza 
et al. 1987). Thus the role of the GRE in HBV is significant in that it may account for the 
observed differences in the epidemiology and outcome of infection between the sexes (see 
below) and for the enhanced replication of the virus that has been reported in patients treated 
with corticosteroids (Tur Kaspa et al. 1988) 
1.3.2 Biology of the hepatitis D vinis 
The hepatitis delta virus (HDV) is a defective RNA pathogen the replication of which 
is Molly dependent on obligatory helper functions provided by H3V, and is acquired either 
as a supeffi-ifection in an individual already carrying HBV or as a coinfection with the initial 
HBV inoculum (Taylor et al. 1987; Hoofnagle, 1989). HDV has still not been classified but 
it has some resemblance to the plant viriods and satellite viruses (Branch et al. 1990). 
The molecular basis of the biologically intriguing association between HBV and HDV 
is still unclear. When HDV superiffection occurs in a chronic HBV carrier, the FlBe status 
appears not to be a determining factor. Both HBe and anti-HBe positive individuals seem to 
have equal susceptibility for HDV infection and seroconversion from HBe to anti-FlBe and 
diminished HBV replication occur as a result of HDV. On the other hand, replication of both 
viruses, evidenced by high levels of the HDV-specific antigen (HDAg) and HBc in serum and 
hepatocytes has been documented. Such cases are more common in drug addicts and are 
notable for the aggressive nature of the disease, which suggests a compound pathogenic effect 
of the two viruses (Kuo et A 1989; Monjardino and Saldanha, 1990). It is not yet known how 
HDV contributes to the worsening of the underlying HBV hepatitis, nor how it induces acute 
ful-minant hepatitis in a number of cases of co-infection with IIBV(Negro and Rizzetto, 1993). 
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HDV is the smallest knoNNn human virus. 'Ihe complete virion is a 36 nm particle 
containing the viral genorne -a circular, single-stranded RNA 1.7 kb in length and of negative 
polarity (Wang et al. 1986; Nbkino et al. 1987; Saldanha et al. 1987). Although several open 
reading frames have been identified, only one (ORF5) has been demonstrated to encode a 
protein (HDAg). The viral RNA has long regions of complementarity that enables the opposite 
ends to bind to each other, resulting in a rod-like structure(Kos et al. 1986). The genomic 
RNA is copied in a rolling circle to give a chain of repeated antigenomic molecules. Each new 
circle is then used as a template to create many new copies of the original molecules. There 
is no evidence of the involvement of any enzymes in HDV replication. Rather, the cleavage 
and subsequent self-ligation of HDV seems to be a ftmction of the genomic RNA 
itself(Shanneen et al. 1989; Wu and Lai, 1989). 
1.3.3 Epidemiology and outcotne of hepatitis B and D vhus infections 
The hepatitis B and D viruses are both transmitted parenterally. HBV has a worldlAide 
distribution. Overall, the frequencies of chronic infection are highest in the Far East, other 
parts of Asia, and in parts of Africa, intermediate in the Mediterranean area and South 
America, and generally low in northern Europe and North America. In the latter areas, 
however, the carriage rate is high in certain risk groups, particularly among promiscuous 
heterosexuals, homosexuals and intravenous drug users (Yoffe and Noonan, 1992). The large 
majority of chronic carriers of HBV elsewhere in the world have been infected perinatally. 
It is generally thought that only about 5% of adults infected with HBV become chronic 
carriers(McMahon et al. 1985) but a recent follow-up study of more than 55,000 U. S. an-ny 
personnel infected through contaminated yellow fever vaccine in World War H suggests that 
the proportion may be much lower (Norman et al. 1993). However, males infected in 
adulthood are more likely to become carriers than females (Jacyna and Thomas, 1993), 
suggesting that host hormonal factors may have a role to play in presistence of the infection 
(see above, Section 1.3.1). 
HDV also has a worlv*ide distribution but tl-ýs is somewhat irregular and data are 
lacking from some areas. In particular, there are few data available on the prevalence of HDV 
in Affica. A high rate of HDV irdection has been reported from the northern part of South 
31 
America. Studies in Colombia and among the Yucpa Indians in Venezuela, where it has been 
associated'"ith outbreaks of severe hepatitis with a high prevalence of fulminant hepatitis, have 
shown that as many as 60-80% of HBsAg carriers are seropositive for anti-HDV antibodies 
(Jacyna and 'Ihomas, 1993; Buitrago et al. 1986). Similarly high rates have been reported 
from Central Affica, Asiatic Russia, Romania and Kuwait (Tapalaga et al. 1987; Greenfield 
et al. 1986; al Kandari et al. 1988). On the other hand, in some areas where the HBV 
carriage rate is very high, such as in China, Japan, Southern Africa and among the Alaskan 
Eskimos, evidence of exposure to HDV is rarely found(Rizzetto et al. 1991). FEgh rates of 
HDV infection among 11BV carriers have been noted in southem Italy but elsewhere in the 
Mediterranean area lower frequencies of exposure to HDV are found (Rizzetto et al. 1991). 
In northern Europe and North America the frequency in the general population is low but, as 
with HBV, in these areas there are certain groups at particular risk. In contrast to HBV, 
however, the rate of HDV infection among homosexuals is relatively low (< 15%) but 30-75% 
of intravenous drug users and multiply-transftised I]BsAg-positive haemophiliacs have evidence 
of HDV exposure (Rizzetto et al. 1988a; Rizzetto et al. 1980; Solomon et al. 1988; Pol et al. 
1989; Smith et al. 1992). The reasons for this variability in HDV infection are not clear. The 
prevalence of intravenous drug use in different populations is clearly a factor, but sexual 
transmission also occurs(Wu et al. 1995). 
The spectrum of liver disease in subjects chronically infected with HBV varies widely. 
Many carriers will remain "healthy", with normal biochemical liver tests and only minimal 
changes on liver biopsy, while others will have a severe periportal hepatitis with rapid 
progression to cirrhosis (Hoofnagle, 1989; Scheuer and Letkovitch, 1994). Prognosis is 
related to the duration and severity of underlying liver disease but is unpredictable and depends 
also on whether there is concomitant infection with HDV or the hepatitis C virus (see below). 
Most patients with periportal hepatitis and cirrhosis remain relatively stable for many years 
before they decompensate, with development of ascites, jaundice, hepatic encephalopathy or 
variceal bleeding but, as noted above, there is also a risk for development of hepatocellular 
carcinoma (HCC) (Szmuness, 1978; Beasley et al. 1981; Kew and Popper, 1984). Whether 
FIBV has inherent oncogenic potential is still uncertain. In most cases of HCC in chronic 
hepatitis B, the malignancy has developed against a background of long standing infection and 
cirrhosis. But cirrhosis itself is an independent risk factor for HCC (Kew and Popper, 1984; 
Zaman et al. 1985). 
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A recent study of 349 Western European patients lAith chronic hepatitis B and cirrhosis 
has shown that the cumulative probability of decompensation was 23% at 5 years and 37% at 
10 years (Fattovich et al. 1995). Five year survival after the first major decompensation was 
only 35%. Advanced stage and duration of cirrhosis, and thrombocytopenia, were the only 
independent variables for development of HCC. Neither I1BeAgTBV-DNA seropositivity nor 
concomitant HDV infection were prognostic factors. Cumulative probability of developing 
HCC was 6% at 5 years and 15% at 10 years. It was concluded that: (1) patients with well 
compensated HBsAg-positive cirrhosis do not experience worsening of their condition for 
several years, but once decompensation occurs life expectancy is poor, (2) HDV does not 
appear to play a pathogenetic role in development of HCC, and (3) the fmdings support the 
concept that HCC development may be a consequence of long-standing cirrhosis. 
1.3.4 Semlogy and diagnosis of hepatitis B and D vitus infections 
The serological events occurring after exposure to HBV define the status of the infected 
individual. The prototype marker is HBsAg. In uncomplicated acute hepatitis B, I]BsAg may 
be detected in the blood shortly before the first rise in serw-n aminotransferases (Fig. 1.4). The 
latter is usually associated with development of the symptoms and clinical features of hepatitis 
including jaundice but, as noted above (Section 1.2.1), anicteric and even asymptomatic 
infections are not uncommon. At this stage also, the patient will usually be seropositive for 
HBeAg and HBV-DNA and will be highly infectious. IgM class antibodies (IgN4 anti-1113c) 
against the HBV core antigen also begin to appear at this time. Seroconversion from HBeAg 
to anti-I-Me (with disappearance of HBV-DNA) occurs between a few weeks to several months 
after the initial acute phase. This coincides with a reduction in viral replication in the liver and 
resolution of hepatic inflammation, and with the development of a secondary (IgG) antibody 
response to I-Mc, and often also of IgA anti-I]Bc (Nomura et al, 1985). IgM and IgA anti- 
I]Bc, along with anti-IlBe, gradually disappear during the recovery phase, followed by the 
appearance of antibodies (anti-HBs) against HBsAg. The latter also declines in titre over the 
succeeding months and may eventually become undetectable, but IgG anti-HBc usually persists 
for life and, on its o"n, is considered to the be best indicator of past (completely resolved) 
infection. 
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Failure to clear HBsAg within six months defmes a chronic HBV carrier state. Such 
individuals are usually also I-MeAg seropositive. IgG anti-HBc very often appears but 19M 
anti-HBc production continues for a time - at reducing titres (SJogren and Hoofnagle, 1985; 
Hoofhagle et al. 1987; Kiyosawa et al. 1988). Persistence of I]BsAg and HBeAg vvithout 
development of anti-HBe or anti-HBs may last for life but the majority of patients will 
seroconvert to anti-IlBe at some stage (six months to several years after infection), remaining 
seropositive only for HBsAg and anti-HBc. Seroconversion is often accompanied by "hat, 
clinically and biochemically, appears to be a second episode of acute hepatitis which, in some 
cases, may be due to delta virus (HDV) superinfection (see below). 
Although these two general patterns of serological events are seen in the majority of 
patients with either uncomplicated acute or chronic HBV infection, recent evidence indicates 
that they are not invariable. For example, it is possible for individuals to clear HBsAg and 
become anti-HBs seropositive while still harbouring the virus in their livers and secreting small 
amounts of IIBV-DNA into the blood (Cbung et al. 1995). The pathogenic significance of 
such small amounts of virus is currently unclear but these individuals may continue to be 
potentially infectious. This situation is thought to arise because of the development of "escape" 
mutants of HBV. In addition to the pre-core mutation discussed above (Section 1.3.1), several 
other mutations have been described which are presumed to develop under selective pressure 
of the host immune system (Mimms, 1995; Kato et al. 1996). Ihese are often associated with 
clearance of HBsAg and/or UBeAg and seroconversion to anti-flBs and/or anti-IlBe, and 
continuing active viral infection can usually be determined serologically only by detection of 
circulating HBV-DNA. 
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Figum 1.4 Diagrammatic mpmsentation of typical semlogical events occuning dwing 
uncomplicated acute (Panel A) and chmnic (Panel B) hepatitis B virus 
infection. For details see text. Ackptedfrom Hoofnagle aO Di Bisceglie, 
(1991). 
The serology of HBV is ftirther complicated if there is concomitant infection 
vdth HDV. The sequence of events depends to some extent on lAhen the HDV infection is 
acquired and the host's response to it. Because of its close dependence on, and inter- 
relationship with HBV, it is customary to measure and interpret serological markers of HDV 
infection in coillunction with HBV markers. Indeed, HDV interferes with HBV replication and 
can thus have profound effects on HBV serw-n markers (Di Bisceglie, 1993; Rizzetto et al. 
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Incubation) Acute phase Recovery phase Post infection 
(4-12 weeks (2-12 weeks) 
ý1 
(2-16 weeks) (years) 
1988b). Co-infection with HDV in the initial I]Bv inoculum can lead to a biphasic acute 
hepatitis with a periodicity of up to six weeks in which the first episode is due to fIBV and 
the second to HDV. Unless specific tests for the latter are performed, this second episode may 
be misinterpreted as a relapse of the HBV-induced illness. In uncomplicated cases, the second 
episode is commonly accompanied by clearance of IIBV and, therefore, also of HDV. In acute 
hepatitis following co-infection, HDV infection manifest by the appearance of HDA9 in the 
blood is rarely demonstrable because the viraemia is usually very transient. 
-HIBsAg titres (reflecting the ITBV infection) rise during the acute phase and fall during 
recovery (Fig. 1.5). At about the peak of the HBsAg, IgN4 anti-HDAg antibodies begin to 
appear (together with high titres of IgM anti-HBc) and rise in titre during the late acute phase 
before falling rapidly. The latter event is accompanied by a switch to the secondary (IgG) 
anti-HDAg response which often coincides with the appearance of anti-I-Ms. Sometimes the 
appearance of IgG anti-HDAg is delayed, and this leaves a "window" between the IgM and 
IgG anti-HDAg responses during which there is no serological evidence of HDV infection 
which, consequently, may be missed. Once it develops, however, IgG anti-HDAg usually then 
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Figum 1.5 Diagranunatic mpmentation of the typical semlogical events associated vAth 
acute hepatitis B (BBV) and delta vinis (HDV) co-infections. For details see 
text. A dcptedfrom Hoofnagle and Di Bisceglie (1991). 
When HDV is acquired as a super-infection in a chronic HBV carrier, the serological 
pattern of events is somewhat different. HDAg usually appears in the serw-n at the onset of 
the acute phase of the HDV-induced hepatitis, together with IgM anti-HDAg (Fig. 1.6). This 
is often preceded by a decline in all of the markers of the underlying HBV infection, due to 
suppression of HBV replication by HDV. The patient may become seronegative for IgM 
anti-HBc or have only very low titres and, in HBeAg-positive individuals, there is almost 
always seroconversion to anti-HBe. Thereafter, the sequence of events depends on the clinical 
outcome. In uncomplicated acute HDV hepatitis, the viraemia will wane quite rapidly, IgM 
anti-HDAg VVIII usually disappear within a few months after recovery, and persistence of IgG 
anti-IIE)Ag will be the only lasting evidence of the HDV infection. However, the majority of 
super-infected individuals seem to develop chronic HDV infections (Rizzetto et al. 1988a; 
Dimitrakakis et al. 1986),, kxith persistence of both IgT\4- and IgG-anti-HDAg, and often, "ith 
on-going liver damage - NAýhether or not there is biochemical evidence of liver dysfiinction. 
Such individuals often also have circulating IgA anti-HDAg antibodies, which seem to bee 





Figum 1.6 Diagranunatic mpmsentation of the typical semlogical events associated with 
acute (Panel A) and chtunic (Panel B) hepatitis delta vinis (HDV) stVer- 
infection in a chmnic hepatitis B canier. For details see text. A dcptedfrom 
Hoofnagle and Di Bisceghe (1991). 
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1.4 TflE IIEPATrM C VIRUS 
1.4.1 Biology of the hepatitis C vinis 
As noted above (Section 1.2) the hepatitis C virus (HCV) was identified by Cboo and 
colleagues in 1989. Intensive investigations over the past seven years have established that it 
is a small enveloped RNA virus that bears some resemblance to the flaviviruses (e. g. dengue, 
yellow fever and Japanese encephalitis viruses) and the pestiviruses (including hog cholera and 
bovine diarrhoea viruses). While there is little primary genomic sequence identity between HCV 
and these viruses, there is considerable similarity to the pestiviruses and flaviviruses with respect 
to its overall organisation, as well as in the putative functional (e. g. protease and helicase) 
activities and an-dno acid sequences of certain motifs of its genomic products (Miller and Purcell, 
1990; Houghton et al. 1994). Accordingly, it has been provisionally classified as a separate 
genus within theRavivindae family (Houghton et al. 1993). 
The HCV genome comprises a single-stranded RNA molecule of positive (sense) 
polarity, with about 9,500 nucleotides (nt) in a single open reading frame (ORF) that encodes 
a polyprotein of approximately 3000 amino acids (Fig. 1.7). The genornic organisation of HCV 
and the structure and functional characteristics of the various domains of its polyprotein have 
been deduced largely from analyses of recombinant HCV cDNA expression systems and have 
been extensively reviewed by Houghton and colleagues (Houghton et al. 1993; Houghton et al. 
1994). Briefly, the genome is envisaged schematically as being comprised of four domains: two 
untranslated regions (UTRs) at the 5' and 3' ends of the RNA strand, and a structural and a 
non-structural region (Fig. 1.7). The 5' leader sequence of 341 nt is highly conserved and has 
a complex secondary organisation involving several stem-loop structures which are thought to 
be important for genomic translation and replication and assembly of the virus. The 3' UTR is 
very short (27-45 nt) and is more variable, but seems to contain some conserved sequences and 
stem-loop secondary structures that may be important in the virus' replication. The structural 
domain encodes three proteins: a capsid (or "core") protein (C) of 21-26 kilodaltons (kD) with 
a basic N-ten-ninal segment and two glycosylated proteins, designated El or gp33 (31-35 kD) 
and E2 or gp72 (68-72 kD), wl-kh are thought to constitute the viral envelope. Like the SUTR, 
the core region is highly conserved. In contrast, the E2 region is hypervariable, and recent 
evidence suggests that rapid amino acid substitutions in the products of this region may be a 
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mechanism by which the virus adapts for persistent infection (Kurosaki et al. 1993; Bonino et 
al. 1993; Yamaguchi et al. 1994). In any event, this variability has major implications for the 
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Figum 1.7 Posttdated genon-ic oiganisation of the hepatitis C vims. 




The products of the non-structural domain are believed to be involved in replication of 
the virus and in cleavage of the transcribed polyprotein. The ftInctions of the products of these 
regions (NS1-NS5) appear to include various proteinase and helicase activities. The large NS5 
region is thought to encode a number of peptides with multiple fimctions which, by analogy with 
other RNA viruses, probably includes a viral RNA-dependent polymerase. 
The HCV genome is not a homogeneous species. Rather, it exists as a quasispecies 
distribution of closely related but heterogeneous genomes (Caban et al. 1993). In addition, the 
process of host selection and adaptation of a rapidly mutating genome has led to the evolution 
of many distinct genotypes (see below), which can be distinguished according to the degree of 
relatedness/divergence at the nucleotide and amino acid sequence levels (Alberts et al. 1991; 
Hadler et al. 199 1; Ricchi et al. 1992). Whether, like HBV (Section 1.3.1), the HCV genome 
includes a glucocorticoid responsive element (GRE) is unknoNNn. However, it is interesting to 
note that, as in I]BV infection, chronic hepatitis C patients treated with corticosteroids show 10- 
fold increases viral genomic material (HCV-RNA) in the serw-n during such treatment, and a 
flare of serwn aminotransferase activity Men treatment is stopped (Fong et al. 1994) 
1.4.2 Epidemiology of hepatitis C 
Hepatitis C virus infection is a global problem. Data are still accumulating but the 
available evidence suggests that the distribution of HCV worldwide is very similar to that of 
HBV, i. e. relatively low prevalence in the temperate zones of northern Europe and North 
America, intermediate in the Mediterranean area, and high in Asia, Africa, parts of the Pacific 
basin and probably also at least in parts of Latin America (Van der Poel, 1994). There are, 
however, important differences from IIBV in the risk factors for acquisition and the outcome of 
HCV infection. 
It seems probable that, like HBV, HCV is transmitted only via the parenteral route. 
Nonetheless, in 30-80% of cases of chronic HCV infection there is no apparent history of a 
direct parenteral contact (Bonino et a]. 1993). Careful anarnnesis may reveal previously 
unsuspected parenteral exposure to blood or blood products in many cases (Chiaramonte et al. 
1996) but, in others, the mode of acquisition in these so-called "community acquired" or 
"sporadic" infections remains an enigma. Studies of sexual and other modes of close-contact 
transi-nission of HCV have yielded conflicting results. Although most studies document a higher 
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rate of evidence of exposure to HCV in households where there is at least one infected member 
than in the general population or households in which there are no index cases, the incidence 
is relatively low (about 5% overall) and varies widely (from 0 to 30%) (Alter, 1994). This may 
be related to the status of the index case, for Buscarini et al [1993] found evidence of HCV 
exposure in 14.9% of members of families Mere one member had active liver disease but none 
in families Mere the index cases had normal serum aminotransferases. Shedding of HCV in 
saliva has been reported (Couzigou et al. 1993; Wang et al. 1992) but, in one of these studies 
(Wang et al. 1992), there was no evidence of transn-fission to spouses. Other studies "U et 
al. 1991; Fried et al. 1992) found no evidence of the virus in the semen or saliva of infected 
individuals and concluded that there was no direct evidence of transmission by these routes. 
This is supported by other fmdings of a low incidence of HCV transmission in homosexual 
populations or between heterosexual partners (Everhart et al. 1990; Melbye et al. 1990; Kolho 
et al. 1991; Shev et al. 1991; Chiaramonte et al. 1996). 
Data relating to vertical (matemal/foetal) transn-fission of HCV are also conflicting. A 
high rate of transmission to neNNborn children of mothers with human immmodeficiency virus 
(HIV) and HCV infections has been reported (Novati et al. 1992) and this is supported by other 
studies showing a high rate of HCV transmission between sexual partners in the IRV setting 
(Eyster et al. 199 1), suggesting that HIV may modulate expression and infectivity of HCV. In 
the absence of FRV, the reported frequencies of matemal/foetal HCV transmission vary widely. 
Wejstdl et al [1992] found that 18 of 21 children bom. to 14 women with chronic hepatitis C 
were transiently seropositive for anti-HCV antibodies during the first 3 to 12 months after birth 
and two had very transient viraen-fia, but concluded that these were probably cases of passive 
transfer of the virus and/or antiviral antibodies. Only one (4.8%) of the children developed a 
sustained viraernia. A very similar frequency (5.6%) was reported by Ohto et al [ 1994] in Japan, 
who noted that transmission to infants occurred only from mothers with high serw-n titres of 
HCV-RNA. In contrast, another Japanese study has reported a maternal/foetal transmission 
frequency of 33% (Kuroki et al. 1993). However, given the opportunity for direct blood-blood 
contact during the birth process, and in marked contrast to FEW the overall picture suggests that 
the risk of maternal/foetal transmission of HCV is relatively low. 
Also in marked contrast to HBV, up to 90% of adults infected with HCV become chronic 
carriers of this virus (" Bisceglie et al. 1991; Yano et al. 1993; Cordoba et al. 1994). The 
frequency with which this occurs may not always be appreciated because of the clinically n-fild, 
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f ar indolent and fluctuating course usually associated with chronic HCV in ection. The I ge 
majority of such individuals are clinically asymptomatic and often have normal serum 
arninotransferases, even in the presence of severe underlying liver disease (Di Bisceglie et al. 
199 1; Alberti et al. 1992; Romeo et al. 1993; Shindo et al. 1995; Silini et al. 1995). It is 
possible that a true "healthy" carrier state exists (Prieto et al. 1995) but, while some chronically 
infected individuals have minimal or no histological changes on liver biopsy (Esteban et al. 
199 1), it seems that in most cases the disease slowly and inexorably progresses to cirrhosis 
(Cordoba et al. 1994). The reasons why there are differences between patients in the course of 
the disease are unknolAn but may be related to the level of viraernia which, in turn may depend 
on the particular genotype with which the individual is infected (see below). The mode of 
acquisition of infection may be another factor. Gordon et al. (1993) have reported that patients 
acquiring the virus through blood transfusion (and therefore presumably receiving a large 
inoculurn) have more aggressive liver disease than HCV-infected intravenous drug users (NAho 
presw-nably receive smaller doses of the virus). 
There is also increasing evidence that (like HBV) HCV is associated with development 
of hepatocellular carcinoma (HCC), particularly in Japan where up to 70% of HCC cases have 
evidence of HCV infection (Saito et al. 1990; Yuki et al. 1992; Shiratori et al. 1995), but also 
in areas of relatively low HCV endemicity (Paterlini et al. 1993). Nonetheless, in almost all 
cases the malignancy develops against a background of cirrhosis which, as noted above (Section 
1.3.3), is itself an independent risk factor for HCC (Kew and Popper, 1984; Zaman et al. 1985; 
Okuda, 1992). Perhaps the most persuasive evidence has come from a recent retrospective study 
of patients with autoinunme hepatitis (MR, in which HCC is nonnally very rare, showing that 
75% of patients with AM who developed HCC had previously undiagnosed superimposed 
chronic HCV infections (Ryder et al. 1995). 
1.4.3 Variants of the hepatitis C vinis 
On the basis of nucleotide sequence divergence of up to 10% within, and of more than 
20% between, HCV-RNA isolates from different countries, it has been established that there are 
a number of genotypes and subtypes of the virus (Simmonds, 1994). By comparison with the 
prototype virus (HCV-1, now more usually referred to as HCV-PT) early studies at Chiron 
Corporation initially led to classification of these variants into three groups: HCV-1, HCV-11 and 
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HCV-111 (Choo, et al. 199 1; Houghton et al. 199 1) From studies of isolates from Japanese 
patients, Enomoto et al. (1990) had proposed an alternative classification: HCV-PT, -KI, -K2a 
and -K2b. Okamoto et al. (1992b) also identified four corresponding genotypes in Japan but 
suggested that they should be designated genotypes 1, H, III and IV. Since ther4 a considerable 
amount of nucleotide sequence data has been obtained by different investigators and this has led 
to propose the classification shown in Table 1.1, which has been used throughout the present 
study (Simmonds, 1995; Mori et al. 1992). 
There are distinct variations in the prevalence of the different genotypes in different 
geographical areas. Data are still accumulating but the available evidence, recently reviewed by 
Simmonds(Simmonds, 1995; Simmonds, 1994), suggests that genotypes I and 2 predominate in 
northern and southern Europe, North America and Japan. Type 3, which is rare in Japan and 
other countries along the north-western rim of the Pacific basin, accounts for the majority of 
infections in Thailand, Bangla Desh and India, while type 4 appears to be concentrated in the 
Nfiddle East and in Central Africa (Simmonds, 1995). Types 5 and 6 seem to show a highly 
restricted distribution, the former having been reported mainly from South Africa and the latter 
from Hong Kong and Vietnam. Other, newer genotypes have been recently reported from 
Vietnam (Tokita et al. 1994). 
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Table 1.1 Pmposed nomenclatum of HCV genoqpes conTamd mith previous assignations 
Genotype CWmn Enomoto Wii/Okanioto 
la I K-PT 
lb 11 K- 1 11 
Ic nc nc nc 
2a K-2a III 
2b K-2b fv 
2c nc nc 
3a IV nc v 
3b IV nc vi 
4 nc nc nc 
5 v nc nc 
6 nc nc nc 
A clcptedfrom Simmonc&, (1995). nc = not classified. For other details see text. 
In attempts to clarify the relationships between the different genotypes and subtypes, 
Simmonds and colleagues have undertaken detailed phylogenetic analyses of the nucleotide 
sequence data from HCV isolates from different parts of the world (Simmonds, 1995), as shown 
in the phylogenetic tree in Fig. 1.8, vvhere branch lengths are proportional to the proposed 
evolutionary distances from each other and from a putative ancestral virus. 
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Figum 1.8 Phylogenetic analysis of nucleotide sequences in pait of the HCV NS-5 mgion. 
Re-drawnfrom (Simmonds, 1995). 
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1.4.4 Semlogy and cliagnosis of hepatitis C vinN infection 
The original cDNA clone, designated 5-1-1, derived from the hepatitis C virus (see 
Section 1.4.1) was ligated Yvith three overlapping clones from the NS3NS4 region of the HCV 
genome to produce a clone designated clOO (Fig. 1.7). This was expressed in Eschefichia cOli 
and the resulting recombinant protein was shoxAn to specifically bind antibodies in the sera of 
patients vvith chronic NANB hepatitis (Cboo et al. 1989; Kuo et al. 1989). Subsequently, c 100 
was expressed in yeast as a fusion protein (c 100-3) vvith human superoxide dismutase (SOD) and 
used as the antigen in an enzyme-linked immunoassay (ELISA) that became the first 
commercially available test for anti-HCV antibodies (Ortho Diagnostic Systems, Raritan, New 
Jersey, USA). 
The new test was widely used initially and served to establish that, in the large majority 
of cases, NANB viral hepatitis is due to HCV [see e. g. Choo et al. 1990; van der Poel et al. 
1989; Alter et al. 1989; Esteban et al. 1989; Hopf et al. 1990; Alter et al. 1992). Other data 
obtained using this assay demonstrated a strong association between HCV infection and some 
chronic liver diseases, particularly cryptogenic cirrhosis, and with primary hepatocellular 
carcinoma (Alter et al. 1992; Colombo et al. 1989; Sansonno and Dammacco, 1989; Hasan et 
al. 1990; Jeffers et al. 1992). It soon became apparent, however, that there were problems with 
this anti-HCV assay. Reports began to appear of false-positive reactivities with sera from 
patients with some liver disorders and other conditions in which there was no other evidence of 
a viral aetiology. These were variously attributed to serw-n factors associated with 
hyperglobulinaemia (McFarlane et al. 1990), to antibodies against the fusion protein (SOD) 
(H., -eda et al. 1990), or to rheumatoid factor (Theilmann et al. 1990). Reactions against 
contaminating traces of yeast proteins in the recombinant c100-3 preparation that might have 
escaped the purification process also provided potential for false reactivity. 
In addition, further studies revealed that the appearance of anti-c 100-3 antibodies is 
unpredictable. Cuypers et al. [1991] found that these antibodies often appeared relatively late 
(and sometimes not at all) in cases of transfusion-related HCV infection, whereas patients 
frequently had antibodies against additional epitopes that had been identified in peptides derived 
from the nucleocapsid (c22) and NS3 (63) regions (Van der Poel et al. 1991). However, the 
patterns of response to these additional peptides also varied between individuals (Fig. 1.9). 
Since several of these different patterns were observed in recipients infected by blood products 
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from a single donor, (Cuypers et al. 1991) concluded that they were determined by the host 


























































Figum 1.9 Antibody msponses to diffemnt HCV peptides in post-tmnsfusion HCV infection. 
Solid horizontal bars represent seropositivity for antibodies against the different 
peptides sho"n on the left. Broken line z-- alanine aminotransferase (ALT) 
activities. Chronic infection was determined by seropositivity for HCV-RNA at 
various times after 250 days post-transfusion. Adcptedfrom (Cuypers et al. 
1991). 
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I La A c! useful as they have been, the early assays based only on clOO-3 are now virtually 
obsolete and new assays for HCV antibodies have been developed that incorporate additional 
epitopes in recombinant (Cboo et al. 1990) or synthetic (Hosein et al. 1991) HCV peptides 
derived from the nucleocapsid and from the NS3 and NS4(Alter et al. 1992) regions and, more 
recently, a peptide from the NS5 region(Courouce and Janot, 1994). The introduction of these 
second- and third-generation anti-HCV assays has served to increase the sensitivity and 
specificity of detection of HCV antibodies as well as allowing for earlier diagnosis of acute HCV 
infection (see below). In addition, to circumvent some of the problems of false positivity, 
recombinant immmoblot assays (RIBAs) have been developed to confirm positive reactions in 
the ELISAs. The RIBAs comprise nitrocellulose strips impregnated with bands of the various 
recombinant HCV peptides used in the ELISAs and, as controls, SOD and two concentrations 
of normal human IgG. The strips are incubated with the patients' sera and antibodies binding 
to the peptides are detected by an enzyme-conjugated anti-human immunoglobulin in a similar 
manner to that used in the ELISAs. To ftirther overcome the problems of false positive results 
due to reactions against SOD or against yeast proteins, other modifications have been introduced 
in the ELISAs and RIBAs, including the use of recombinant antigens produced in E coli as 
fusion products with proteins other than SOD. Most of the REBAs are not confirmatory assays 
in the strict sense, since they do not involve neutralisation and are really only a variation on the 
ELISA theme. They are more correctly described as "supplemental" assays. 
Although the currently available anti-HCV tests are much more reliable, problems of 
interpreting positive and negative results remain. The antibodies detected by these assays are 
not neutralising antibodies. On its own, therefore, a positive anti-HCV test gives no indication 
of xNhether the patient has had an acute infection and has recovered completely or NNhether there 
is ongoing (chronic) infection. In contrast to IIBV and HDV, it has not yet been possible to 
identify or detect circulating HCV antigens that might distinguish between patients with chronic 
infection and those NNho have cleared the virus and in -, Ahom the anti-HCV antibodies are merely 
a reflection of past infection. 
Detection of circulating viral genomic material (HCV-RNA) is currently the only 
serological method of determining whether a positive anti-HCV test result reflects active HCV 
infection. This requires use of the reverse transcription polymerase chain reaction (PCR) 
technique, which has become the "gold standard" and is described in detail in Chapters 3 and 4. 
It is necessary to use such a sensitive technique because viraemia in HCV infections usually 




ongoing HCV infection because the viraemia fluctuates and patients can be seronegative for 
HCV-RNA while continuing to harbour the virus in their livers or at extrahepatic sites (Romeo 
et al. 1993; Myhre et al. 1994; Saleh et al. 1994b; Barrera et al. 1995; Blajchman et al. 1995: 
Koskinas, et al. 1995; Pereira et al. 1995; Schmidt et al. 1995). 
Using a combination of PCR for HCV-RNA, a second-generation anti-HCV test 
(ELISA 2, Ortho Diagnostic Systems) incorporating the c22, c33 and c 100 peptides and a four- 
antigen RIBA comprising these and the 5-1-1 peptide (Cbiron Corp. ), Barrera et al. (1995) have 
recently described some of the serological events following transfusion-related HCV infection. 
By following 41 patients who developed post-transfusion NANB hepatitis for eight years, these 
investigators defined three main patterns of outcome (Fig. 1.10). At onset of the hepatitis, only 
22 (54%) were seropositive for any of the anti-HCV antibodies sought, although within one 
month 94% had seroconverted and by six months all were seropositive. Ten patients had an 
uncomplicated ("self-limiting") acute hepatitis with apparent complete recovery as evidenced by 
sustained normalisation of serum alanine aminotransferase (ALT) activities, but liver biopsies 
were not performed. In these cases, the incubation period was significantly shorter and the 
patients had significantly higher ALT activities during the initial acute hepatitis than the other 
31 patients who progressed to chronic liver disease. However, five of the ten patients with 
apparently self-limiting hepatitis continued to have fluctuating viraernia throughout the follow-up 
period despite persistently non-nal ALT activities and, although they eventually lost anti-clOO 
antibodies, they remained seropositive for anti-c22 and anti-63. In the five who appeared to 
completely clear the virus, the various anti-HCV antibodies persisted for several years at 
declining titres before they all eventually disappeared. Whether complete disappearance by 
rigorous testing for antibodies against all of these HCV peptides does reflect complete recovery 
from infection is, however, still uncertain. Barrera et al. (1995) did not specify the limits of 
detection of the PCR assay for HCV-RNA that they used but Yuki et al. (1994), using a very 
sensitive quantitative PCR assay, have shown that about 60% of patients with low levels of 
viraemia do not have antibodies against the c22, c33, clOO, 5-1-1 peptides or against proteins 






















Figum 1.10 Semlogical events associated v4th diffewnt outcomes of transfusion-mlated HCV 
infection. Panel A= Acute infection with complete recovery and clearance of 
the virus. Panel B= Chronic infection with fluctuating serui-n alanine 
aminotransterase (ALT) activities. Panel C= Persistent infection with fluctuating 
viraernia and normal ALT activities. Anti-HCV antibody results are shown as 
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The serology of HCV infection is still evolving. To date, all of the commercial 
anti-HCV assays measure only IgG antibodies to the various peptides. However, Yuki et al. 
(1995) have recently shown that 19M antibodies to the core protein show a significant correlation 
with levels of viraei-nia, and Quiroga et al. (1995) have suggested that this isotype of anti-HCV 
may be useful in the assessment of HCV replication and in monitoring biochemical and 
virological responses to interferon treatment. As happened in the early years during development 
of the serology of HAV, FIBV and HDV, therefore, it is likely that new tests'V"* II evolve as more 





1.5 THE IHEPATHIS GB VIRUSES 
The GB agent was first identified by Deinhardt and co-workers, (Deinhardt et A 1967) 
through a series of experiments demonstrating that marmosets inoculated with serum from a 
patient vvith acute hepatitis developed clinical, biochemical and histological features of acute 
hepatitis, and that this could be transmitted through serial passages to other healthy monkeys. 
However, it was only very recently that Simons et a]. (1995b) cloned the virus from serum of 
tamarins in which it had been seriallY passaged from an inoculum from the original senun used 
by Deinhardt et al. (1967). In fact, Simons et al. (1995b) demonstrated that there were two 
flavivirus-like RNA genomes capable of inducing hepatitis in the tamarins and this was 
confirmed in ftirther studies by Simons et al. (1995b). The two agents have been designated 
GBV-A and GBV-B. A third agent, GBV-C, demonstrated in some patients with hepatitis, was 
found to have considerable nucleotide sequence homology with GBV-A (Simons et al. 1995a). 
All three viruses have positive stranded linear RNA genomes of approximately 10 kb in length. 
Like HCV, and the flaviviruses and pestiviruses, each possesses a single large open reading 
frame that appears to code for structural proteins at the 5' end and non-structural proteins at the 
3' end. GBV-A and GBV-B are closely related to HCV based on amino acid sequence 
homology of the putative RNA helicase (GBV-A 47.21/cý GBV-B 57.0%) and have conserved 
nucleotide triphosphate (NTP) binding motifs, but the genetic distance between the three viruses 
and HCV is too great for them to be considered as genotypes of HCV and they show sufficient 
divergence from HCV at the amino acid sequence level to indicate that they form a separate and 
distinct viral group. 
Evidence relating to the clinical significance of the GB viruses is still emerging, but they 
appear to be an important cause of fulminant non-A-E hepatitis (Yoshiba et al. 1995). Initial 
serological surveys of the prevalence of antibodies to the viruses indicate that their geographical 
distribution is similar to that of HCV, with nearly a third of African patients showing evidence 
of exposure to GBV but much lower (about 2%) rates among one study of blood donors in the 
USA. However, there seem to be important differences within populations (Zuckerman, 1995). 
Patients with HCV infection seem to be at increased risk of GBV-C infection, with the highest 
incidence (24%) being recorded in HCV-infected intravenous drug users (Aikawa et al. 1996). 
52 
CHAPTER 2 
RATIONALE AND PLAN OF INVESTIGATIONS 
2.1 RATIONALE 
2.2 PLAN OF ENVESTIGATION 
2.3 PROGRESS OF INVESTIGATION 
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2.1 RATIONAILJE 
As noted in Cbapter I(Section 1.1), the original aim of the present study was to 
investigate the impact of chronic viral hepatitis on hepatic schistosomiasis in Libya. When the 
study began in 1992, little was knoAn about the background prevalence of viral hepatitis in that 
country and it was therefore considered essential to begin by collecting serum samples fi7om 
subjects without evidence of Schistosomiasis to provide controls for these investigations. Sera 
were obtained from 301 apparently healthy volunteers and from 52 hospitalised patients(16 with 
a diagnosis of chronic non-A, non-B hepatitis and 36 undergoing regular haemodialysis for 
chronic renal failure who had received multiple blood transfusions). The serwn samples were 
frozen immediately and shipped to the U. K Unfortunately, this had only just been completed 
when the United Nations imposed sanctions against Libya. Collection and transportation of 
ftwther frozen samples became impracticable because travel was possible only via a roundabout 
route through Malta, Egypt, and/or Tunisia. However, preliminary screening of the samples that 
had been collected revealed that a very high proportion (35.2%) of the "healthy" subjects had 
at least one marker of exposure to the hepatitis B virus (HBV), with 11.6% actively infected 
(HbsAg seropositive)at the time of testing, and that 6% had evidence of exposure to the hepatitis 
C virus (anti-HCV seropositive). Additionally, nearly 90% of the multiply-transfused 
haernodialysis patients had evidence of exposure to HBV and/or HCV. 
In view of the above, it was decided to use the material collected to mdertake a detailed 
study of hepatitis viral infection in this population. Since detailed follow-up to determine 
clinical outcome in any cases of acute infection was impossible, it was decided to concentrate 
the study on those viruses (B, C and D) knovm to be capable of chronic infection, with particular 
reference to hepatitis C. Although this would clearly not constitute a full epidemiological survey, 
it was felt that the results might provide useful information about viral hepatitis in Libya. 
2.2 PLAN OF UNVESTICATION 
In addition to screening for the full range of HBV markers (HBsAg, anti-HBs, HBeAg, 
anti-UBe and anti-I]Bc), it was decided to test all I]BsAg-positive subjects for HBV-DNA to 
deten-nine how many had actively replicating virus, and for antibodies against the hepatitis delta 
virus (IJDV) to obtain infonnation about the frequency of concomitant FDV infection in this 
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Population. Anti-HCV positive subjects would be re-tested for antibodies against a range of 
epitopes in a panel of synthetic peptides corresponding to gene products of different parts of the 
HCV genome, for purposes of confmrdng results of the initial screening assay and to determine 
whether any of these epitopes appeared to be immunodominant. HCV-RNA would be determined 
by the polymerase chain reaction(PCR) to assess how many had active HCV infection, and HCV 
genotypes would be determined in all HCV-RNA positive individuals to obtain infon-nation about 
which variants of the virus were prevalent in Libya. Results would be correlated with 
demographic parameters, clinical findings, serum biochen-fical liver tests and, Mere possible, 
with severity of disease assessed histologically. 
2.3 PROGRESS OF INVESTIGATION 
Once the initial screening and other investigations relating to the prevalence of hepatitis 
B5 C and D virus infection in this Libyan population was satisfactorily completed, the study 
progressed to genotyping of all HCV-RNA seropositive individuals. It was decided that, partly 
for control purposes and partly for pw-poses of comparison of the geographical distribution of 
the various genotypes, it would be useful to also genotype approximately 100 patients with 
chronic hepatitis C from other parts of the world Mo were attending the Institute for Liver 
Studies. Initially, the genotyping was undertaken by restriction fragment length polymorpl-ýism 
(RFLP) analysis but, as this method was not capable of defining subtypes of the virus, the 
studies were repeated using the type-specific primer(TSP)"nested"PCR method of Okamoto et 
al (1992). This was not found to be particularly satisfactory, mainly because a large number of 
the isolates could not be assigned specific types, and the process was repeated again using type - 
specific primers obtained from Dr. Masashi Mzokarni in Nagoya, Japan. Sequencing of the 
5'UTP, core and NS5 regions of the HCV genornic material in these isolates was then 
undertaken and phylogenetic analysis was performed to determine Mether there were any new 
HCV variants among the various isolates and to resolve questions about the results of genotyping 
by various methods used. 
Finally, during the latter stages of the study, the opportunity arose to collaborate v6th 
Dr. Nfizokan-ii to investigate the prevalence of the GBV hepatitis in the Libyan subjects, and 
these data have been included. 
55 
CHAPTER 3 
SUBJECTS & METHODS 
3.1 SUBJECTS 
3.2 METHODS 
3.2.1 Serum Biochemical Liver Tests 
3.2.2 Hepatitis B and D Viral Serology 
3.2.2.1 Testing for hepatitis B (HBV) viral markers 
3.2.2.2 Screening for hepatitis D 
3.2.3 Hepatitis C Virus (HCV) Serology 
3.2.3.1 Anti-HCV antibodies 
3.2.3.2 Detection of HCV-RNA by polymerase chain reaction (PCR) 
RNA extraction 
Reverse transcription 
Polymerase chain reaction (PCR) 
3.2.3.3 Southern blotting of PCR products 
3.2.4 Genotyping the hepatitis C virus 
3.2.4.1 Typing by restriction fragment length polymorphism. (RFLP) analysis 
3.2.4.2 Typing by the method of Okamoto et al 
3.2.4.3 Typing by the type-specific primer (TSP) method 
3.2.5 Sequencing of hepatitis C virus cDNA 
3.2.6 GBV-C virus detection 
3.2.7 Phylogenetic analysis 
3.2.8 Liver histology 
3.2.9 Statistical analyses 
56 
3.1 SUBJEMN 
A total of 353 indigenous Libyan subjects was studied. These comprised 301 apparently 
healthy individuals, 36 patients with chronic renal failure undergoing regular haemodialysis who 
had received multiple blood transfusions from Libyan donors, and 16 patients with non-alcoholic 
liver disease who had never received blood transfusions and inAhom the working diagnosis was 
chronic non-A, non-B viral hepatitis. Haemophiliacs were excluded because they had received 
blood products from abroad. Full details of these subjects are given in Cbapter 5. 
Serum from 10 ml of blood from each subject was immediately separated, frozen in I n-d 
aliquots, and stored at -70'C. The samples were then transported to the U. K in dry ice and 
stored at -20'C until used for the various investigations detailed in Chapters 5 to 8. All subjects 
gave informed consent to clinical examination at the time of sampling, Aith particular attention 
to signs and symptoms of liver disease Oaundice, ascites, hepatomegaly, splenomegaly, and 
cutaneous stigmata). 
For purposes of comparison with Libyan patients with hepatitis C virus (FICV) infection, 
an additional 106 consecutive patients from other parts of the world with chronic hepatitis C, 
who were attending the Institute of Liver Studies, were also studied. Details of these patients 
are given in Chapter 6. 
3.2 NWMODS 
3.2.1 Semm Biochemical Uver Tests 
Total serum bilirubin, alkaline phosphatase, gammaglutarnyl transferase, total protein and 
albumin were determined by standard automated techniques (SMAC, Technitron) by the routine 
chemical pathology services of the Libyan hospitals involved. Full blood count and prothrombin 
time (by the Quik technique [Quik, 1935]), were perfonned by the routine haernatology 
departments of these hospitals. 
Senim aspartate (AST) and alwiine (ALT) aminotransferase activities were deten-nined 
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on the stored sera at the Institute of Liver Studies by colorimetric assays (505[AST/GO-fl and 
505-P[ALT/GPT], respectively, from Sigma C-bemical Co., Poole, Dorset). The measurements 
were made strictly according to the manufacturer's instructions and using the standard curve 
provided, with an upper non-nal lin-fit of 50 I-U/l for both assays. 
3.2.2 Hepatitis B and D Viral Semlogy 
3.2.2.1 Testing for hepatitis B (BBV) viral nmdwis 
Screening for infection NNith hepatitis B virus (flBV) was performed initially by the Red 
Crescent Blood Transfusion service in Libya by testing for HBV surface antigen (11BsAg) using 
the Wellcotest haemagglutination assay (Wellcome Diagnostics, Beckenham, Kent, UK). All 
samples were re-tested in the Institute of Liver Studies for HBsAg and 'e' antigen (11BeAg), and 
for antibodies against I]BeAg (anti-Me), UBsAg (anti-HBs) and the 11BV core antigen (anti- 
HBc) by commercial automated enzyme immunoassays ("Mx", Abbott Laboratories, Chicago, 
Ill., USA) vvith the kind assistance of Ms. Heather Smith, Principal Biochemist. 
Hepatitis B viral DNA (HBV-DNA) was detected by using a commercial manual 
molecular hybridization assay (Abbott Laboratories, Chicago, Ill., USA) according to the 
manufacturer's instructions. Briefly, the procedure involves treating 100 pl of serum with 
proteinase to release any protein-encapsulated DNA in the sample. Any DNA present is then 
uncoiled by addition of sodium hydroxide in sodium chloride solution and incubating the sample 
overnight at 65'C with a 1251_1abelled probe comprising a short nucleotide sequence 
corresponding to the FIBsAg-encoding region of the HBV genome, which will hybridize with 
any HBV-DNA present. The sample is then passed over a small (1.5 cm diameter) column of 
sepharose and washed through with a Tris buffer, to separate unbound probe (which is retained 
by the column) from the probe/HBV-DNA complex. The latter passes through the column with 
the first colurnn volui-ne of wash buffer and is collected and radioactivity in the sample 
deten-nined by counting (in the present studies using a Packard Cobra 11 autogamma counter). 
Specimens with counts equal to or greater than the manufacturer's cut-off value are considered 
positive for HBV-DNA, which is then quantified and expressed in pg IIBV-DNA/n-d by 
calculation with a fon-nula derived from a standard curve provided by the manufacturer. 
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3.2.2.2 Scmening for hepatitis D 
Total (IgK IgG and IgA) antibodies against the delta virus antigen (HDAg) were sought 
by a commercial enzyme immunoassay (Sofirt/Biomedica, Italy). This is a competitive ELISA 
in which anti-HDAg antibodies in the patient's senun compete with a peroxidase-conjugated 
human anti-HDAg antibody for binding to HDAg. Briefly, purified HDAg is added to the wells 
of microtitre plates coated with a monoclonal anti-HDAg antibody which "captures" the HDAg- 
Excess HDAg is washed off and 10 pl of patient's serum is added, followed immediately by 
100 ýd of the peroxidase-labelled anti-HDAg. The plates are incubated overnight at room 
temperature, then the wells are aspirated and washed. To detect binding of the peroxidase anti- 
HDAg to the immobilized HDAg, 100 [tl of tetramethyl benzidine in 0.005% hydrogen peroxide 
is added. After incubation for 30 min at room temperature, the enzyme reaction is stopped by 
addition of 100 [d of the manufacturer's blocking reagent (sulphuric acid). The intensity of the 
resulting color reaction is quantified by spectrophotometric measurement of the absorbance at 
450 nm. Anti-HDAg antibodies in the patient's serum competing with the peroxidase-anti-HDAg 
for binding to the HDAg on the plate cause a reduction in the intensity of the colour developed. 
Positive results are defined in relation to the absorbance values given by the manufacturer's 
positive and negative controls, which are run concurrently. 
3.2.3 Hepatitis C Vims (HCV) Semlogy 
3.2.3.1 Anti-HCV anfibocfies 
For the reasons discussed in detail in Chapter 4, screening of sera for anti-HCV 
antibodies in the present study was perfort-ned with a commercial second/third generation enzyme 
immunoassay (HCV-ELA, United Biomedical Inc., Raritan, NJ, USA). This assay employs two 
synthetic peptides immobilized on microtitre plates - one corresponding to a segment of the 
highly conserved core region of the HCV genome (see Chapter 1, Fig. 1.6) and the other to an 
overlapping part of the NS3NS4 region(Hosein et al. 199 1). Samples giving positive reactions 
in this assay (defined by reference to the manufacturef s positive and negative controls run 
concurrently) were re-tested in duplicate to confirm the positive result. In addition, each anti- 
HCV positive sample was ftirther tested in five separate ELISAs (produced by United 
Biomedical Inc. ) for antibodies against these two peptides individually and against additional 
synthetic peptides corresponding to the envelope (EI /E2), NS I and NS5 regions of the genome. 
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All assays were performed exactly according to the manufacturer's instructions using the 
positive and negative controls supplied. Briefly, sera are incubated in the antigen-coated 
microtitre plates at 37'C for between 15 min and I hour (depending on which assay is being 
used) and the plates are then washed. Antibodies binding to the antigens in the wells are then 
detected by adding peroxidase-conjugated anti-human IgG, incubating for 15 min to I hour at 
37C. washing thoroughly, then adding either 0-phenylenediamine-HCI or tetramethyl benzidine 
as instructed and incubating for the same period as above. Reactions are stopped by addition 
of 1N sulphuric acid and the absorbance of the colour produced is read at 492 or 450 nm, as 
appropriate. 
3.2.3.2 Detection of HCV-RNA by polymerase chain maction (PCR) 
RNA e-Wraction 
Total RNA from serw-n was extracted by the guarudinium thiocyanate/phenol/ cWorofonn 
method of (Chomczynski and Sacchi, 1987) using RNAzol B (Biogenesis, Bournemouth, UK) 
according to the manufacturer's instructions. Briefly, 200 [tl of RNAzol was added to 100 [d 
of serum in a 1.5 ml polypropylene n-ficrocentrifiage (Eppendorf) tube and the mixture was 
incubated with continuous vortex mixing for 15 min at 4'C. Chlorofon-n (30 ýA) was then added 
to disrupt any viral envelope present and, after mixing for I min, the sample was centrifuged at 
13,000 rpm for 15 min to separate the aqueous and non-aqueous phases. The RNA-containing 
aqueous phase was then carefully pipetted into a fresh, sterile, Eppendorf tube and the RNA was 
precipitated by adding an equal volume of isopropanol containing 20 [tg of glycogen as a carrier, 
incubating for I hour at -20'C, then centrifuging at 13,000 rpm for 15 min. The resulting RNA 
pellet was washed twice with cold 70% ethanol and dried under vacuum. Two normal human 
sera and two sera from patients known to have chronic hepatitis C were similarly processed as 
negative and positive controls, respectively, concurrently throughout. As additional internal 
"assay controls", parallel experiments were run using the primers DM151 and DM152 (Table 
3.2) supplied with the GeneAmp kit produced by Perkin-Ehner/Cetus. The rationale for use of 
these conditions, and those of the procedures described below, is discussed in Chapter 4 (Section 
4.2.2). 
Reverse tramcription 
DNA complementary (cDNA) to the freshly extracted RNA was synthesised by reverse 
transcription using Moloney Murine Leukemia Virus reverse transcriptase (NIMLV-RT, Promega, 
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Southampton, UK). RNA pellets from above were resuspended in 20 PI sterile water treated 
with diethylpyrocarbonate (DEPC) and heated at 65'C for 10 min to destroy secondary structure. 
2.0 ýil of the RNA suspension was then added to 8 ýd of a mixture containing I nunole/l of each 
of the four deoxynucleotide triphosphates (adjusted with NaOH to pH 7.0), 5MM MgC12, and 
I O-fold strength (I OX) RT buffer (500 mM KCI, 100 mM Tris-HCL, pH 8.3). The mixture was 
overlaid with 2 drops of mineral oil (Sigma) and incubated at 70'C for 10 min to reduce RNA 
secondary structure formation. To the cooled sample was then added 100 units of NUVILV-RT, 
20 units of recombinant RNAase inhibitor (Promega), random hexamers (hexameric nucleotides 
containing all possible combinations of G, A, T and Q, and DEPC-treated water to give a fmal 
volume of 20 pl. This "reverse transcriptase mixture" (Table 3.1) was incubated for 30 min at 
42'C, then for 5 min at 98'C to inactivate the NMEV-RT. After the cDNA synthesis, all 
samples were boiled for 30 min to ensure complete denaturation of the reverse transcriptase - 
any residual activity of which could give rise to false-positive results in the subsequent PCR 
steps. To avoid contamination, the recommendations of (Kwok and FEguchi, 1989) were strictly 
followed. In addition, preparation of samples, performance of PCR and subsequent analysis of 
the products were each conducted in separate laboratories. 
Table 3.1 Composition of the "mveise tramciiptase nixtum". 
























































RNA extract 2.0 gl 
.. 
Total volume 20 gI 
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Polynwmse chtdn rewtion (PO? ) 
To amplify the cDNA produced above "nested" PCR (the principles of which are 
described in Cbapter 4) was performed according to (Saiki et al. 1988) using primers 
corresponding to segments of the highly conserved 5' untranslated region (TUTR) of the HCV 
genorne (Okamoto et al. 1990). The procedure was optimised by starting the reactions "hot", 
with a preliminary incubation of the sample at 85'C prior to addition of Taq polymerase (Perkin- 
Elmer/Cetus, Norwalk, CT, USA), as suggested by (Erlich et al. 1991). The first round of PCR 
was Performed with the "outer" primers JR12 and JR19 described by (Uhich et al. 1991): the 
downstream (Y) primer designated JR19 representing nucleotides 197-216 of the HCV genome, 
and the upstream (5) primer JR12 representing nucleotides 1-20 (Table 3.2). The "inner" 
primers JR13 and JR14(Romeo et al. 1993) corresponding respectively to nucleotides 35-53 and 
14-161 were used in the second round. All of the primers and the oligonucleotide probe used 
for Southern blotting (below) were synthesised and sequences validated by the Department of 
Molecular Medicine, Kings College School of Medicine & Dentistry, London. 
Table 3.2 'Nested" pflmer paits used in the polymerme chain maction 
Ptinjets Position Sequence (F-3) 
"Outer": 
JR12 nt 1-20 GGCGACACTCCACCATAGAT 
JR19 nt 197-216 CGCCCAAATCTCCAGGCATT 
"Inner": 
JR13 nt 35-53 GAACTACTGTCT-fCACGCA 
JR14 nt 140-161 GGCAA'ITCCGGTGTACTCACC 
Controls: 
DM151 - GTCTCTGAATCAGAAATCCTTCTATC 
DM152 CATGTCAAAT fTCACTGCTTCATCC 
* Corresponding to nucleotides (nt) in SUTR of HCV genome 
For the first round of PCR, to 5.0 pl of the cDNA sample in a sterile 1.5 n-A Eppenclorf 
tube was added 5.0 ýtl of 10-fold strength (IOX) PCR buffer (200 mM Tris-HCI, pH 8.8, 
500 mM KCI, 15 rnM Mgc'2,0.5% Triton X-100), 1.0 ýtl of an equirnolar mixture of the four 
deoxyribonucleotides (dNTPs: dATP, dCTP, dGTP, dUP), 0.25 ýtl each of the outer sense and 
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antisense primers, Taq DNA polymerase and DEPC-water to give a total volume of 50 PI (Table 
3.3). The sample was then immediately subjected to 25 cycles of denaturation at 94'C for 
35 sec, primer annealing at 50'C for 40 sec, and primer extension at 681C for 150 sec in an 
automatic thenwal cycler (Perkin-Elmer/Cetus). The amplified DNA was then stored at 4'C 
overnight or at -20'C if longer storage was anticipated. 
Table 3.3 Composition of polymerase chain maction nixtures 
First round PCR Second mund PCR 
Component ]Final Final 
Volume concentration Volume concentration 
hiffial cDNA sample 
.................................................................. I 
5.0 [d 
................................... ........................................... .................................... ................................................ First round product 
.................................................................. ................................... I ........................................... 
1.0 [d 
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................................................ DEPC-water 38.25 ýtl 16.4 gI 
Total volume 50 ýd 20 gl 
For the second round of amplification, 1.0 ýtl of the first round product in a total 20 [d 
of reaction mix (Table 3.3) was subjected to a ftwther 25 cycles as above. The entire sample was 
then electrophoresed in a 3% Nusieve gel (Gibco), equivalent to I% agarose, at I OOV for I hour 
in TAE buffer (40 mM Tris, 10 rnN4 sodiwn acetate, I mM EDTA, 28 mN4 acetic acid), stained 
with ethidiw-n bromide and examined under UV light. Molecular size markers, (123 ladder, 
Gibco) spaming the range of expected bands of the PCR product were run on each gel. All 
PCR assays were perfonned in duplicate with positive, negative and internal "assay" controls for 
all steps as noted above. Interpretation of results is discussed in Cbapter 4 (Section 4.2.2). 
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3.2.3.3 Southern blotting of PCR products 
The specificity of the HCV-RNA detection by PCR was conflinmed in all cases by 
Southern blotting using a "P-labelled synthetic oligonucleotide probe with a sequence 
(nt 116-136 VvIRL 757 5-GAGGCCATAGTGGTCTGCG-3') internal to, and not inclusive of, 
that of the inner nested primers. The oligonucleotide bands obtained by PCR were transferred 
electrophoretically to nylon membranes (Hybond N+, Amersham, Bucks., UK) using a dot blot 
apparatus (Bio-Rad, Hernel Hempstead, Herts., UK) according to the manufacturer's instructions. 
The membranes were pre-hybridised by incubation at 65'C for 4 hours in 5-fold strength (5x) 
Denhardt's solution (5g Ficoll, 5g polyvinylpyr-rolidine, 5g bovine serum albumin in 100 nil), 
with 5X SSPE (20X SSPE =3M NaCl, 0.2 M NaH2PO4. H20,20 mM EDTA) 0.5% sodiw-n 
dodecyl sulphate (SDS) and 200 ýtgýffl sonicated salmon spenn DNA before addition of the 
radiolabelled probe and overnight hybridisation at 40T. The membranes were then 
successively washed at room temperature with 5X SSPE for 10 min, 2X SSPE with 0.1% SDS 
for 10 min, 1X SSPE with 0.1 % SDS for 10 min, and finally with 0.2X SSPE with 0.1 % SDS 
at 65T for 10 min. After drying at 80T, the membranes were autoradiographed at room 
temperature using Hyperfilm Bmax (Amersharn) for 48 hours. 
3.2.4 Genotyping the hepatitis C Aim 
3.2.4.1 Typing by wstfiction fragment length polymoqIgsm (RFLP) analysis 
RNA was extracted from 100 [d of senun and cDNA prepared by reverse transcription 
as described above. The cDNA was then amplified by PCR as above but using the outer primers 
209 and 939 shown in Table 3.4 for the first round of amplification and the inner primers 211 
and 940 for the second round(Garson et al. 1990b). This was done in the presence of 10% 
dimethylsulphoxide (DMSO) for 30 cycles of the following program: I min at 94'C, 1.5 min 
at 45'C, 3 min at 68'C. The resulting PCR products were electrophoresed in 3% low melting 
point agarose gels and the oligonucleotide fragments were detected by ethidiurn bromide staining 
and ultraviolet illumination as above. 
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RFLP analysis was perfonned. by digesting 25 pI of the second round PCR product 
overnight at 37'C. The reaction was carried out in the presence of '"ith 10 units in 5 ýtl 10-fold 
strength enzyme reaction buffer (10 mM Tris-HCI, 10 MM MgC12,50 MM NaCl, I MM DTI) 
of each of the restriction endonucleases HaelITRsaI, HinflMunl or MvaI[ in a total volw-ne of 
30 gI of IOX enzyme reaction buffer. The digestion products were visualized under UV light 
after electrophoresis in 4% Metaphor agarose gel (FMC BioProducts, Sittingbourne, Kent, UK) 
in Tris-borate buffer (134 mM Tris-HCI, 68 mM sodiw-n borate, 25 mM disodium ethylene 
diamine tetraacetate (EDTA), pH 10.0) containing 0.5 ýtg/ml ethidium bromide. The 
oligonucleotide fragments were sized by comparison with the migration distances of standard 
DNA markers (50-1000 bp size range; AMS Biotechnology (LJK) Ltd., Witney, Oxon) and 
results were interpreted as described in Chapters 4 and 6. 
Table 3.4 Details of pfimeis used for genotfong of the 5UTR wgion of the HCV genorne 




(nt) Polatity Sequence (F-3) 
209 8 to -21 ATACTCGAGGTGCACGGTCTACGAGACCF 
939 -297 to -278 + CTGTGAGGAACTACTGTCTT 
- 279 to -260 + TIFCACGCAGAAAGCGTCTAG 
211 -54 to -29 CACTCrCGACiCACCC'TATCACiGCAGT 
* Numbering from start of main open reading frame. 
3.2.4.2 Typing by the method of Okamoto et al 
The strategy for genotyping of HCV by the "nested" PCR method of Okamoto et al. 
(1992b) is discussed in Chapter 4 (Section 4.4). In the present study, the procedure described 
by these investigators was followed precisely. cDNA from the RNA extracted from 100 ýtl of 
serw-n was reverse transcribed, and the first round of PCR was performed for 35 cycles as above, 
but using the universal primers Nos. 186 and 256 (Table 3.5). 1.0 pl of the product was then 
subjected to a second round of PCR for 30 cycles of. - 94'C for I min, 60'C for I min and 72'C 
for 1.5 rnin. In tl-iis second round, the universal primer No. 104 was used together v6th a 
mixture of four type-specific antisense primers: Nos. 132 to 135, Table 3.5. The products were 
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then subjected to electrophoresis in 2% agarose gels made from 1.5%Nusieve and 1.5% SeaKem 
(Gibco, Paisley, UK), equivalent to 2% agarose, stained v6th ethidium bromide and examined 
under UV light. 
Table 3.5 Details of pfimen used for genoqping of the HCV cow tegion by the method 




(nt) Polarity Sequence (5'ý-3) 
104 148-167 + AGGAAGACTTCCGAGCGGTC 
186 391-410 + ATGTACCCCATGAGGTCGGC 
256 139-158 + CGCGCGACTAGGAAGAC-fTC 
132 185-204 TGCC'ITGGGGATAGGCTGAC 
133 272-291 GAGCCATCCFGCCCACCCCA 
134 302-321 CCAAGAGGGACGGGAACCTC 
JL_ 135 251-270 ACCCTCGTfTCCGTACAGAG 
* Ntunbering from start of main open reading frame. 
3.2.4.3 Typing and sub-typing by the type-specific pfimer (TSP) method 
The strategy used for typing and sub-typing by the TSP method, and interpretation of 
results, are discussed in Cbapters 4 (Section 4.4) and 7, respectively. RNA was extracted from 
100 ýtl of serum, reverse-transcribed and subjected to two rounds of PCR as above. The 
primers used for each round are detailed in Table 3.6. In the first round, 5.0 ýtl of the resulting 
cDNA was amplified through 20 cycles of. 94'C for I min, 45'C for I min and 72'C for I min, 
using the outer primers Sc2 and Ac2. In the second round, two aliquots of 1.0 ýd of the first 
romd product were amplified for a ftirther 20 cycles of- 94'C for I min, 60'C for I min and 
72'C for I min, using a mixture of primers S7, S2a, Glb, G2a, G2b and G3b (Mix I- for 
genotypes lb, 2a, 2B and 3b) with one aliquot and primers S7, Gla, G3a, G4a, G5a and G6a 
(Nfix 2- for genotypes I a, 3 a, 4,5 and 6) with the other. 
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Table 3.6 Details of pfimets used for genotyping of HCV by the ý[SP method 
Pfimer 
- 
Seqmnce (5ý-3) t- 
TPosition 






................................... Ac2 ................................................. GAG(AC)GG(GT)AT(AG)TACCCCATGAG(AG)TCGGC ..... 417 to 391 




............................................................................................................................................ ....... ... 
-12 to +8 
........................................ S2a 
.............................. 
. . ........ AACACTAACCGTCGCCCACAA 
................................................................................................................................................................ 















325 to 306 
........................................ G3b CGCTCGGAAGTCTTACGTAC 164 to 145 

























308 to 289 
........................................ 
G6a I GGTCATrCiCiGGCCCCAATGT 334 to 315 
Notations Ia to 6a are according to the nomeclature of Simmonds et al. ( 1994a). 
Parentheses indicate degenerate nucleotide pairs 
Nwnbering is from the start of the main open reading frame 
3.2.5 Sequencing of hepatitis C vims genonic matefial 
Viral sequences were amplified by reverse transcription and PCR from 100 pl of serum 
as above (Section 3.2.3.2), except that one of the inner primers (No. 211, Table 3.4) was 
biotinylated (supplied by the Dept. of Molecular Medicine as above). 40 ýtl of a suspension of 
streptavidin-coated magnetic beads ("Dynabeads", Dynal Ltd., Wirral, Merseyside, UK) which 
had been previously washed with 40 [d of 0.1% aqueous bovine serw-n albumin were placed in 
a 1.5 inl Eppendorf tube. 40 [d of the second round PCR product was added to the beads and 
incubated for 20 min at room temperature vdth occasional stining. The beads were then pelleted 
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with a magnet, washed with 40 ýtl of extraction buffer (10 mM Tris/HCI, pH 7.5, with I mM 
EDTA and 2M NaCl), resuspended in 8 pl of 0.15M NaOH and incubated for 10 Min at room 
temperature to separate the double-stranded DNA. The beads, with attached single-stranded 
antisense DNA were again pelleted by magnet, and the supernatant (containing unbound single- 
stranded sense DNA) was removed and stored. Finally, the beads were washed once with 50 ýtl 
of NaOR once with 50 gl of extraction buffer, and once with 50 gl of TE buffer (10 MM 
Tris/HCI with I m. M EDTA, pH 7.5) to remove traces of the supernatant, then resuspended in 
20 Vtl of TE buffer. 
Sequencing of the single-stranded PCR products was perfonned using the "Sequenase" 
kit supplied by United States Biochemicals (Cleveland, Ohio, USA) according to the 
manufacturer's instructions but with slight modifications to reduce secondary structure formation, 
namely, by carrying out the reactions in 10% DNISO and heat-denaturing the DNA template 
before primer annealing(Winship, 1989). For sequencing of the HCV core region, primers 954 
and 410 (Table 3.6) were used in the first round and 953 and 410 in the second round. For 
sequencing of the 5'UTR region, primers 940 and 211 (Table 3.4) were used. 
For each sequencing reaction, I ýtl DMSO, 2 ýd of reaction buffer, 10 ng of each of the 
appropriate primers in 2 [d, and 5 gI of either the fmal Dynabead suspension or the supernatant 
from the above PCR were mixed together in a 1.5 ml Eppendorf tube and incubated for 3 min 
at 60'C. After allowing the tube to cool to room temperature, it was transferred to an ice/water 
bath and DUSO was added to a final concentration of 10%. 2.5 gI of each of the four 
dideoxynucleotide (ddn) termination mix solutions (80 [tM dATP, dCTP, dGTP and HIP, 
supplemented with 8 [tM ddnTP in 50 mM NaCl) were pipetted into separate wells of a 96-well 
round bottomed microtitre plate and warmed to 37'C in a water bath. To the DNA sample in 
the Eppendorf tube was added I gI of 0.1% dithiothreitol (DT-0, I [d of labelling n-fix (dATP, 
dCTP, dGTP and dT-fP, 600 gM each), I gI a-["S]-dATP (approximately 20 ttCi, Amersham), 
and 2 units of T7 DNA polymerase (Promega) in I gI of TE buffer. After mixing, 3 gl of the 
DNA sample was then added to each of the four termination mixtures in the microtitre plate and 
incubation continued for 5 n-fin. Reactions were terminated by addition of 4 gl of 
95% formamide containing 20 mM EDTA, 0.05% Xylene and 0.05% bromophenol blue. 
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Polality Sequence (F-3) 
410 Core 410 to 391 ATGTACCCCATGAGGTCGGC 
954 Core 330 to 349 + ACGCCGGGGGT(AG)CATGGCCCA 
953 Core -21 to +3 + AGGTCTCGTAGACCGTGCACCATG 
955 Core 118 to 140 GCAGGGGCCCCAGGTTGGGTGTG 
242 NS5 8304 to 8275 GGCGGAATTCCTGGTCATAGCCTCCGTGAA 
555 NS5 8227 to 8208 CCACGACTAGATCATCTCCG 
243 NS5 7904 to 7934 + TGGGGATCCCGTATGATACCCGCTGCT17FGA 
554 NS5 7935 to 7958 + CTCAACCGTCACTGAACAGGACAT 
* Numbering from start of main open reading frame. 
The reaction products from the above were heated for 5 min at 90'C, allowed to cool, 
then electrophoresed in an 8% denaturing polyacrylamide gel containing 5% urea and 
0.02% NNN, N-tetratnethylethylenediamine (TENMD), in TBE buffer (890 m1\4 Tris-Borate, 
890 mM Boric acid, 20 mM EDTA) at 40-60 watts. The gel was then fixed with two changes 
of I litre of 5% acetic acid with 5% methanol, dried on a gel drying apparatus and 
autoradiographed for 3 days as above (Section 3.2.3.3). To detennine the genotype from 
sequence data, individual sequences were compared to the EMBL database using the BLAST 
alignment search program (Altschul and Lipman, 1990; Karlin and Altschul, 1990). 
Interpretation of results is discussed in Chapter 8. 
3.2.6 Hepatitis G vim detection 
Detection of hepatitis GBV-C genomic material in serum samples in the present study was 
kindly perfon-ned by Dr. Masashi Mizokami of Nagoya City University Medical School, Japan, 
using cDNA produced by reverse transcription vith the primers shoAAn in Table 3.8 and a 
hen-ý-nested PCR protocol very similar to that described above. Briefly, I ýd of the cDNA 
was amplified with 20 pmol each of the antisense primer NIUGRI and the sense primer G8 
(Table 3.8) in a mixture containing 200 [tM dNTPs, 10 mM Tris-HCI (pH 8.3), 50 mM KCI, 
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1.5 MM mgC12 and 0.001% gelatin, for 35 cycles of 94 OC for I min, 50 OC for I min and 
72 T for I min. A hemi-nested second round of PCR amplification was done by using I ýtl 
of the first round product with the sense primer G8 and antisense primer MUGR2 (Table 3.8). 
Ten ýtl of the second round product was then electrophoresed on a 2% agarose gel, stained 
with ethidium bromide and photographed. The expected size of the hemi-nested PCR 
products to be derived from GBV-C genornic RNA by this procedure is 140 bp. Two positive 
and two negative controls were included in each assay run. For confinnation, the 
amplification products were inserted into MI 3 phage vectors and three independent clones of 
each product were sequenced. 
Table 3.8 Details of ptimeis used for detection of hepatitis GB vinis 
Ptimer Polafity Sequence 
G8 + 5'-TATGGGCATGGAATACCCCT-3' 
MUGRI 5'-TCTII-FGATGATAGAACTGTC-3' 
N4UGR2 5-'TCCTTACCCCTA(G)TAATAGGC-3' 
3.2.7 Phylogenetic analysis 
The nucleotide sequences deten-nined from the sequencing procedure described above 
were fon-natted and analysed initially by programs available in the University of Wisconsin 
Genetics Computer Group (GCG) sequence analysis package, version 8.0 (Devereux et al. 
1984). All sequences were edited using the sequences editor, aligned by the PELEUP program 
and then formatted using the multiple sequence formatting (MSF) file in the GCG package. 
Distances between pairs of sequences were estimated using the DNADIST program of the 
PHYLIP version 3.4 package kindly provided by Dr. I Felsenstein (Felsenstein, 1991), using 
a model which allows for different rates of transition and transversion and different frequencies 
of the four nucleotides. Phylogenetic trees were constructed using the neighbour-joining 
algorithm with the NEIGH30R program. Equivalent phylogenetic relationships were 
determined by maximum likelihood analysis with the DNAML program and 2000 bootstrap 
replicates of neighbour-joh-iing trees v6th the SEQBOOT and CONSENSE programs, in the 
PHYLIP package. The rationale for phylogenetic analysis is discussed in Chapter 4. 
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3.2.8 liver histology 
f1istological examination of liver biopsies in the present study was kindly undertaken 
by Dr. Bernard Portmann, Consultant Histopathologist in the Institute of Liver Studies, Kings 
College Hospital, London, who reported on the degree of necroinflammatory activity and 
whether there was evidence of fibrosis or established cirrhosis. Necroinflanunatory activity 
was sen-fiquantitatively classified as follows: 
Inactive - inflammatory infiltrate, if present, mild and confined to portal tracts. 
Afild - moderate inflammatory inflitrate in portal tracts, vvith occasional foci in lobules, 
but with no hepatocellular necrosis. 
Moderiffe - dense inflammatory infiltrate in the majority of the portal tracts, with disruption of limiting plates in some and periportal piecemeal necrosis, but v6thout 
significant lobular activity or bridging necrosis. 
Severe - dense inflammatory infiltrate in all portal tracts, vith disruption of the lin-fiting 
plates in the majority and periportal piecemeal necrosis extending into lobules with 
bridging necrosis. 
However, because it is difficult to precisely defme disease activity on the basis of a 
single liver biopsy taken at one time point and because, in some instances, classification under 
these four categories would have led to small numbers of patients in some groups, in the 
present study patients were broadly classified as having either inactive/mild or moderate/severe 
disease for purposes of analysis. 
3.2.9 Statistical Analyses 
The methods for statistical treatment of data for phylogenetic analysis were 
incorporated within the computer program packages as described above (Section 3.2.7) and in 
Chapter 8. Statistical analyses of other data were performed by using non-parametric tests: 
the Mann-Wbitney U test for continuous variables, and the Chi-Square test with Yates' 
correction for small number for dichotomous variables. 
statistically significant when p<0.05 by two-tailed analysis. 
Ditlerences were considered 
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4.1 DiAcNosLs OF F1FPATnTS B AND D VIRUS kiFF-CnON 
Hepatitis B (IIBV) and Delta (HDV) virus infections are usually associated with the 
presence in serum of one or more of a wide range of viral proteins, antibodies and other 
specific markers of these viruses, and the rationale for selection of appropriate parameters for 
investigation of HBV and HDV infections is related to the serological events that non-nally 
follow exposure to these viruses - discussed in detail in Chapter I (Section 1.3.4). 
As noted in Cbapters 3 (Section 3.2.2.1 and 5 (Section 5.1.2), for economic reasons 
testing for HBV infection in Libya is undertaken using only the Wellcotest haemagglutination 
assay for HBsAg. This was one of the earliest tests to become commercially available and is 
generally regarded as relatively insensitive. Furthennore, since part of the purpose of the 
present study was to gather background infort-nation on the extent of previous exposure to the 
virus in this population, it was decided to screen all sera for the full range of markers available, 
using the automated Abbott IN4x system (Section 3.2.2.1). To obtain additional infonnation 
about the status of infection in HBsAg-positive subjects, HBV-DNA in serw-n samples from 
these individuals was sought using the Abbott molecular hybridization assay. At the time, this 
was a relatively new technique that had not been widely used and it was felt important to 
validate it. This was done by comparing it vvith an "in house" spot hybridization assay (see 
below). The commercial IIBV-DNA and its validation were kindly perfortned for the present 
study by Dr. Leila Pereira of the Institute of Liver Studies, Kings College Hospital, London. 
Since Delta virus infections almost invariably occur against a background of IIBV 
infection (Section 1.3.2), and suppression of HBV very rarely extends to complete 
disappearance of HBsAg, it was decided to screen for HDV only in subjects who were found 
to be HBsAg seropositive and to test initially only for total anti-HDAg antibodies (Section 
3.2.2.2). Any patients found to be positive for these antibodies would then be ftirther 
investigated by testing for IgM anti-HDag to determine NNhether they had current HDV 
infection. 
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4.1.1 - Validation of Commemial BBV-DNA Assay 
The spot hybridization assay for HBV-DNA described by (Fagan et al. 1985)was used, with 
some modifications, for validation of the commercial HBV-DNA assay. Double-stranded DNA 
was partially purified from 50 [d of serum from an HBV carrier by layering it on 600 pl of 
30% sucrose (in 0.0 1M Tris, 0.05 M NaCl, 0.002 M EDTA, 0.1% bovine serum albumin 
(BSA) and 0.1% mercaptoethanol) in 2 ml polycarbonate tubes, incubating overnight at 4'C 
and centrifuging at 25,000 rpm for 4.25 hours at 4'C. The resulting pellets, containing the 
DNA, were resuspended in 50 [d of a 10-fold strength (IOX) sodium citrate buffer (SSC: single 
strength (I X) = 0.15 M NaCI, 0.0 15 M Na-citrate) and incubated for 15 min at 3 70C. The 
DNA was then denatured by mixing 50 pI of the suspension with 100 pl of IM NaOH and 
incubating at room temperature for 10 min. 200 pl of this mixture was applied to a pre- 
determined spot on a pencil-draNNu grid on a Gene Screen Hybridization filter (Gene ScreenTm, 
Du Pont, USA), which had been pre-soaked in 2X SSC for 10 min at room temperature. The 
DNA was fixed to the filter by drying under gentle vacuum (-20 mmHg) on a 96-well manifold 
(Bethesda Research Labs, Cambridge, UK) and washed with 200 pl of 0.5 M Tris-HCI in 
3M NaCI (pH 7.4), containing two drops of 0.6% bromophenol blue (in 20% glycerol, 0.5% 
SDSI 0.2 M Tris, 0.005 M EDTA, 0.1 M Na-acetate, pH 8.2) for subsequent identification of 
the points of application of samples on the screen. The filter was then dried, first for I hour 
at room temperature and finally at 80'C for two hours. 
The dried membrane filters were pre-hybridized by incubating overnight in glass 
cylinders in a rotary oven at 42'C with 200 pI per cmý of membrane of 6X SSC containing 
50% fort-namide, 0.5% SDS5 10 ggln-A denatured salmon sperm DNA, 0.02% Ficoll, 
0.02% polyvinylpyrrolidone and 0.02% BSA. Hybridization was effected using 100 ýd of this 
solution/crný of membrane containing denatured 32p_labelled I-IBV-DNA and incubating at 420C 
overnight in the rotary oven. The membranes were washed twice for 5 min in 2X SSC at room 
temperature, twice for 30 min at 65'C in 2X SSC with 1% SDS, and finally for 30 min in 
0.1 X SSC at room temperature, then dried at room temperature and autoradiographed for 
48 hours at -70'C using Kodak X-Omat film to identify positive spots. To quantify the HBV- 
DNA in the samples, the filter grid squares were cut out, placed in counting vials containing 
4 ml water and 32 P radioactivity deten-nined by Cerenkov radiation counting (Scintran, BDFL 
Poole, Dorset, UK) in a TRI-CARB 460C/460CD counter (Packard Corp., USA). Results were 
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expressed in picograms of HBV-DNA by reference to a standard curve prepared using kno"n 
amounts of cloned HBV-DNA run in parallel. 
Sera from six patients (vvho were not part of the present study) that had been found to 
be positive by the commercial HBV-DNA assay were selected to represent a range of 
HBV-DNA concentrations and, together výith six randomly selected sera that were negative by 
this assay, were re-tested using the spot hybridization assay. The negative sera were all found 
to be negative also by the latter assay. Results from the two assays for the positive sera 
showed a good correlation (Fig. 4.1), although the slope of the regression line suggests that the 





pglml HBV-DNA by spot hybridization assay 
Figure 4.1 Compaiison between the spot hybfidization and conummial IHBV-DNA 
assays 
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4.2 DUCNons OF HEPATmS C VIRUS (HCV) kiFECnONS 
4.2.1 Fimyme-linked hmnunoassays (ELJNAs) for Anti-HCV Antibodies 
As noted in Cbapter I (Section 1.4.4), the reliability of the early tests for anti-HCV 
antibodies had been called into question. At the time that the present study was begun in 1992 
improved, second/third generation, anti-HCV antibody assays were beginning to become 
available but were quite costly. United Biomedical Inc. (UBI: Raritan, NJ, USA) had 
developed a series of enzyme immunoassays (ELISAs) based on synthetic peptides (Hosein et 
al. 1991): a screening assay using peptides corresponding to products of the core (c22) and 
NS3/NS4 regions of the HCV genorne (Cbapter 1, Fig. 1.7), and a series of supplemental 
assays employing the individual peptides derived from these and from the envelope, NS I and 
NS5 regions. The manufacturer very kindly offered to provide the assay kits for this research 
at no cost. 
A, r-% Apart from the considerable cost saving, the main advantage of employing the UBI 
system was that, by using synthetic peptides, it avoided problems of false-positivity due to 
antibodies in patients' sera that react with the fusion proteins used for the recombinant peptides 
(Ikeda et al. 1990) or with residual microbial proteins (from the microbial expression systems) 
that might have escaped purification of the recombinant antigens. An added advantage was 
that, perhaps because it employed synthetic peptides (or for other reasons not divulged by the 
manufacturer), it seemed to be a generally "cleaner" assay in that it had a very low cut-off to 
define positivity. With almost all ELISA plate readers, the linear range of optical density 
(OD) readings reaches a maximum at between 2.0 and 2.5 OD units. The UBI assay had a 
maximum cut-off of about 0.15 OD units and, consequently, positive/negative (P/N) ratios of 
12-20 were usually observed with strongly positive sera. In contrast, the other assays available 
at the time (the Ortho, Innotest, and Abbott systems) had cut-offs of 0.4 - 0.6 OD units, which 
gave maximum PN ratios of only 4-6. Thus, the UBI system allowed for much greater 
discrin-dnation between positivity and negativity, particularly with less strongly reactive 
samples. 
76 
For the above reasons, it was decided to use the UBI system throughout the present 
studies employing the screening assay for initial testing of sera and the ELISAs against the 
individual peptides as "confirmatory" tests. By way of validation, the UBI screening assay 
was compared with a second-generation Abbott HCV-EIA, based on recombinant c22 and c200 
PePtides (Chapter 1, Fig. 1.7). Sera from eight HCV-RNA seropositive patients with chronic 
hepatitis C and 10 sera from autoirnmune hepatitis patients with hypergammaglobulinaemia 
who were seronegative for HCV-RNA were tested simulataneously by the two assays. From 
Fig. 4.2 it can be seen that there was good agreement between the assays although, as noted 






S/CO Abbott assay 
Figure 4.2 Compadson between the United Biomedical Inc. (UBI) and Abbott anti-HCV 
antibody ELJLSAs. Results are shoAn as sample/cut-off (S/CO) ratios calculated 
from the observed optical densities (ODs) in relation to the manufacturers' 
recommended cut-offs for positivity (broken lines). HCV-RNA seropositive 
sera from patients with chronic hepatitis C are indicated by closed circles, while 
open circles show results for HCV-RNA negative sera from patients with 
autoimmme hepatitis and hypergammaglobulinaemia. 
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4.2.2 Polymeme Cbain Reaction (PCR) 
The development of the PCR process is one of the most important technical advances 
in molecular biology in the past decade (Scharf et al. 1986; Mullis and Faloona, 1987; Erlich, 
1989; Saiki et al. 1988). It is the only method NNhereby the very small amounts of circulating 
hepatitis C virus genomic material (HCV-RNA) can be detected which, as discussed in 
Chapter- I (Section 1.4.4), is necessary in order to distinguish between on-going and previous 
infections in patients with anti-HCV antibodies. 
Amplification by PCR enables production of sufficient material for separation by gel 
electrophoresis and visualization of a characteristic band under ultraviolet light after staining 
with ethidium bromide (Chapter 3, Section 3.2.3.2). For confirmation of a positive result, the 
electrophoresed product may be transferred to a nitrocellulose sheet (Southern blotting) and the 
band identified by probing with a radiolabelled or chemiluminescent nucleotide sequence 
corresponding to part of the HCV genome (see Section 3.2.3.3). Further confirmation may be 
obtained by sequencing the amplified product to ensure that its nucleotide sequence corresponds 
to that of HCV-RNA. The PCR process itself and these contirmatory procedures are 
exceedingly laborious. Sequencing of the amplified product from large ntunbers of sera is 
therefore almost never undertaken on a routine basis and even Southern blotting is usually 
perfortned as a control only on a proportion of samples under test. However, in the present 
study it was decided to confirm all PCR-positive results by Southern blotting and sequencing 
was also undertaken because of the need to obtain information about genotypes of the virus. 
The first step in the PCR procedure, as applied to the detection of HCV-RNA in serum, 
involves extraction of the total RNA in the specimen. Complementary DNA (cDNA) copies 
of all extracted RNA are then made, using an exogenous, reverse transcriptase. To detect 
cDNA copies that are specifically complementary to HCV-RNA, the cDNA product is 
arnplified through 30 to 60 cycles by use of a DNA polymerase and the appropriate mixture 
of individual nucleotides, together vvith a "primer" comprising a short nucleotide sequence 
corresponding to part of the HCV genome. In the present study, to mcrease specificity, the 
so-called "nested" PCR technique (Garson et al. 1990a; Romeo et al. 1993) was used, NAbereby 
w-nplification is perfon-ned in two stages with two separate pairs of primers: an "inner" and an 
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"outer" set, the nucleotide sequences of which correspond to parts of the highly conserved 
S-untranslated (5'UTR) segment of the HCV genome. 
Several laboratories around the world have been evaluating the ideal reagents and 
conditions for the development of a sensitive and specific PCR assay for HCV-RNA, and there 
are several n-finor (and a few major) variations between the different centres. In the present 
study, the procedure adopted represents an amalgam of conditions and reagents reported by the 
different centres to give optimal results. Firstly, for the initial extraction of RNA from serum 
samples, it was decided to use the commercially available guanidinium thiocyanate/phenol/ 
chlorofon-n reagent RNAzol' B produced by Biogenesis because it is a high quality reagent 
designed for simple RNA isolation. On mixing vvith an aqueous solution such as serum, it 
fornis a two-phase system. RNA complexes with the guanidinium and water and remains in 
the aqueous phase. Hydrophilic interactions of DNA and proteins are abolished and these 
components partition with the organic phase. Inclusion of a blue dye in the reagent facilitates 
aqueous/organic phase identification. The system allows for the isolation of all RNA species, 
including small RNAs, in a pure undegraded form protected from ribonucleases. An added 
advantage is that it is a one-step procedure that takes only about 1.5 hours to perform. 
The PCR technique used here allows for the detection of as few as 100 viral RNA 
molecules per ml of serw-n (see (Ulrich et al. 1993), and below). However, as with all PCR 
processes, this extreme sensitivity is also a major disadvantage because the risk of false 
positive results due to contamination of the samples is very high, and great care has to be taken 
to avoid this (Kwok and Higuchi, 1989). False positive reactions from carry-over of 
previously amplified DNA in reagents or on equipment, and from cross-contamination with true 
positive samples, are the main complications(Kwok and Higuchi, 1989). Contamination can also 
arise from foreign unamplified DNA (from sloughed skin cells or aerosols) entering the 
reaction vessel. In addition to the usual rules of common sense generally applied to molecular 
biological techniques, therefore, several specific precautions were taken in the present study 
to avoid these problems. Thus, the RNA extraction and amplification steps were performed 
in separate rooms, reagents were prepared in a PCR product-free environment, autoclaved, and 
stored in aliquots that were used only once, and cDNA samples were added last to each tube. 
Additionally, dedicated equipment and consurnables were set aside for all PCR work, with 
separate sets of automatic positive displacement pipettes and sterile pipette tips for each 
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procedure, and great care was taken not to allow tubes to become contaminated during insertion 
of the reagents. To detect cross-contamination, samples containing PCR mix without 
templates during the amplification process (negative controls) and two positive controls were 
run concurrently in each batch of assays. In addition, the positive controls were regularly 
checked by colleagues in the laboratory and every sample was tested at least twice to confirm 
the validity of the results. All PCRs were also carried out with the positive "assay controls" 
provided by Perkin-Ehner/Cetus, as a check that the assays were working properly. 
Several other precautions were taken to avoid erroneous results. To prevent direct 
interference with Taq polyrnerase by the reverse transcriptase after the cDNA synthesis from 
the extracted RNA, all cDNA products were heated at 98'C for 10 min to inactivate any 
residual reverse transcriptase prior to amplification. Amplification requires multiple, carefully 
controlled cycles of heating, to separate (melt) the double-stranded DNA to allow for copying 
of the two strands by the DNA polymerase, and cooling (to anneal the newly-synthesised 
strands). The temperatures range from ambient to nearly 100'C during the cycles and 
markedly influence the rates of reactions in the system. Thus, accurate temperature control is 
essential. To achieve this, the fully automatic Perkin-Elmer/Cetus DNA Thermal Cycler was 
used in the present studies. Reactions were carried out in 0.5 nil Polypropylene tubes placed 
in the wells of the thermal cycler heating block. The rate of heat transfer can be influenced 
by variations in thickness of the walls of tubes and of the air spaces between the tubes and 
the block. In the present study, tubes from a single supplier were used throughout (to ensure 
miifonnity of wall thickness) and were always carefully pressed do"n into the heating block 
to reduce the air space between the tube and the block in order to enhance efficient and 
reproducible heat transfer. 
Conventional three-temperature PCR protocols require heating the cDNA sample at 
92-97'C to denature double-stranded DNA into two single strands. Because of the high 
nw-nber of G/C bonds in the cDNA, melting at 97'C for the first five cycles is normally 
required to produce the single stranded template for the PCR reaction but, in subsequent cycles, 
a melting temperature of 94'C is used because the smaller PCR product usually melts 
completely at a lower temperature than the starting cDNA. The temperature is then reduced 
to 50'C to permit annealing of the target-specific primers onto the sIngle-stranded DNA. 
Finally, the temperature is raised again to 68'C (the optirnw-n reaction temperature for Taq 
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polymerase) to add complementary nucleotides and thereby extend the primers to produce two 
copies of the original target strands. In the present study, the initial five cycles at 97T was 
replaced by the "hot start" procedure involving a preliminary incubation at 850C for 10 min 
which, as suggested by (Erlich et al. 1991), is optimal for reducing formation of secondary 
structures and for denaturing any residual reverse transcriptase. The PCR was then repeated 
25 times in the first round with the outer primers (Chapter 3, Section 3.2.3.2). Then, I ýd of 
the resulting reaction product mixture was transferred to a second tube containing the inner 
primers and subjected to a ftuther 25 cycles for the second round of amplification. In our 
laboratories, it was found that the addition of more than I gl to the second round PCR reaction 
leads to the appearance of multiple non-specific bands in the product, which can reduce the 
sensitivity of the PCR 
The selection of the genomic sequences to be used in designing the primers for 
detection of HCV-RNA by PCR is also crucial. Such sequences must be well conserved in 
different HCV variants to ensure good sensitivity and, to avoid non-specificity, should not be 
present in other viruses. The non-translated segment comprising approximately 324 
nucleotides at the 5' end of the long open reading frame of the HCV genome has been found 
to be the region that best fulfils these requirements(Garson et al. 1990a; Okamoto et al. 1990). 
A munber of different primer sequences based on this region have been used in different 
laboratories but the ones chosen for the present study (detailed in Cbapter 3, Table 3.2) are 
reportedly the most sensitive and specific (Romeo et al. 1993; Ulrich et al. 1990; Garson et al. 
1991). 
As noted above, the PCR procedure used in the present studies is extremely sensitive. 
Theoretically, the nwnber of copies of the target sequence doubles with each cycle of the 
reaction. This could produce up to 10" - 10" copies of any HCV-RNA present in the 
specimen under test but, in practice, the yield with this protocol is only approximately 1012 
copies(lvinson, 1991; Sallie, 1993). There are several reasons for this apparent shortfall. 
Firstly, it is only after the third cycle that there is a doubling of the defmed sequence. 
Secondly, The DNA polymerase is only relatively heat stable (Gelfand and VVIfite, 1990) and 
repeated exposure to the high denaturating temperature progressively inactivates the enzyme, 
resulting in plateauing of the growth in copy numbers. Ajso, with successive cycles, there is 
a progressive decrease in the concentrations of the nucleotide substrates required for the new 
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strand synthesis and these become rate-limiting. Nevertheless, an amplification factor of 1012 
copies is more than adequate for most purposes. 
With protocols výfiere incubation times at each temperature are very short, e. g. < 30 
seconds, the sample temperature may not reach the optimum required for denaturation and 
annealing, and lower yields will be obtained. The timing of the synthesis step is one of the 
most critical. Too short a time will not allow complete synthesis of the new strand, whereas 
too long a time will encourage non-specific amplification. The incubation times used in the 
present study (35 sec for denaturation, 40 sec for annealing and 150 sec for extension) were 
determined by a process of trial and error to be the optimum times required for maximum yield 
of specific product under the conditions employed and with the primers used. 
Finally, during the course of this study, a number of techniques for quantitative 
measurement of HCV-RNA levels became available. These include the quantitative 
chemiluminescent PCR recently described by (VVhitby and Garson, 1995) and the branched 
DNA (bDNA) assay, which represents a new approach to detection of nucleic acid directly in 
clinical samples at physiological concentrations (Urdea et al. 1991; Alter et al. 1995). The latter 
has been applied to the detection of cytomegalovirus, HBV and YRV, and has been used by 
several investigators for monitoring viral load during antiviral treatment in chronic HCV 
infection but, while it gives good reproducibility, it seems to be less sensitive than standard 
PCR for detection of HCV in that it reportedly detects only 72% of PCR-positive samples(Lau 
et al. 1993). However, as it was felt that quantitation of HCV-RNA would add little to the 
present tindings, it was decided not to repeat the studies using these techniques. 
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4.3 DIAGNOSIS OF HEPATTM GB INFFE110N 
Tests for anti-GBV antibodies are not yet widely available. Therefore, in the present study, 
it was necessary to rely only on PCR to detect GBV genomic material in the sera of the 
subjects studied. Because of the close similarity between GBV-A and GBV-C (Chapter 1, 
Section 1.5), it was decided to use primers corresponding to sections of the 5'UTR region of 
GBV-C according to Yoshiba et al. (1995)as described in Chapter 3 (Section 3.2.6). 
4.4 GENOTYMG 
Traditionally, viruses have been classified according to serotypes. Attempts are being made 
to do this with HCV (Stuyver et al. 1993; Simmonds, et al. 1993c) and serological methods for 
HCV typing, based on the ability to distinguish antibodies elicited by infection with different 
genotypes (without using PCR-based methods), have been developed and have been used to 
detect antibodies against group-specific recombinant proteins in the putative NS4 (Bhattacheý ee 
et al. 1995; Kao et al. 1996) and NS5(Simmonds et al. 1993a) protein regions. However, there 
are not yet sufficient data to make global comparisons. Accordingly, the present study has 
relied only on genotyping for identifying HCV types in Libya and comparing these with types 
in other parts of the world. 
Methods for genotyping HCV are still evolving. Those that have been most widely used so 
far include restriction fragment length polymorphism (RFLP) analysis, type-specific probing 
(TSP), a reverse hybridization assay (line probe assay, LIPA) based on the highly conserved 
SUTP., and nucleotide sequencing. Each has a number of advantages and disadvantages. 
The LIPA allows for typing and subtyping of the most common genotypes (Stuyver et al. 
1993), but it has been suggested that about 8% of cases would be mistyped by this method 
(Maertens et al. 1993). The development of typing assays based on RFLP requires 
considerable amounts of comparative sequence data, because there is some intratypic sequence 
variability that may result in each genotype showing more than one electropherotype. For this 
reason, it is necessary to compare the electropherotypes obtained with different combinations 
of restriction endonucleases, but previous methods have not always proved reliable. For 
example, by comparing the electropherotypes produced after digestion with the restriction 
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enzyme combinations Haeffl-Rsd and ScrFl it is possible to identify HCV genotypes 1,2 and 
3 (McOn-fish et al. 1993) but, at the outset of the present study, it was fourid that type 4 
showed the same electrophoretic pattern as type I in this system. This was overcome by using 
Mva III-Hinf I instead of ScrH , as described by Davidson et al. (1995). 
The TSP method, first described by Okamoto et al (1992) using primers corresponding to 
sections of the core region (Chapter 3, Table 3.5), was devised for identifying genotypes I a, 
lb, 2a and 2b. Because RFLP does not allow for identification of sub-types of the virus, it 
was decided to apply Okamoto's method in the present study. In the first round of PCR a 
fragment of 276 bp is generated with a mixture of primers based on highly conserved 
sequences and the second round , with mixtures of subtype-specific primers generates subtype- 
specific amplification products(Okarnoto et al. 1992b). The best results are obtained when 
each HCV sub-type is separately amplified. However, a high number (sometimes up to 201/o) 
of apparent la and lb co-infections is very often found "hen using the nested sub-type primer 
132 (Chapter 3, Table 3.5). This primer is theoretically predicted to hybridize to many lb 
sequences. Normally, two mismatches lead to the difference between both sub-types at the 
primer 132 position. Due to non-specific priming of primer 132, it is possible to introduce 
a greater degree of apparent co-infections, and also a greater number of unidentified types. As 
discussed in Chapter 7 (Section 7.3), these problems were encountered in the present study 
and, indeed, it was found that a large number of the HCV-positive individuals could not be 
sub-typed by this method. The method was therefore modified as described in Chapter 3 
(Section 3.2.4.3), using primers kindly provided by Dr. Masashi Mizokami of Nagoya City 
University medical School, Japan. 
4.5 Sequencing and Phylogenetic analysis of HCV genotyM and GBV-C 
The "gold standard7' for genotyping is nucleotide sequence analysis. Although not usually 
considered practicable for large-scale typing of clinical samples, because it is so time 
consming and expensive in reagents, it was decided to undertake this for the present study 
because of the detailed infortnation required and to provide the possibility of investigating 
whether new genotypes exist in Libya. 
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Nucleotide sequence analysis has played a ftmdamental part in virological research. 
However, sequencing of the entire genome of a virus requires relatively large amounts of 
template DNA which are often available only by virus culture in vitro and cloning, and the 
dependence on virus culture and the time required to construct and screen libraries is a major 
impediment to this approach. The polymerase chain reaction (PCR), which allows for 
amplification of DNA specifically from any viral nucleotide sequence in clinical samples, is 
a useful alternative that eliminates the need for prior virus isolation and cloning. Its main 
limitation is its dependence on detailed sequence information to specify the primers needed for 
amplification. Consequently, most PCR studies have to rely on comparing large nwnbers of 
sequences over a relatively short region of the viral genome and construction of libraries and 
screening with cloned viral DNA is likely to remain the method of choice for large sequencing 
projects for the foreseeable future. 
Nucleotide sequencing of PCR products is carried out using the dideoxy (dd) 
termination method. The amplified product can be sequenced directly or it can first be cloned 
into a suitable plasmid or phage vector and sequenced from primers close to the cloning site. 
Sequencing of cloned DNA is not different from sequencing other types of recombinant DNA. 
Detailed protocols are described in Cbapter 3 (Section 3.2.5). This method has been used 
successfully on a wide variety of combinations of viral DNA and primers. Double stranded 
DNA (either the PCR product or its cloned derivative) is heat denatured in the presence of a 
single primer and strand synthesis is allowed to take place initially in the presence of 
unlabelled dGTP, dCTP and dTIP with a limiting concentration of radiolabelled dATP, 
followed by incubation in the presence of each ddNTP to allow termination. A primer that 
has a 3' base after annealing which is one base upstream from the variable site is annealed, and 
a single biotinylated or radiolabelled dNTP complementary to one or other of the sequence 
variants is added in the presence of DNA polymerase. Addition of a labelled nucleotide to 
the primer takes place if the target sequence matches, whereas little or no incorporation of label 
occurs if a different base is present. The primer can then be separated from unreacted dNTPs, 
and the partial transcripts formed in each of the four termination reactions (i. e. with ddGTP, 
ddATP, ddTTP, and ddCTP) sized, by electrophoresis on a high-resolution denaturing 
polyacrylamide gel to allow the nucleotide sequence to be read. Double-stranded sequencing 
reactions are readable from 10-20 bp downstream from the 3' base of the sequencing primers 
to about 250 bp. 
The nucleotide sequence data obtained by this method in the present study were 
subjected to phylogenetic analysis to determine the evolutionary relationships between the HCV 
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variants by using the various computer programs described in Chapter 3 (Section 3.2.7). At 
the outset, it was recognized that such analyses necessarily make a number of assumptions 
about the evolutionary process and that it is therefore advisable to seek concordance from a 
number of different methods in order to increase confidence in the results. Phylogenetic trees 
were inferred by using two different prograrns available in the PHYLIP package of Felsenstein 
(1993), DNAML and NEIGHBOR The DNAML program finds the tree of the highest 
likelihood (maximum likelihood tree) given a particular stochastic model of molecular evolution 
that has been shoAn to perform well in simulation studies (Saitou and Nei, 1987). The global 
(G) option was used in the present studies because this searches a greater proportion of all 
possible trees. The NEIGUBOR program clusters a matrix of nucleotide distances previously 
estimated using the DNADIST program (Section 3.2.7). The latter was set, using the D option, 
to use the stochastic model that underlies DNAML in order to estimate distances corrected for 
the probability of multiple substitutions. 
Nonetheless, the topology obtained by any of these procedures can be considered only an 
estimate of the phylogenetic relationships between groups ofvariants, and it is clearly important 
to know whether two groups on a tree are really distinct or NNhether their apparent separation 
falls within the error associated with estimating the tree. Most methods for estimating tree 
topologies do not give any information on the statistical significance of their structures. As 
in the present study, this is usually overcome by the use of a non-parametric statistical 
procedure known as "bootstrapping", which involves re-sampling the data on which the tree 
was based in order to generate a distribution of datasets from each of which a new tree can be 
detennined. The frequency with which particular branches are observed in the re-sampled 
datasets then allows for probability statements to be attached to them in the original tree. The 
maximwn likelihood approach has a number of advantages: it is based on an explicit model 
of sequence evolution; a probability statement can be associated with each inten-nodal segment, 
as mentioned above; and the complete nucleotide sequence information is used in the 
determination of the phylogeny. In all cases in the present study, the maximum likelihood and 
neighbour joining procedures produced congruent trees. 
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5.1 CONTROL SUBJFEfS 
5.1.1 Demographic, Clinical and Biochen-fical Charactedstics 
The 301 control subjects studied comprised 143 males and 158 females (median age 
42 years, range 10-78) consecutively recruited from centres in one of three cities in Libya: 156 
from Benghazi city, 115 from Tripoli and 30 from Sebha (Fig. 5.1). Seventy-six were unpaid 
volunteer donors attending the Red Crescent Blood Banks in these cities, who were not 
members of the medical or paramedical professions. They had no risk factors for viral 
hepatitis, i. e. no history of blood transfusions, drug misuse or contact with hepatitis, had not 
previously undergone surgery, did not admit to homosexuality. The remaining 225 comprised 
82 medical students, 69 hospital workers, and 74 subjects attending outpatients clinics 
(ear/nose/throat, dermatology, obstetrics and gynaecology, superficial traw-na) for minor 
conditions unrelated to liver disease, at the 7th October, Hawari, or AI-Jamahiya Hospitals in 
Benghazi city, or the Sebha General Hospital. These 225 also had none of the above risk 
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Figum 5.1 - NIap of Libya showing the thme locations fmm whem subjects wem mcruited 
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Each subject agreed to clinical examination immediately after giving blood. Although 
all professed to be healthy, six were found to have signs of underlying liver disease 
(Table 5.1). Two were clinically jaundiced vvith hepatosplenomegaly and elevated serum 
bilirubin concentrations and alanine (ALT) and aspartate (AST) aminotransferase activities. 
Two others had enlarged spleens on palpation (>16 cm below costal margin) with 
hepatornegaly and mildly elevated (! ý-10% above the upper normal limit) ALT and AST 
activities, and a ftirther two (vvith non-nal ALT and AST activities) had splenomegaly without 
hepatornegaly. Other signs of chronic liver disease (ascites, spider angiornata., or pahnar 
erythema) were not found in these six nor in any other subject. 
Table 5.1 Details of the six contml subjects with clinical signs of liver cfisease 
Subject nuinber 
1 2 3 4 5 6 
Age 36 45 52 51 48 45 
Sex m m F m F m 
Jaundice Yes Yes No No No No 
Hepatomegaly Yes Yes Yes Yes No No 
Splenomegaly Yes Yes Yes Yes Yes Yes 
Bilirubin, [tmol/I (< 20)* 44 36 10 7 6 7 
AST, ITJ/1 50)* 328 102 86 76 46 38 
ALT, IUI 50)* 254 132 74 94 42 28 
ILAllal! ae phosphatase, IU/I 120)* 155 125 101 90 65 75 
* Upper non-nal limits in brackets 
Overall, a surprisingly high number of these subjects had abnormal biochemical liver 
test results (Table 5.2). Fifty-eight (19.3%) had elevated senun bilirubin concentrations 
(mean±SD = 40.6±15.1 gmol/1) vvith raised activities of both ALT (254±135 RJ/1) and AST 
(369+121 IU/1), 10 of Ahom also had elevated serw-n alkaline phosphatase activities 
(239±75 W/1). A ftirther four subjects had elevated ALT (range 80-120 ItJ/1)) and 
AST (80-160 IU/I) activities with non-nal serwn bilirubin and alkaline phosphatase levels - 
making a total of 62 (20.6%) NNho had abnormal serw-n biochemical liver tests. In 22 subjects 
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these abnormalities were n-fild (! ý 10% above the upper normal limits) but in the remaining 40 
they were of sufficient magnitude (55482 IUI, median 128) to suggest significant underlying 
liver disease. Interestingly, abnonual liver test results occurred more frequently in housev6ves 
(27/120 == 22.51/o) than in females (5/38 = 13.2%) with other occupations, but this difference 
was not statistically significant (p > 0.3). However, subjects with AST and/or ALT activities 
> 10% above the upper nonnal limits were significantly older (p < 0.02) than those with 
abnonnal values of :! ý 10% above upper nonnal limits (Table 5.2). 
Table 5.2 Demographic infonnation on the 62 contwl subjects with abnonnal biochemical 
liver test msults. 
Number with elevated ALT or AST 
10% above UNL* > 10% above UNL* Percent vAth 
abnornial 
No. ALT AST ALT AST ALUAST 
Sex: 
Male 143 10 10 20 27 25.9% 
Female 158 12 12 20 13 20.3% 
Occupation: 
Housewives 120 10 11 16 16 22.5% 
Students 82 8 9 5 5 17.1% 
Office workers 35 2 2 4 4 17.1% 
Manual workers 34 3 3 3 3 17.6% 
Others 30 1 1 2 3 13.3% 
Devated senun: 
Bifirubin 58 40 38 18 20 100% 
Alk. Phos. 10 3 2 7 8 100% 
Age: median years (range) 26(16-36) 48(30-72) 
* LJNL = upper non-nal limit (50 IUI) 
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5.1.2 Results of fkpafitis B Scmening 
Although all of the blood donors had been found to be seronegative for MBsAg by 
haernagglutination (Wellcotest: Wellcome Diagnostics, Beckenham, Kent) NAben tested at the 
Blood Banks in Libya, at the outset of the present study it was considered important to re-test 
all sera for HBsAg to confkm this and to test for additional HBV markers to obtain 
inforniation on the extent of previous exposure to I-EBV. Screening of the 301 control subjects 
by automated ELISA (Chapter 3) revealed that 106 (35.2%) had at least one marker of hepatitis 
B Virus (HBV) infection (Table 5.3). Seven had anti-HBc as the only marker of exposure to 
IIBV, one had only anti-HBs and 62 were seropostive for both anti-HBc and anti-HBs. The 
remaining 35 (11.61/o) were seropositive for HBsAg and anti-HBC (Table 5.3). None of the 
HBsAg-positive subjects had circulating antibodies against the hepatitis delta virus (HDV). 
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Medical students 82 10 20 17 30 (3 6.6%) 
Outpatients 74 1 11 20 19 31 (41.9%) 
Totals 301 35 (11.6%) 70 (23.6%) 63 (20.9%) 1 106(35.2%) 
There was no significant difference in frequency of seropositivity for FEBsAg or other 
HBV markers between the different groups of control sub ects. From these data, it appears that 
ni-I about 35% of the general Libyan population may have been exposed to HBV. 
Eleven of the 35 HBsAg-positive subjects were positive for 'e' antigen (HBeAg) and 
I-N. - negative for anti-HBe. One of these had ongoing active viral replication as indicated by a 
serw-n HBV-DNA of 205 pg/n-fl (Fig. 5.2). A finiher seven of these 35 had both I]BeAg and 
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anti-HBe (three being also positive for UBV-DNA at 175 -2 10 pgýnl), and six were anti-HBe 
positive vithout HBeAg. The remaining II IlBsAg-positive subjects were seronegative for 
IHBeAg, anti-HBe and IIBV-DNA. 
T= 
r,. BsAg positive 
35 
18 17 
Positive HBeAg Negative 
C76 
11 c 
Positive Negative Anti-HBe Positive Negative 
HBV-DNA 
00 positive 
Figum 5.2 - Details of hepatitis B viral murkets in the 35 H%Ag-positive subjects. 
Three of the FEBsAg-positive subjects were among the six Aith clinical signs of liver 
disease, including the two with j aundice (Subjects I and 2, Table 5.1). The latter two were 
from Benghazi (one a manual worker, the other an office worker) and the third (Subject 4, 
Table 5.1) was a blood donor from Tripoli. The other three subjects with clinical signs 
(Subjects 3,5 and 6) were seropositive for anti-HBs and anti-HBc. 
There were no significant differences (p> 0.1) in the frequencies of UBsAg 
seropositivity between subjects of different occupations or from the different centres but 
sub . ects from Sebha had a higher rate of exposure to HBV, overall, than those from Benghazi 9 
or Tripoli (Table 5.4). 
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Table 5.4 Dishibution of hepatitis B virus nuflwts between subjects fmm the dime cities- 
XID 
ImRsAg negative Total positive 
Blood bank 




for any lHBV 
madwr 
Benghazi 156 18 (11.6%) 32 (2 0.5 O/o) 30 (19.2%) 50 (3 2.1 O/o) 
Sebha 30 4 (13.3%) 12 (40.0%)* 12 (40.0%)' 16 (53.3%)* 
Tripoli 115 13 (11.3%) 27 (2 3.5 O/o) 20 (17.4%) 40 (34.81/o) 
Totals 301 35 (11.6%) 71 (23.6%) 63 (20.9%) 106 (35.2%) 
Significantly (p < 0.05) higher frequency than in subjects from Benghazi but not significantly 
different (0.1 <p>0.05) from those from Tripoli. 
t Significantly higher frequency than in subjects both from Benghazi (p < 0.025) and 
Tiýpoli (p < 0.02). 
All of the 35 HBsAg positive subjects had abnonnal serurn aminotransferases, with 13 
(including the four UBV-DNA positive cases) having ALT and/or AST activities > tvAce the 
upper normal limits (Fig. 5.3). Elevated ALT and AST activities > t"4ce upper normal limit 
were found in 32 of the 63 anti-I-EBs positive subjects and in four of the eight who tested 
positive for anti-HBc alone. 
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Figum 5.3 Alanine aminotransferase values in mlation to UBV nzuiwr 
status in the 106 subjects with BBV nwiwis. 
5.1.3 Resudts of Hepatitis C Scmening 
Eighteen (61/o) of the 301 subjects were found to be anti-HCV positive on initial 
screening. These comprised five blood donors, three students, three hospital workers and 
seven outpatients, and included the three HBsAg-negative subjects with clinical signs of liver 
disease (Sections 5.1.1 and 5.1.2). Sixteen (88.9%) of the 18 were positive for antibodies 
against at least one of the individual HCV peptides (Table 5.6), with 15 having antibodies 
against core, II against envelope, and 10 each against NS 1, NS3NS4 and NS5. Two subjects 
did not react against any of the five peptides despite being seropositive in the screening assay. 
Twelve (66.61/o) of the 18 had circulating HCV-RNA, including three of the five anti-HCV 
positive blood donors. All 18 were seronegative for HBsAg, but seven were positive for anti- 
I]Bc and five for anti-IlBs. 
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Table 5.5 Pmfiles of senun anfibodes against imfiviclual HCV pepfides and of HCV-RNA 
in the 18 subjects who wem sempositive for anti-HCV in the scmening assay. 
No. Age (y) Sex 
Antibodies against the diffemnt HCV peptides indicated 
com env NS1 NS3/4 NS5 HCV-RNA 
1 23 m ++000 0 
2 24 F +0++0 + 
3 25 m +++0+ + 
4 27 F 00000 0 
5 33 m +++0+ 0 
6 34 F +0000 0 
7 35 F +++++ + 
8 35 m +0+++ + 
9 35 F +0000 0 
10 39 F +0++0 + 
11 43 F ++0++ + 
12 48 F +++++ + 
13 51 m +++++ + 
14 55 m ++00+ + 
15 56 m ++++0 + 
16 58 m 0+0++ 0 
17 58 m +++++ + 
18 65 m 00000 + 
TOTALS 15 11 10 10 10 12 
Fourteen of the 18 anti-HCV positive subjects had elevated serLun aminotransferase 
activities (means±SD ALT = 192±95, AST = 186±67). The four subjects with nonml AST 
and ALT values included the three HCV-RNA positive blood donors (Table 5.6). Together 
with the 35 I]BsAg-positive subjects, these 14 accounted for 49 of the 62 control subjects v6th 
abnonnal biochen&al liver tests (Section 5.1.1). The renmining 13, NNho were seronegative 
for HBsAg and anti-HCV but Positive for anti-HBs and anti-I]Bc, were tested for HCV-RNA 
by PCR and three were found to have circulating HCV-RNA. In total, therefore, 21 (7.0%) 
of the 301 control subjects were found to be seropositive for either anti-HCV or HCV-RNA, 
or both. 
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Table 5.6 Requency of hepatitis C viral (HCV) muhets in the cliffemnt gmups of cOntmI 
subjects. 
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Medical students 82 2 1 1 4(4.9%) 
Outpatients 74 5 2 2 9(12.2%) 
Totals 301 12 6 3 21(7.0%) 
* Only the 13 patients with elevated serum aminotransferases were tested for HCV-RNA 
Ihe highest frequency (12.2%) of seropositivity for HCV nmrkers was found in the 
outpatients but this was not statistically significantly different (p > 0.2) from the frequencies 
in the other groups. The frequency of seropositivity for both anti-HCV and HCV-RNA 
increased steadily vvith age (to 12.8% and 10.3% for anti-HCV and HCV-RNA respectively) 
v, ith none of the 49 subjects under the age of 20 years being found positive (Fig. 5.4), but 
there was no statistically significant difference between the sexes, nor in the prevalence of 










Figum 5.4 Age-mlated pmvalence of anti-HCV and HCV-RNA in the 
266 IHBsAg-negative contml subjects. 








Total positive for 
any HCV maiiker 
Benghazi 156 10(6.41/o) 13 13 (8.3%) 
Sebha 30 l(3.3%) I 1 (3.3%) 
Tripoli 115 7 (6.1%) 1 7 (6.1%) 
Totals 301 18(6.0%) 15 (5.0%) 21(7.0%) 
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5.2 HMý2vmmLysrs PATuivrs 
5.2.1 Demographic, Clinical and Biochemical Char-actefistics 
Serum samples were obtained from 36 patients (19 males, 17 females; median age 45, 
range 25-75 years) vvith chronic renal failure at Hawari Hospital in Benghazi, "ho had been treated 
v6th haemodialysis for more than 4 years (range 4-12 years, median 8) and had received multiple 
blood transfusions (mean±SD 210 ± 120 units), mainly from Libyan donors. The causes of the 
chronic renal failure were: chronic glomerulonephritis in 25 patients, diabetic nephropathy in nine 
and polycystic kidney in two. Nineteen (52.8%) had abnormal serw-n ALT and/or AST activities 
(mean±SD ALT = 193±77, AST = 183±8 1). Eighteen of these 19 also had elevated serum 
alkaline phosphatase activities (204±69 IU/1), of "hom seven had elevated bilirubin concentrations 
(33±8 ), and prothrombin time was also prolonged in two. The seven with elevated serum 
bilirubin were clinically jaundiced, v6th hepatomegaly in six and splenomegaly in three. 
Hepatomegaly was found in two (with splenornegaly in one) other patients vAth non-nal 
biochemical liver tests. None of the patients had ascites or any cutaneous stigmata of liver 
disease. 
5.2.2 Results of IIIBV Scmening in Haemodialysis Patients 
Thirty (83.3%) of the 36 patients were seropositive for anti-HBc antibodies (Fig. 5.5). 
This was a significantly higher apparent rate of exposure to the vn-us than in the control subjects 
(, V-- 28.96, p< 0.0001). There was also a significantly higher (p < 0.001) rate of chronic HBV 
infection in the renal dialysis patients, with 12 (40%) of the 36 cases being seropositive for 
HBsAg. None of these 12 was seropositive for I]BeAg but seven had anti-HBe antibodies, of 
NNbom. three were positive for serw-n HBV-DNA (at 5,24 and 36 pg/ml). Of the 18 I]BsAg- 
negative patients vvith anti-HBc, nine were positive for anti-flBs (Fig. 5.5) but all were negative 
for anti-HBe and IIBV-DNA. None of the patients had circulating antibodies against the hepatitis 
Delta virus (HDV). Thirteen of the 19 patients vvith abnormal biochemical liver tests had markers 






Positive ý HBsAg ý Negative 
Negative Positive ý Anti-FEBs ý Positive Negative 
36 5 




Figum 5.5 Details of hepatitis B vinis semm nudwis in the 36 haemodialysis patients 
Table 5.8 Details of the 13 haemocNalysis patients with abnonnal biochemical livertests who had 
senun nudwis of BBV exposum 
Patient number 
1 2 3 4 5 6 7 8 9 10 11 12 13 
Age 25 38 45 26 39 49 52 31 62 42 55 75 48 
Sex M F M F F M M F M F M M F 
Jaundice + + + + + + + 
Hepatomegaly + + + + 
Splenornegaly + + + - - - - - - - - - 
ALT 80 90 130 1 210 190 290 1 350 160 170 1 190 250 130 150 
AST 65 75 110 260 240 150 180 290 210 230 180 90 310 
Bilirubin 25 31 41 28 45 34 25 18 10 6 13 9 12 
Alk. phos. 135 180 145 210 235 165 178 198 324 126 180 210 360 
Anti-HBc + + + + + + + + + + + + + 
HBsAg + + + + + + + + + + + + 
Anti-HBe + + + + + + 
Ant -HBs + + + + + + + + + 
HBV-DNA + I -I - + +I - - - - I- I- 
* Non-nal upper limits were 50 IUI for ALT and AST, 120 IUI for alkaline phospatase, and 17 Pmol/I for bilirubin. 
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5.2.3 Results of HCV Scmening in Haemodialysis, Patients 
Six (16.7%) of the 36 haemodialysis patients were positive for anti-HCV by the screening 
assay. This was a significantly higher apparent rate of exposure to the virus than in the control 
subjects (V = 4.05 p<0.05). All six were found to be positive for HCV-RNA by PCR and 
for antibodies against at least two of the individual HCV peptides (Table 5.9). None of the 
patients was jaundiced and all had normal serum bilirubin concentrations, but four (patients 2, 
3ý 4 and 6, Table 5.9) had abnormal serw-n ALT (260,425,380 and 120 IUA, respectively) and 
AST (180,385,415 and 160 IU/1) activities. These four were all seropositive for anti-HBc but 
had no other markers of I]BV infection. All four had hepatomegaly and one also had an 
enlarged spleen. The remaining two patients had normal serum biochemical liver tests and no 
markers of I]BV infection, but one had hepatomegaly and another had splenomegaly. Overall, 
therefore, 32 (88.9%) of the 36 haemodialysis patients had evidence of exposure to IIBV and/or 
HCV, with 18 (50%) having current infections with either hepatitis B (Section 5.2.2) or C 
viruses. 
Table 5.9 HCV serology in the six anti-HCV positive haemoclialysis patients 
No. Age (y) Sex 
Antibodies against the different peptides indicated 
core env NSI NS3/4 NS5 HCV-RNA 
1 30 m ++000 + 
2 32 F +++++ + 
3 30 m +++++ + 
4 35 m +00++ + 
5 52 m ++0+0 + 
6 43 F +++++ + 
TOTALS 65354 6 
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5.3 PATugvis YmH aRmc livER DisEAsE 
5.3.1 Demogra*c, Clinical and Biochemical Char-actelistics 
Sixteen patients with chronic liver disease (9 males, 7 females; median age 45 
years, range 35-62) with no history of excessive alcohol consumption or risk factors for 
viral hepatitis (intravenous drug use, tattooing, blood transfusion, surgery, or history of 
homosexuality) were recruited from the hospitals in Tripoli and Benghazi (Section 5.1.1). 
They had all tested negative for HBsAg by haernagglutination (Wellcotest) and had no 
evidence of schistosorniasis or other parasitic infections. The working diagnosis in these 
cases was chronic non-A, non-B viral hepatitis. All had had abnormal biochemical liver 
tests together with one or more of the following signs and symptoms for more than 6 
months (in the absence of raised jugular venous pressure): j aundice, ascites, hepatomegaly, 
splenornegaly, spider angiornata, and palmar erythema (Table 5.11). 
At the time of sampling, all 16 had elevated serum ALT activities (mean±SD = 
329±124 IU/1), and 15 also had raised AST activities (450±180 IU/1), with abnormal 
prothrombin times (> 13 sec). Fourteen had raised serum bilirubin concentrations (61±50 
gmol/1), with elevated alkaline phosphatase activities (245±1 10 IUA) in nine. Twelve had 
abnormally low serum albumin concentrations (25.0±4.0 g/1). However, none of the 
patients had a flapping tremor, or other evidence of incipient or overt hepatic 
encephalopathy. 
Liver biopsies were available for all patients and were reviewed for the present 
study (Chapter 3, Section 3-2.8). Six patients were classified as having inactive disease, 
with minimal portal inflammation and at most only occasional foci of necrosis with mild 
fibrosis and well preserved architecture (Table 5.10). Seven patients had moderate fibrosis: 
five with mild and two with moderate necroinflammatory activity. Re remaining three 
patients had cirrhosis, one inactive and two with severe periportal hepatitis. 
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Table 5.10 Clinical, biochetnical and histological data on the 16 patients with chronic 
liver disease 
Iffistological activity * 
Inactive NEW Nioderate Sevem Total 
M/F 4/3 3/2 1/1 1/1 16 
Jaundice 5 4 2 2 13 
Hepatornegaly 6 5 2 2 15 
Splenornegaly 1 1 2 4 
Ascites 2 2 2 6 
Spider angiornata - - I I 










































Cirrhosis 2 3 
* Necroinflammatory activity as defined in Chapter 3 (Section 3.2.8) 
5.3.2 Resudts of Scmening Chmnic Liver Disease Patients for lkpatitis B and C 
Ten of the 16 patients were found to be seropositive for anti-HBc, four of Mom were 
HBsAg-positive and the remaining six all had anti-HBs. All were seronegative for anti-I]Be 
antibodies. None had evidence of active viral replication, as indicated by seronegativity for 
both I-EBV-DNA and HBe-Ag, and none had anti-HDV antibodies. 
Ten patients were seropositive for anti-HCV on initial screening and all 10 were also 
positive for HCV-RNA by PCR- All 10 also had antibodies against at least one of the 
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individual HCVpeptides (Table 5.11). None of these 10 was positive for HBsAg but four had 
anti-HBc and anti-HBs. Overall, therefore, 14 of the 16 patients had chronic infections with 
I]BV (flBsAg positive, 4 patients) or HCV. The remaining two patients (both anti-I]Bs 
positive) probably had chronic hepatitis B but appeared to have cleared the virus, at least from 
their blood. 
Table 5.11 HCV serology in the ten anti-HCV positive chmnic liver clisease patients 
No. Age (y) Sex 
HCV 
Screen 
Antibodies against the different HCV peptides indicated 
com env NSI NS3/4 NS5 HCV-RNA 
1 56 F + 0+0+0 + 
2 46 F + +0+++ + 
3 62 m + +++0+ + 
4 35 m + 000++ + 
5 48 m + +00+0 + 
6 43 F + +++++ + 
7 40 F + 0++0+ + 
8 37 m + +000+ + 
9 49 F + +0+++ + 
10 38 m + ++000 + 
TOTALS 10 75567 10 
* Patients positive for anti-HBc and anti-HBs 
5.4 SCREENING FM FlFrATrnS GBV-C VIRUS IN ]LIBYAN SUBJECrS 
Sera from all of the 74 control subjects NNho had elevated serum an-finotransferases 
(Table 5.2), all of the 36 haemodialysis patients and the 16 patients with chronic liver disease 
were tested by PCR for evidence of infection with the GBV-C virus (Cbapter 3, Section 3.2.6). 
None of the control subjects or patients with chronic liver disease were found to be positive. 
GBV-C genon-fic material was, however, detected in sera from four of the haemodialysis 
patients. Two of these (patients 2 and 4, Table 5.9) had chronic HCV infection. The other 
two were seronegative for HBsAg and anti-HCV, and had normal biochemical liver tests with 
no clinical evidence of liver disease. 
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5.5 DLsmssioN 
The above results indicate that there is a high rate of exposure to the hepatitis B and C 
viruses among the Libyan population at large. Overall, 112 (37.2%) of the 301 control subjects 
had at least one serological marker of fMV or HCV. The proportion exposed to HCV may, 
however, be an underestimate because testing for HCV-RNA in the present study was confined 
to serum of subjects NNho were anti-HCV positive and/or had abnormal biochemical liver tests. 
There is evidence that HCV infected individuals may remain seronegative for anti-HCV and 
HCV-RNA while harbouring the virus in their livers or peripheral blood mononuclear cells 
(Pereira et al. 1995; Schmidt et al. 1995), and that up to 20% of anti-HCV negative blood donors 
with normal serw-n aminotransferases whose blood can be implicated in post-transfusion hepatitis 
may be HCV-RNA seropositive (Villa et al. 1991). 
Significantly, seven of the professedly healthy blood donors were I]BV carriers (HBsAg 
seropositive) and a ftwther three had current HCV infection (HCV-RNA positive). Thus, 13.2% 
of the blood donor population was actively infected v6th one or other of these viruses. This 
might account for the very high incidence of exposure to HBV and HCV among the 
haemodialysis patients studied here, v6th 30 of the 36 patients having at least one IIBV marker 
and a ftwther two having chronic HCV infection v6thout IIBV markers, i. e. a total of 88.9% who 
had been exposed to either or both viruses. 
For economic reasons screening of donated blood in Libya has involved testing only for 
HBsAg and only by using the Wellcotest haemagglutination assay. The present findings 
indicate that this approach is inadequate for eliminating the risk of transmission of IIBV via 
blood transfusion. Had serum aminotransferase activities been used as a surrogate marker, the 
seven HBsAg-positive blood donors would have been identified, since all had elevated AST and 
ALT activities, but this would not have excluded the three HCV-RNA positive blood donors (all 
of whom had non-nal aminotransferases). One additional control subject who, was seropositive 
for HCV-RNA also had non-nal AST and ALT values, making a total of four (22%) of the 18 
anti-HCV positive subjects "ho had chronic HCV infection vvith normal biochemical liver tests. 
This is in keeping with previous reports that the use of surrogate markers would not detect 
20-50% of blood donations involved in transmission of non-A, non-B hepatitis(Polesky and 
Hanson, 1989) or, more specifically, of HCV(van der Poel, 1994; Villa et al. 1991; Garson et 
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al. 1990a) and that up to 70% of patients vith chronic hepatitis C may have persistently normal 
serum aminotransferases (Esteban et al. 1991; Alberti et al. 1992; McGuinness et al. 1993; 
Romeo et al. 1993; Shindo et al. 1995; Silini et al. 1995). 
It is noteworthy also that there were ten of the control subjects with abnormal 
biochemical liver tests výho, although seropositive for anti-I]Bc and anti-HBS, did not have any 
markers of ongoing HBV or HCV infection. All were apparently healthy with no clinical signs 
of liver disease. As screening for hepatitis A (HAV) and E (IIEV) viruses was not included 
in the design of this study these might have been cases of sub-clinical infection with one or other 
of these viruses. On the other hand, detailed investigations to exclude other liver diseases such 
as autoinimune hepatitis, Wilson' s disease and haemochromatosis were not undertaken and it is 
possible that they may have been asymptomatic cases of some such disorder. 
The high rate of exposure to IJIBV (35.2%) and high carriage rate of the virus (11.6% 
HBsAg-positive) observed in the present study is in keeping with reports of the prevalence of 
HBV in areas with inten-nediate-high endemicity (Chapter 1, Section 1.3.3) and is comparable 
to the HBsAg positive rate of 16.4% recently reported for Egypt (Waked et al. 1995). 
Interestingly, none of the control subjects or patients studied was found to have circulating 
antibodies against the delta virus (HDV), which is in contrast with the frequencies of 6-27% 
anti-HDV seropositivity reported for populations studied in Ethiopia and Cameroon (Rapicetta 
et al. 1988; Ndumbe, 1991). The reason for this difference is unclear, but there is very little 
intravenous drug abuse in Libya (see Cbapter 1, Section 1.3.3). However, it indicates that 
failure to detect 1]BV-DNA in nine of the HBsAg positive subjects in the present study was not 
due to suppression of HBV replication by HDV (Chapter 1, Sections 1.3.2 and 1.3.4). 
The frequency of exposure to HCV in the non-nal Libyan population (7.0%) documented 
here is more than twice that (3.0%) which has been reported (Coursaget et al. 1990a) for the 
neighbouring country of Tunisia to the north-west (Fig. 5.1) but much lower than that (14-24%) 
reported for Libya! s eastern neighbour, Egypt(Darwish et al. 1992; Kamel et al. 1992; Waked 
et al. 1995), and is more in line with the prevalence (6.4-14.5%) of HCV found in other African 
countries (Darwish et al. 1993; Ngatchu et al. 1992; Delaporte et al. 1993; Mets et al. 1993; 
Waked et al. 1995). Among the control subjects in the present study, no significant difference 
was noted in the frequency of anti-HCV or HCV-RNA positivity between blood donors and 
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hospital workers or medical students, who might have been considered more "at risk". Since 
none of these subjects had any other kno, "n risk factors for viral hepatitis, all of the cases of 
HCV exposure documented in the control subjects therefore seem to be instances of "sporadic" 
infection (Cbapter 1, Section 1.4.2). It is noteworthy also, that these sporadic infections appear 
to be acquired either many years ago or later in life, since none of the 49 control subjects in the 
present study who were under the age of 20 years was found to be anti-HCV positive. This is 
in agreement with other reports that the seroprevalence of HCV markers increases with age 
(Stevens et al. 1990). 
Screening for antibodies against the individual HCV peptides provided little additional 
information over and above that acquired from results of the anti-HCV screening assay and PCR 
for HCV-RNA. All but two of the 34 control sub ects and patients who were anti-HCV positive 
by the screening assay also had antibodies reacting with at least one of the five HCV peptides 
tested and 30 reacted with two or more. Antibodies against the HCV core peptide were found 
most frequently (in 28 of the 34) and anti-NS I antibodies least frequently (18/34), but there was 
no particular correlation between the various patterns of reactivity and any of the parameters 
investigated. Of the two subjects (both in the control group) -, Ahose sera gave positive reactions 
in the anti-HCV screening assay but did not react against any of the peptides, one was 
HCV-RNA seropositive and the other was seronegative. In this latter patient, positivity in the 
screening assay may have been a false-postive result. Alternatively she may have had a previous 
acute (or subacute) infection, for anti-HCV antibodies have been sho'"n to persist for six to 12 
months after recovery in the majority (90%) of patients with acute hepatitis C and for up to 10 
years in about 15% (Dittmam et al. 1991; Barrera et al. 1995). This might also be the case in 
the other five anti-HCV positive control sub ects who were HCV-RNA seronegative. However, j 
interpretation of these results is very difficult because the viraen-fia in asymptornatic infections 
may fluctuate (Romeo et al. 1993); Bruno et al, 1994; (Myhre et al. 1994; Barrera et al. 1995; 
Blajchman et al. 1995) and, as noted above, patients can be seronegative for HCV-RNA while 
still harbouring the virus in their livers or at extrahepatic sites (Koskinas et al. 1995; Saleh et 
al. 1994b; Pereira et al. 1995; Schmidt et al. 1995). 
It is interesting to note that in the present study chronic I-1BV and HCV i ections nfi 
appeared to be mutually exclusive, in that although 24 of the 37 control subjects and patients 
with evidence of HCV exposure (anti-HCV or/and HCV-RNA positive) had anti-1113c and 12 had 
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anti-HBs antibodies, none was HBsAg seropositive. HBV/HCV co-infections have been widely 
reported in patients with chronic liver disease (Fong et al. 1991; Porchon et al. 1992; Liaw et 
al. 1994; Villa et al. 1995) or hepatocellular carcinoma (Paterlini et al. 1993; Shiratori et al. 
1995), and such patients tend to have greater severity of liver disease than those infected with 
only one of these viruses. However, considering that some of the risk factors for acquisition 
are sirrý lar for both viruses, overall such co-infections seem to be relatively rare (about 10- 1 5/o) 
(Porchon et al. 1992; Esteban, 1993; Liaw, 1995). Earlier studies in chimpanzees vvith chronic 
HBV had sho-An that superinfection with non-A, non-B (presumably Q virus was accompanied 
by a marked reduction in serum HBsAg titres (Bradley et al. 1983). This has since been 
confmned in chronic hepatitis B patients with acute HCV superinfections. In such cases, there 
is a gradual decrease in serum HBV-DNA with eventual HBeAg/anti-HBe seroconversion and, 
in some cases, eventual disappearance of I1BsAg (Liaw et al. 1994; Liaw et al. 199 1; Pontisso 
et al. 1993);. It has been suggested that this may be due to suppresion of HBV replication by 
HCV (Fong et al. 1991; Liaw et al. 1994). The mechanisms by which HCV may achieve this 
are not yet clear but a cotransfection study demonstrating suppression of HBV replication by 
HCV in a human hepatorna (Huh-7) cell line has suggested that the processes of transcription 
and encapsidation of HBV pregenomic RNA are involved and that the HCV core protein may 
have a gene-regulatory ftmction (Shih et al. 1993). Unforunately, it is impossible to say NNhether 
these considerations apply in the present study because the various groups of subjects were 
investigated at only one time point and Mether some were cases of HCV superinfection on a 
background of chronic hepatitis B, with HCV-induced clearance of HBV, cannot be determined. 
Finally, it is also interesting to note that GB virus infection (at least in so far as reflected 
in seropositivity for GBV-C genornic material) seems to be very rare in the Libyan population. 
Of the 126 sera tested, only four (3.2%) were positive for GBV-C by PCR and these four were 
all multiply transfused haemodialysis patients. This contrasts with findings elseNNhere in Affica 
that nearly 30% of subjects tested had evidence of exposure to the GBV viruses on the basis of 
seropositivity for anti-GBV antibodies(Zuckerman, 1995). 
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CHAPTER 6 
IHEPATT11N C VIRUS CENGINPES 
IN LIBYA AND EISEVVHERIE 
6.1 SUBEUS 
6.1.1 Biochemical and I-Estological Data 
6.1.2 Screening for Hepatitis GB Virus Infection in the Non-Libyan Subjects 
6.2 GENOTYMG OF HCV BY RESTWCnON PRACNENT UNGHI POLYNmPmm 




Genotyping of the hepatitis C virus was perfonned in 25 of the 31 Libyan subjects NNho 
had been found to be seropositive for HCV-RNA, These comprised the 15 control subjects and 
the 10 NNho had been hospitalised vivith chronic liver disease who were found to be carrying the 
virus (Chapter 5). The study was confmed to these 25 because none had had any risk factors 
for acquiring viral hepatitis and it was felt that their genotypes would be more representative of 
the population at large than might be the case vvith the multiply transfused haemodialysis 
patients. Genotypes were compared with those in a consecutive series of 106 patients with 
chronic hepatitis C from other parts of the world attending the Institute of Liver Studies, who 
were typed concurrently before institution of any anti-viral therapy. For purposes of analysis, 
patients were grouped according to geographical origin as sho"n in Table 6.1. 
Table 6.1 Demographic details of subjects stuclied 
Age (yeats) Total 
Counhy of in 
Gwup Ofigin Number W C3MUP 
Range Nlechan 
I (Libya) Libya 25 14/11 24-65 43 25 
2 (Egypt) Egypt 32 26/6 38-64 50 32 
3 (Middle East) Bahrain 2 1/1 40/45 40/45 
Iran 1 1/0 30 30 
Jordan 3 1/2 15-49 47 
Saudi Arabia 2 2/0 51/71 51/71 
Oman 1 0/1 34 34 
Kuwait 3 1/2 51 -64 59 
UAE 5 4/1 31 -56 44 
Yemen 2 2/0 55155 55 19 
4 (U. K. ) England 25 17/8 30-66 42 
Scotland 2 2/0 30/34 30/34 27 
5 (Southern Europe) Italy 5 2/3 35-53 45 
Portugal 1 0/1 43 43 
Spain 2 1/1 29/51 29/51 8 
6 (Sub-Saharan Affica) Gambia 1 1/0 45 45 
Nigeria 2 2/0 49/52 49/52 
South Affica 1 0/1 61 61 
Senegal 1 1/0 39 39 5 
7 (Asia) India 4 1/3 36-61 45 
Pakistan 6 4/2 33-72 46 10 
8 (Caribbean Area) Guayana 1 0/1 43 43 
Jamaica 3 3/0 35-47 44 
Venezuela I1 1/0 1 61 1 61 5 
Totals 13 1_ 87/44 15-72 46 131 
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6.1.1 Biochemical and I-Estological Data 
Serum biochemical liver tests were performed in all 131 subjects. Serum aspartate (AST) 
and alw-dne (ALT) aminotransferase activities varied v6dely: from nonnal (in 31 subjects) to ten 
times the upper non-nal limit (Fig. 6.1). Marked elevations (> 2x upper nonnal limit) in serw-n 
bilirubin concentrations and/or alkaline phosphatase activities were seen in only six subjects. 
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N gum 6.1 Senun biochemical liver tests in the 131 subjects stuclied 
AST = aspartate aminotransferase; ALT = alanine aniinotransferase; 
Bil = bifirubin; ALP = alkalme phosphatase. Upper nonual firaits 
were: AST and ALT 50 IU/11 Bil 20 [tmol/l, and ALP 120 IU/I. 
Histological data from liver biopsies were available for all except the 15 Libyan control 
subjects (above). On the basis of the histological findings, patients were grouped according to 
whether they had inactive/mild or moderate/severe disease as described in Chapter 3 (Section 3.2.8). 
Within each histological group there was no correlation between seruin biochemical abnormalities 
and the presence or absence of cirrhosis, but patients with inactive/mild disease had abnon-nal serw-n 
ai-ninotransferase activities significantly less frequently than those with moderate/severe disease (19 
of 32 = 59.4% vs. 70 of 84 = 83.30/cý respectively; p=0.013). However, in patients with 
abnon-nal serw-n arninotransferases, there was no significant correlation with histological disease 
110 
activity as shoNNn for example for AST values in Table 6.2. FEstological assessment was therefore 
felt to be a more reliable index of necroinflammatory activity than serum biochemical liver test 
results and was used for all fi-irther analyses of the data. 
Table 6.2 Conpuison of semm aspattate an-inotransferase activities with histologically 
assessed disease activity. 
Abnonnal aspartate aminotransferase 
Histological activity 
Total No. Mean ± SD IIJ/1 p 
Inactive/mild 32 19 (59.4%) 132 ± 89 
Moderate/severe 84 70 (83.3%) 162 ± 83 
0.163 
* Liver biopsies were not perfonned in 15 Libyan control subjects (see text). 
Patients výith inactive/mild disease (with or vvithout cirrhosis) were significantly younger 
(median age 40 years, range 15 - 64 years) than those with moderate/severe activity with (median 
48, range 30 - 71 years; p=0.0022) or without (50,30 - 72 years; p=0.0025) cirrhosis. The age 
difference between patients with and without cirrhosis who had moderate/severe activity was not 
significant (p = 0.748). NIales tended to have moderate/severe disease more frequently (60 of 78 
= 76.9%) than females (24 of 38 = 63.2%) but this difference was not statistically significant 
0.182). 
In 75 cases (57.3%) no obvious risk factors for acquisition of hepatitis C virus infection 
could be identified and these were presumed to be instances of "conununity-acquired" or "sporadic" 
infection (Table 6.3). Of the remainder, presumed routes of infection were: via blood transfusion 
in 33 cases (25.20/o), intravenous drug use in 17 (13.00/o), and occupational exposure (in medical 
or paramedical workers) in six (4.6%). There was no correlation between histological severity of 
liver disease and the presumed route of acquistion of the virus (Table 6.3): moderate/severe disease 
on liver biopsy being fourid in 72.7%ý 70.6%, 66.7% and 73.3% of those in which acquisition was 
related to blood transfusion, intravenous drug use, occupational exposure, or "sporadic" infection, 
respectively. 
III 
Table 6.3 Distfibution of subjects acconfing to mode of acquisition of hepatitis C vi'm 
infection and histological sevefity of liver c5sease 
Numbeis of subjects vAth feature indicated 
Nlode of acquisition liver histology 
Group BT 1VDU OcCUP6 Unlinown Inactive/mild Am: 1ende/severe 
Libya 0 0 0 25 4* 6* 
Egypt 11 0 2 19 6 26 
Middle East 9 0 0 10 4 15 
U. K. 9 14 3 1 9 18 
Southern Europe 0 3 0 5 3 5 
Sub-Saharan Affica. 0 0 0 5 1 4 
Asia 4 0 1 5 3 7 
Caribbean Area 0 0 0 5 2 3 












Liver biopsies were perfonned on only 10 of the 25 Libyan subjects (see text). 
BT = Blood transfusion IVDU = Intravenous drug use Occup. = Occupational exposure 
6.1.2 Scmening for Hepatitis GB Vinis bdection in the Non-Libyan Subjects 
All of the 106 non-Libyan chronic HCV patients were screened for GB virus infection by 
PCR for circulating GBV-C RNA (Cbapter 3, Section 3.2.6). As reported in Cbapter 5, none of 
the 25 HCV-RNA positive Libyan subjects in this phase of the study had GBV infection. By 
contrast, overall 36 (33.9%) of the 106 non-Libyan chronic HCV patients were seropositive for 
GBV-C RNA (Table 6.4), výith 55% (15/27) in the U. K group infected. The latter was due mainly 
to the high proportion of IVDUs among the U. K- patients tested, 12 (85.7%) of the 14 of Mom 
were seropositive for GBV-C RNA. One of the two Italian IVDUs was also positive. The 
incidence was also high in the Sub-Saharan African (60%) and the Asian (50%) groups, but the 
nurnbers, were quite small. Twenty-five percent of the Egyptian patients were seropositive for 
GBV-C RNA, while arnong the Nliddle Eastern patients only four (21%) were positive: the two 
Saudi Arabians and two of the five from the United Arab Emirates. 
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Apart from the IVDUs, the majority (15) of the other GBV-positive individuals were 
apparently cases of sporadic infection. Blood transfusion could be implicated in only five cases 
and there was one case in which HCV and GBV seem to have been acquired as a consequence of 
occupational exposure. It is noteworthy that 29 (80.6%) of the 36 GBV-positive cases had 
histologically moderate/severe disease compared with 48 (68.5%) of the 70 GBV-negative 
non-Libyan patients, but this tendency towards more severe disease in the GBV-infected individuals 
was not statistically significant (p > 0.2). 
Table 6.4 Restdts of scmening for GBV-C RNA in sera fmm non-Libyan patients. 






tested Number Percent 
IVDUs positive 
Egypt Egypt 32 8 25% 
Middle East Bahrain 2 0 - - Iran 1 0 - - Jordan 3 0 - - Kuwait 3 0 - - Oman 1 0 - - Saudi Arabia 2 2 - UAE 5 2 40% - 
Yemen 2 0 - - 
U. K. England 25 13 52% 10/12 (83.31/o) 
Scotland 2 2 2/2 
Southern Europe Italy 5 1 20% 1/2(501/o) 
Portugal 1 0 - 
Spain 2 0 - 0/1(00/0) 
Sub-Saharan Affica, Gambia I I - 
Nigeria 2 2 - 
Senegal 1 0 - - 
South Africa 1 0 - - 
Asia ;n India 4 2 50% - 
Pakistan 6 3 50% 
Caribbean Area Guayana 1 0 - 
Jamaica 3 0 
Venezuela 1 0 
Totals T 106 36 33.9=1/o ý 13/17 (76.5%) 
* IVDUs - Intravenous drug users, number positive/number tested 
6.2 GENOTYMG BY RESTWCIION FRACMENT LENGTH lOLYNURPIUSM (161P) ANALysiLs 
As described in Cbapter 3, genotypes of the hepatitis C virus can be predicted from the 
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distinctive patterns of electropherotypes produced after digestion of RT-PCR products by different 
restriction enzymes. In the present study, RFLP analysis was perforined on the RT-PCR products 
from each of the 131 HCV-RNA positive subjects by examining the electropherotype patterns 
produced after digestion with the restriction enzyme combination Haelll-Rsal and comparing these 
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FIguw 6.2 Diagrxnmatic mpmsentation of the electmphomtic pattems ptoduced by (fiffemnt 
hepatitis C vitus genotypes after c1igestion of RT-PCR pmducts by the wstfiction 
enzyme combinations Haelff-Rud and Mval-IKnj7. For details see text. 
The expected patterns produced by the different HCV genotypes after digestion with 
these tNvo restriction enzyme combinations are sholAn diagrammatically in Fig. 6.2 and a typical 





Figum 6.3 A ty0cal gel showing pattems of bands obtained after digestion of heptatitis C 
vims RT-PCR pmducts with the mstfiction enzyme combinations HaelIP&al 
and Mvat-Di'njl. [ Lane 1,4,6, and 8: genotype 3; Lane 2: genotype 5; 
Lanes -3,7, and 9: genotype 1; Lane 5: genotype 4; 
































Figum 6.4 Dishibution of HCV genotypes 1 to 5 in the 131 subjects acconling to 
geographical atea. Each digit represents a single patient with the genotype 
indicated by the digit. 
The results of the RFLP analysis showed that the subjects from North Africa were almost 
exclusively infected with HCV genotype 4, which was found in 21 (84.0%) of the 25 Libyans 
and in 30 (93.8%) of the 32 Egyptians (Fig. 6.4). Of the four Libyans with other genotypes, two 
had type 3 and one each had types I and 2, while both of the two Egyptians wýithout type 4 had 
type 3. Type 4 was equally common amongst patients from the Middle East, being found in 16 
(84.2%) of the 19 subjects studied from this area - two of the remaining three having type 3 and 
one type 2. 
Genotype 4 appeared to be entirely restricted to North Africa and the NEddle East, since 
it was not identified in any subject from any of the other areas. Among the U. K patients, types 
I and 3 predominated - these two types being found respectively in 14 (51-91/o) and 11 (40.70/0) 
of the 27 cases studied. The two U. K- patients without these types were both from England and 
both had type 2. The Southern European cases represented a mixture of types 1,2 and 3, with 
two of the five Italians and one of the two Spanish patients having type 1, the third Italian and 
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the sole Portugese patient having type 2, and the remaining two Italians and the second Spanish 
Patient having type 3. All of the 10 patients from India and Pakistan were infected with 
genotype 3, while all of the five cases from Sub-Saharan Africa had type 5. Type 5 was also 
found in one patient (a Jamaican) from the Caribbean area. The two other Jamaicans in this 
group had type 1, as did the one patient from Guayana, while the one Venezualan was infected 
with type 2. 
Examination of the distribution of genotypes in those groups in which there were 
sufficient numbers for statistical analysis revealed no significant associations between genotypes 
and the presumed routes of infection in the Egyptian, Middle Eastern and Asian patients. Thus, 
among the 32 Egyptian patients, 18 (60.0%) of the 30 vith type 4 were cases of sporadic 
infection and 11 (36.7%) had a history of blood transfusion - the remaining cases being two with 
occupational exposure (one type 3 and one type 4) and one sporadic case with type 3 (Table 
6.5). Similarly, of the 16 Nliddle Eastem patients with type 4, eight each had a history of blood 
transfusion or were cases of sporadic infection - the remaining three cases comprising two with 
sporadic infection (one type 2 and one type 3) and one vvith genotype 3 -vNho had a history of 
blood transfusion. Of the 10 Asian patients (all type 3), four had a history of blood transfusion, 
five were sporadic cases and one had a history of occupational exposure. 
Table 6.5 Analysis of genotypes with respect to presumed mutes of infection 
Number with genotype inclicated 
Route of infection 1 2 3 4 5 Totals 
Blood transfusion 9 0 5 19 0 33 
Intravenous drug use 3 0 14 0 0 17 
Occupational 1 2 2 1 0 6 
Unknovm ("sporadic") 8 5 9 47 6 75 
Totals 21 7 30 67 6 131 
In contrast, in the U. K and Southern Europe, genotype 3 was confined to intravenous 
drug users (IVDUs). Of the 17 IVDUs from these areas, 11 (78.6%) of the 14 from the U. K- 
and all of the three from Southern Europe (two Italians and one Spanish) had genotype 3. The 
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remaining three IVDUs (one from England and the only two patients from Scotland) all had 
genotype 1. Genotype 3 was not found in any other patient from these areas. Of the 13 non- 
v lVDU patients from the U. K, nine vith a history of blood transfusion had type 1, one with 
occupational exposure had type I and two other such cases had type 2, and the one case of 
sporadic infection had type 1. The five non-IVDU Southern European patients were all cases 
of sporadic infection. Tbree had t)W I and two had type 2. 
Moderate/severe disease activity on liver biopsy was found least often in patients with 
genotype 2 and most frequently in those with type 5 (Table 6.6) but, perhaps because of the 
small numbers, this difference was not statistically significant (p = 0.677) and there were no 
significant differences (p > 0.1) in histological severity of disease between these and/or any of 
the other groups of patients infected výith the different genotypes. 
Table 6.6 ffistological activity in mlation to hepatitis C vinis genotype in the 116 patients 
in whom liver biopsies wete pedonned 
Flistological activity (nos. of patients) 
Genotype Number Inactive/mild Moderate/severe 
1 20 8(40.0%) 12 (60.01/o) 
2 7 3 (42.9%) 4(57.11/o) 
3 29 9(31.0%) 20 (69.0%) 
4 54 11 (20.4%) 43 (79.6%) 
5 6 1 (16.7%) 5 (83.31/o) 
Totals 116 32 (27.6%) 84 (72.4%) 
6.3 GENoTymG oF DBYAN HAEmoiALYsLs PATmvrs 
Among the six Libyan haernodialysis patients with HCV infections (Chapter 5, 
Section 5.2.3), the two females and one male (patients 1,2 and 6, Table 5.9) were found to have 
genotype 4. Of the remaining three patients (all male), patient 3 had type 3, patient 4 had 
type 2, and patient 5 had type 1. There were no apparent correlations between the infecting 




Aa 12 the hepatitis C virus has not yet been cultured in vitro it has not been possible to 
apply traditional methods for its classification, and progress in this area has had to rely on 
nucleotide sequence analysis. This has been achieved by a variety of methods, including 
restriction fragment length polymorphism (RFLP) analysis, type-specific oligonucleotide probing 
(TSP), and direct sequence analysis. From data obtained using these techniques, a standardized 
system of HCV nomenclature has recently been agreed upon that reflects the two-tiered sequence 
of variability (Simmonds et al. 1994a). All knoNNn variants of the virus have been classified 
into a total of six major genotypes (types I to 6), of which four (types I to 4) each contain a 
number of more closely related subtypes (e. g. a, b, C, etc. ). 
In the present study, genotyping was initially perfon-ned by RFLP analysis and the data 
obtained were used for comparing the HCV genotypes in the Libyan subjects with those in 
patients from other parts of the world. The main drawback of this technique is that there are 
few (if any) consistent differences in the S-noncoding region (5'UTR) sequences between 
subtypes within a single genotype (e. g. between types la and lb) and it has only very recently 
become possible to differentiate reliably between different subtypes by RFLP analysis (Davidson 
et al. 1995). Thus, comparisons could be made only between the major genotypes, without 
attempting to identify subtypes. 
The results clearly showed that genotype 4 predominates in Libya. This is in keeping 
with previous reports that type 4 is the major genotype in the neighbouring countries of Egypt 
and the Middle East in general (Simmonds, 1995), which was also confirmed in the present 
studies of patients from these areas. Of the present patients from the Asian sub-continent, on 
the other hand, all were found to have type 3. This high prevalence of type 3 in fl-iis area has 
also been described previously (Simmonds, 1995). The highest prevalence of type 3 so far 
reported outside of Asia has been among intravenous drug users (IVDUs) in Scotland 
(Simmonds, 1995). Unfortunately, only two Scottish patients were included in the present study 
and, although both were IVDU: s, they both had type 1. 
Interestingly, however, all of the patients from elselAhere in Europe vvho had type 3 were 
IVDUs. In particular, 11 (91.71/o) of the 12 English IVDUs had type 3. Clearly type 3 has 
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spread to the English IVDU population, but NNhether this is via IVDUs from Scotland or has 
been due to the increased travel to Asia (particularly India and Thailand) in recent years is 
unknown. 
Type 5 was previously reported to predominate in Southem Aftica 
(Simmonds, 1995; Ohno et al. 1994), and this has been confmned in the present study - "here 
all of the five patients from The Gambia, Nigeria, Senegal or South Africa had this genotype. 
The only other patient with type 5 in the present study was an Afro-Caribbean gentleman'"ho 
was an immigrant from Jamaica to the U. K- There has been very little direct travel between 
Affica, and the West Indies over the past 150 years and there are very few native (first 
generation) Afficans, in the Caribbean area. It is not known how long this gentleman had been 
in the UK or whether he might have inadvertently acquired his type 5 infection through contact 
with a native African in the UK, but he had no obvious risk factors for acquisition of HCV. 
However, the fmding that he has this genotype raises the intriguing question of whether type 5 
may have reached the Caribbean area during the transportation of African slaves more than 150 
years ago. 
Ihere was no apparent association between infection with any particular HCV genotype 
and co-infection with GB virus. The highest frequency of GBV infection was found in patients 
with HCV genotype 3 (16 of 30 = 53.31/o) but II of these were IVDUs. By comparison, five 
(23.8%) of the subjects with type I (including two IVDUs) and 12 (17.9%) of the 67 with type 
4 were GBV-C RNA seropositive, while none of the seven with type 2 and three of the six with 
type 5 had GBV infection. Thus, although the frequency in the type 3 subjects was 
significantly higher (p < 0.001) than in those with type 4, it seems likely that this was 
attributable to intravenous drug use rather than a particular propensity for type 3 to favour 
co-infection. A surprising finding, however, was that none of the 25 Libyan subjects was 
GBV-C RNA positive while 25% of the Egyptian patients apparently had GBV infection. The 
reasons for this large discrepancy in the prevalence of this virus between two neighbouring 
comtfies are mclear. 
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CIHLkPTER 7 
SUB-TWING OF HTATHTS C VIRUS GENOrYPES 
7.1 INMODUMON 




Sub-types of the hepatitis C virus genotypes were determined in all 131 HCV-infected 
subjects, partly to confirm the results of the RFLP genotyping (Chapter 6) and partly to determine 
whether there might be important differences between subjects with different sub-types. Intially, 
sub-typing was performed according to Okamoto et al [1992] but this method does not detect 
genotypes 3,4 and 5. The exercise was therefore repeated using type-specific primers (TSP). 
Details of these two methods are provided in Chapter 3 (Sections 3.2.4.2 and 3.2.4.3) but, briefly, 
they differ with respect to the sequences of the primers and stringency of the PCR conditions used. 
Sub-types were detern-fined from the electropherotype patterns shown diagrammatically in Figs. 
7.1 and 7.3 and the examples of electrophoresis gels shown in Figs. 7.2 and 7.4. Where there was 
more than one pattern of bands, these are defined here as "mixed types". When no bands were 





1 11 111 IV 
(1a) (lb) (2a) (2b) 
Figure 7.1 Diagrammatic representation of the electrophoretic patterns produced by 
hepatitis C virus genotypes I to IV using the method of Okamoto et al as 
described in the text. The corresponding types according to the Simmonds 
classification are shown in brackets. 
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Figum 7.2 Typical electmphomsis gels after ethiditun bmniide staining showing pattents of 
bands obtained when sub-typing the hepatitis C vhus by the method of Okamoto 
et al as desciibed in the text. [ Lane 1: genotype niixed[I(Ia)+II(Ib)+111(2a)]; 
Lane 2 and 7: genotype I(I a); Lane 3: genotype II(I b); Lane 4: genotype 111(2a); 
Lane 5: genotype IV(2b); Lane 6,8,9, and 10: undefined genotypes. 
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Figum 7.3 Diagranunatic mpmsentation of the electmphomtic patteins pmduced by diffemut 
hepatitis C virus sub-types by the type-specific primer (TSP) method as 
desciibed in the text. 
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Figure 7.4 Typical electmphoresis gels after ethiditun bmmide staining showing pattems of 
bands obtained when sub-typing the hepatitis C vinis by the type-specific pfimer 
(TSP) method as desctibed in the text. [Lane 1: genotype lb; Lane 2, and 8: 
genotype 4; Lane 3: genotype 5; Lane 4: genotype 2b; Lane 5: genotype I a; 
Lane 6, and 7: genotype 3a. ]; M=Marker I kb ladder. 
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8M1 
7.2 CowARLsaN oF GENoTypEs By DmmRENT NWams 
For those sub-types where it was possible to make direct comparisons, i. e. types la, lb, 
2a and 2b, there was good concordance between the Okamoto and TSP methods. Thus, 24 of 
26 subjects with these four sub-types were identified as such by both methods (shaded boxes in 
Table 7.1). The two anomalies were: one TSP t)W 2a which was defmed as a "mixed" type 
(I a+I b) by the Okamoto method, and one TSP type 2b which appeared to be type 2a in the 
Okamoto system. No coherent results were obtained by the okarnoto method for TSP types 
3ý 4 and 5. Of the 82 subjects identified by TSP as having these latter three types, one was 
defmed by the Okamoto method as type I a, three as type Ib and two as type 2a. Forty-five of 
the remainder gave mixed patterns and 31 were undefinable. 
Table 7.1 Con4urison of results of hepatitis C virus genotype sub-typing by the type- 
specific primer (TSII) and Okwmto methods 
Sub-typing by 
Otcamoto 
Sub-typing by TSP System Totals 
n-wthod la 
TIb 
2a 2b 3a 3b 4 5 1 b+2a+3 a Undefined 
by 
Okamoto 
Ia 15 - - I - - 16 
1b 5 2 1 1 9 
2a - 2 1 - 2 1 6 
2b 2 - - - 2 
Ia+Ib - 6 11 4 - - 22 
Ia+2a - 2 - I - - 1 4 
la+2b - 2 2 3 - 2 - 9 
Ib+2a I I - - 2 
2a+2b 2 5 - 2 9 
I a+ I b+2b I - - 1 6 
I b+2a+2b 3 - - 1 4 
Uncle ined 2 24 5 5 9 45 
Totals by TSP 15 5 3 3 13 18 46 5 9 131 
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In contrast, there was very good agreement between the results of TSP sub-typing and 
genotyping by RFLP analysis. The main discrepancy occurred in the type 4 patients Mere there 
was only 68.7% concordance, with nine RFLP type 4 subjects showing "mixed" (1a + 2a + 3a) 
electropherotype patterns by TSP and 12 giving patterns that were undefinable. Overall, 
however, concordant results were obtained in 108 (82%) of the 131 subjects (Table 7.2). In 
view of these findings, the results obtained with the TSP method were used for analysis of the 
relationship between sub-types of the virus and the various demographic and clinical features of 
the subj ects. 
Table 7.2 Con4urison of msults of hepatitis C vinis genotyong by RFLP analysis and by 
sub-typing with the type-specific ptimer (TSP) method 
Genotype 
b RFIP 
Sub-tyOng by TSP System Totals 
y 
analysis 
7q Ib 2a 2b 3a 3b 4 5 lb+2a+3a Undefmed 
by 
RELP 
1 15 6 - - - 21 
2 3 3 1 7 
3 - - 12 18 - - - 30 
4 46 - 9 12 67 
5 5 1 6 
Totals by TSP 15 6 3 3 12 18 46 5 9 14_j ! 131 
lbree of the nine mixed types were Egyptians and the remainder were Libyan cases. 
Of the 12 RFLP type 4 subjects NNho were undefined by TSP, seven were from the Mddle East 
and five were Egyptians (Table 7.3). A ftirther patient from the Middle East (Jordan), "ho was 
undefinable by TSP had type 2 by RFLP. 'I"he remaining undefinable case was the lone patient 
from South Africa who had type 5 by RFLP. It is noteworthy that all but two of the 23 cases 
that were either mdefmable or defted as "mixed" type by the TSP method had RFLP type 4. 
These represented 31.3% of the 67 RFLP type 4 cases. 
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Table 7.3 Geographical clistribution of hepatitis C vinis genotypes and sub-types 
Genotylvs and sub-tyM Total 
f 
Group la lb 2a 2b 3a 3b 4 5 Mixed Undefined 
or 
Group 
Libya 1 2 - 14 6 1 25 
Egypt - - 2 22 3 5 32 
Middle East - 2 - 10 - 7 19 
U. K. 12 2 1 6 5 - - - 27 
Southern Europe 1 2 1 1 - 3 8 
Sub-Saharan Affica - - - - - - 4 1 5 
Asia - - - - 2 8 - - 10 
bbean Area 2 1 1 - - - - 5 
Totals for type 15 16 3 13 12 18 46 5 9 14 131 
There were no striking associations between any one sub-type and presumed modes of 
infection (Table 7.4). In particular, of the 14 IVDUs with type 3, six had 3a and eight had 3b. 
Table 7.4 Analysis of hepatitis C vinis genotypes and sub-types with tespect to ptesumed 
mode of infection 
Sub-tyOng by TSP System Total 
f 
Group la lb 2a 2b 3a 
3b 4 5 Mixed Undefined 
or 
Gwup 
Blood transfusion 7 2 3 2 12 - 2 5 33 
Intravenous drug use 3 - 6 8 - - - - 17 
Occupational exposure I - I I - 2 1 - - - 6 
Unknown ("Sporadic") 4 4 2 2 3 6 
F33 5 7 9 75 
Totals for type 15 6 3 3 12 18 
1 46 5 9 14 1 
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Similarly, no significant associations were found between sub-types and severity of liver 
disease in the 116 patients in Ahom liver biopsies were performed (Table 7-5). For example, 
inactive/mild disease was found most frequently in patients vvith type 2a (2 of 3= 67-71/o) and least 
frequently in those -Aith type 4 (6 of 37 = 16.2%) but this difference was not statistically significant 
(p = 0.177). This may have been due to the small numbers but even Men groups with larger 
ntunbers were compared there were still no significant differences, e. g. type la vs. type 4 (6 of 15 
vvith inactive/mild disease = 40.01/% vs. 6 of 37 = 16.2%, p=0.139). 
Table 7.5 Analysis of hepatitis C vinis genotypes and sub-types with Wspect to histologically 
assessed disease activity in the 116 subjects in whom liver biopsies wew peffonned 
Ili l i l 
Sub-tyong by TSP System TOW 
f sto og ca 
Activity 
la lb 2a 2b 3a 3b 4 5 Nfixed Undefined 
or 
Gwup 
inactive/n-fild 6 2 2 - 4 5 6 - 3 4 32 
Mod rate/severe 9 3 1 3 7 13 31 5 3 9 84 
ToWs for ty[w 15 5 3 3 11 18 37 1 5 6 13 116 
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7.3 DmussioN 
The reliability of PCR-based genotyping techniques depends heavily on the specificity 
of the primers employed and the stringency of the PCR conditions. It is well established that 
the matching of two or three nucleotides at the 3' end is an important parameter for specific 
priming. Therefore, the fewer the number of HCV isolates employed in designing a specific 
primer, the lower will be the specificity of the primers designed. The typing system devised 
by (Okamoto et al. 1992b) has been considered to be the most appropriate system in Japan and 
has also been used in several centres around the world. However, it is based on primers 
corresponding to sequences of HCV isolates derived from individuals infected with genotypes 
la, lb, 2a, or 2b (Okamoto et al. 1992b). Thus, the Okamoto system is unlikely to identify 
genotypes from countries Ahere HCV types other than types I or 2 are prevalent. Indeed, (Lau 
et al. 1995) have recently reported that the Okamoto system yields a high nw-nber of "mixed" 
types WMch they found to be either non-specific assignments of type lb or types other than 
I or 2. The new TSP system used here is based on nucleotide sequences derived from all of the 
representative genotypes so far reported and therefore has the capability to identify a much wider 
range of genotypes. The findings confirm those of (Wan and Mathews, 1994), but on a much 
larger scale, with 45 (91.81/o) of the 49 subjects 1Aho were assigned as having "mixed" types by 
the Okamoto system being found to be neither type I or 2 NNhen typed by the TSP system. 
Nonetheless, experience has shown that there are always some serum samples where 
genotype cannot be determined whatever system is used (Davis et al. 1994). This is illustrated 
in the present study Mere, of the 45 subjects in Mom the genotype could not be defmed by the 
Okamoto system, nine (20%) were also undefinable even by the TSP method. There are several 
possible reasons for this. Firstly, initial diagnosis of HCV infection relies on seropositivity for 
anti-HCV antibodies and, in some anti-HCV positive sera, the level of HCV-RNA may be too 
low for detection. But this is unlikely in the present study, because all of the typed samples had 
previously been tested positive for HCV-RNA by the nested PCR reaction. Secondly, although 
the primers for genotyping in the present study were designed from relatively well conserved 
regions within the core region of each genotype, minor variations between strains within a 
genotype may still render PCR unsuccessful within the stringency defmed for the TSP method. 
Third, a deletion in the HCV genome might result in amplification of DNA bands of different 
lengths that do not allow proper genotype assignment. Indeed, during the present study one 
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patient (, "ho was not part of this study) was encountered who was classified as "indetertninate" 
by the Okamoto method but who could be assigned as type lb by TSP typing. Nucleotide 
sequencing (see Chapter 8) of the core gene from the HCV isolate from this patient revealed a 
deletion of 117 bp, resulting in a PCR product that was too small for proper genotyping. This 
might have been due to defective interfering particles but, if this is a new variant, from the 
available literature it would seem to be uncommon. 
Finally, these "hard-to-type" isolates n-fight represent new genotypes that have not yet 
been identified. To explore this possibility ftuther, PCR products from all of the HCV-RNA 
positive Libyan patients and all of the other patients classified as having "mixed" or "undefineff' 
types were sequenced. The findings are reported in the next Chapter. 
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CHAPTER 8 
SEQUENCING AND PHYLOGENEDC ANALYSILS OF 
IIEPATITLS C AND GB VIRUS ISOILAM 
8.1 INTRODUCIJON 
8.2 SEQUENCE ANALYSILS OF THE HCV 5UTR REGtON 
8.3 SEQUENCE ANALYSIS OF TBE HCV CORE REGION 
8.4 SEQUENCE ANALYSIS OF TBE HCV NS5 REGION 




IL &a As noted in Chapter 7, accurate genotyping and sub-typing of all HCV isolates could 
not be achieved by RFLP analysis or the TSP method, and a number of HCV isolates from 
the various groups of subjects studied gave electrophoretic patterns that could not be assigned 
to a particular genotype and had to be classified as "mixed" or "undefmed" (Table 7.3). 
Direct sequence analysis of the TUTR and core regions of HCV genomic material in isolates 
from the various groups of subjects was therefore undertaken as described in Chapter 3 
(Section 3.2.5). This was applied to all of the 25 HCV-RNA positive Libyan control subjects 
and chronic liver disease patients (Table 7.3) and the six Libyan haernodialysis patients with 
HCV (Cbapter 6, Section 6.3). Of these 31 subjects, two had been assigned as genotype I by 
RFLP ± TSP genotyping analysis, two others as type 2, three as genotype 3, and 17 as 
genotype 4, while six of the remaining seven were classified as "rnixed" and one as "unde- 
fmed" genotypes. In addition, isolates from all of the 16 non-Libyan patients who had been 
classified as having either "mixed" or "undefined" genotypes (Table 7.3) were also 
sequenced. 
8.2 SEQUENCE ANALYSIS OF THE HCV 51TIR REGION 
The nucleotide sequences of the PCR products from the 31 Libyan subjects are 
shown in Table. 8.2. In the 17 cases who had been assigned to genotype 4 (Table 7.3 and 
Section 6.3), the sequences were found to be identical and showed 100 % homology with 
several sequences in GenBank and EMBL(Table 8.1) that have been assigned to genotype 4. 
Further evaluation of the relationship between these isolates and isolates reported to 
GenBank was undertaken by constructing a phylogenetic tree (Fig. 8.1), which shows that 
they all cluster around genotype 4. By comparing the sequences of these isolates with 
those of previously identified sub-types, it was found that the 17 cases could be ftuther 
subdivided into five sub-types: 4a, 4b, 4c, 4d, and 4e. 
Of the two Libyan subjects Aho had been initially assigned as having genotype 1, the 
one who had been assigned to type lb by TSP typing (Table 7.3) was found to cluster with 
type 4, and the other showed 97% homology with the published sequence for type Ia. The 
two who had been assigned to types 2 (one previously classified as type 2b, Table 7.3) and 
the three who had been assigned to type 3 showed 99% homology with published sequences 
for types 2a and 3a, respectively. These findings were confirmed by neighbour-joining 
phylogenetic tree (grow-tree) analysis, in which more than 95% of the bootstrap replicates 
supported the separation of types 2 and 3 from any of the other sequences. 
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Finally, the seven Libyan subjects and 14 of the 16 non-Libyan patients who had 
been initially assigned as having "n-fixed" or "undefmed" types were found to cluster with 
genotype 4. Of the remah-ling two non-Libyans, one clustered vith type 2 and the other vvith 
type 5. 
To detennine the extent of sequence variability vithin the SUTR of the HCV 
genome, the above data from the 31 Libyan subjects were combined with that of 20 
sequences reported in the literature and a multiple sequence alignment on all 5'UTR 
sequences was performed. From the resulting consensus sequence, the total nucleotide 
variation (defmed as the total number of nucleotides differing from the consensus sequence) 
was fourid to be only 2%. Single and double nucleotide insertions are not uncommon, but 
sequences of HCV genotypes I to 3 were found to be entirely collinear. However, it is 
noteworthy that, in all of the genot3W 4 sequences from the Libyan subjects, there were 
single base insertions between positions -139 and -138. In addition, there was a nucleotide 
variation at position -2 in six, but the nucleotide sequence at position +8 to -65 was 
invariant among all isolates. In view of the fact that the primary sequence around the AUG 
initiation codon of a gene is important for initiation of translation(Tsukiyama Kohara et al. 
1992), and is a particularly well conserved region, it is also interesting to note that the 
polyprotein start codon in all of the 31 Libyan isolates occurs at the same location compared 
with the prototype sequence. 
8.3 SEQUENCE ANALYSILS OF THE HCV CORE REGION 
To clarify the relationship between different HCV Isolates, the nucleotide 
sequences of the core region were aligned to maximum homology (Table. 8.3). The 
numbers of nucleotide substitutions per site at all codon positions were estimated using 
the 6-parameter method of Saitou and Nei, (1987). Based on these numbers of 
nucleotide substitutions, a phylogenetic tree was constructed by the neighbour-joining 
method (Fig. 8.2). The fmdings completely confirmed those obtained by sequence 
analysis of the SUTR region reported above. 
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8.4 SEQUENCE ANALYSIS OF THE HCV NS5 REGION 
Further evaluation of the phylogenetic relationships between the various 
genotypes and subtypes was undertaken by sequencing 339 bp fragments of the NS5 region 
of the HCV genome between nucleotides 7975 and 8313 (Chapter 3, Section 3.2-7) of a 
limited number of isolates (Table. 8.1). These comprised 14 of the Libyan subjects NNfio had 
been assigned to genotype 4 and seven non-Libyan patients: two U-K (both genotype 2), two 
Pakistan (both genotype 3), and three genotype 5 patients (one each from The Gambia, 
Nigeria and the Caribbean). 
By this analysis, 12 of the 14 Libyan type 4 subjects were fourid to cluster with 
genotype 4 (Figs. 8.3 and 8.4), and it was possible to subdivide these into six subtypes (4a to 
40. The remaining two (LIB-30 and LIB-29), both of výhom were haemodialysis patients, 
both clustered vvith type lb. Among the non-Libyan patients, the two UK cases clustered 
v6th type 2a and the two Pakistanis with type 2b. The three t: ype 5 cases from Africa and 
the Caribbean were all confkmed as having type 5a. 
The additional sequence variation within the NS5 region allows for classifica- 
tion of six types (I - 6) and 21 distinct subtypes by phylogenetic analysis. However this 
method is computationally intensive, so simple pair-wise comparisons (which achieves the 
same results) were made. This showed a wide range of evolutionary distances among the 
HCV variants tested. Using the DNADIST program from the PHYLIP package (Chapter 3, 
Section 3.2.7), which directly provides estimates of these molecular evolutionary distances, 
and based on 1275 pair-wise comparisons, gaps were found between the ranges of evolution- 
ary distances. The gaps ranged from 0.0136 to 1.062 (mean: 0.0599 ± SID 0.0147) within 
subtypes, 0.1256 to 0.3211(0.2233 ± 0.0149) between different subtypes, and from 0.3662 to 
0.8719 (0.6190± SD 0.0124) between different types. The sequence sin-filarity between 
different types is 56-720/cý between different subtypes is 74-86% and within subtypes is more 
than 88%. Recently Tokita et al. (1994) reported the identification of three other major 
genotypes (types 7,8 and 9) on the basis of sequence analysis of the NS5 region of isolates 
from Vietnamese blood donors but, as can be seen from Fig. 8.4, in the present analysis 
these were found to cluster with the Hong Kong isolate (HK-2) as new subtypes: 6a to 6e. 
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8.5 SEQUENCE ANALYSIS OF GB vIRUS 
GBV isolates from all of the 40 GBV-C RNA positive sera from the four Libyan 
haemodialysis patients (Cbapter 5, Section 5.4) and the 36 non-Libyan chronic HCV patients, 
(Cbapter 6, Section 6.1.2) were sequenced as described in Chapter 3, Section 3.2.6. 
Nucleotide sequences of the putative RNA helicase domain were maximally aligned together 
vvith HCV types I (HCV-1), 2 (HC-J6) and 3 (NZLI). Using the ODEN version 1.1.1 
progran-4 the number of amino acid substitutions per site between all possible pairs of these 
isolates was estimated according to Kitnura! s formula: d= -1n(J-p- 0.2PI), NAfiere p is the 
fraction of different an-fino acids (Gojobori et al. 1990; Kimura, 1983). From these values, 
a phylogenetic tree was constructed by the unweight pair-group (UPGMA) method v6th 
arithmetic mean(Nei, 1975), and the neighbour-joining method Saitou and Nei, (1987). 
PHYLIP version 3.5c was used to elucidate evolutionary distance, the genetic distances 
between pairs were estimated using the PROTDIDT program with DAYOFF PAM matrix 
and the phylogenetic tree was constructed using the NEIGIIBOUR and DRAWIREE 
programs. The nucleotide sequences from these patients conformed to published sequences 
for GBV (Table 8.4), confmi-fing the PCR results. As shoNNU in Fig. 8.5, the phylogenetic 
analysis of these sequences clearly demonstrates the diversion of GBV from HCV. 
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8.6 DESCUSSION 
Being an RNA virus, HCV is capable of rapid evolution. It has been estimated that 
its mutation rate is of the order of 1.44-1.92 x 10' base substitutions per site per year 
(Okamoto et al. 1992a; Ogata et al. 1991). Consequently, many variants of the virus have 
been discovered that can be classified into distinct genetic groups. To date, at least four 
genotyping systems have been proposed. In one system, HCV isolates have been classified 
into genotypes 1, H, 111, IV and V based on comparisons of full-length genomic sequences, 
with intra-genotypic divergence of < 9.2% and inter-genotypic divergence of > 19.9% 
(Sakamoto et al. 1994). In another scheme, based on phylogenetic analysis of part of the 
NS5 region, six major types (1,2,3,4,5 and 6) are recognized, along with a series of 
subtypes designated a, b, c, etc. (Simmonds et al. 1993a; Stuyver et al. 1993). A third 
classification system proposes at least 12 genotypes through phylogenetic analysis of a 
sequence of 192 amino acids encoded by the El gene (Bukh et al. 1993b). The fourth 
scheme, based on phylogenetic comparisons of the entire El sequence of 576 bp and an NS5b 
sequence of 1093 bp, identifies at least nine major groups of HCV, which break down into 
23 genotypes (Tokita et al. 1994). Whether classification into such large nurnbers, of variants 
has virological, clinical or epidemiological significance is not yet clear (for finiher discussion 
please see Cbapter 9). 
The data from the present sequence analysis of the 5'UTR and core regions of the 
HCV genome were entirely confmnatory, and concordance vvith the genotypic assignations 
by these methods was found in 17(81%) of the 21 isolates subjected to NS5 analysis. The 
sequence analyses also confm-n the data described in Cbapters 6 and 7 indicating that type 4 
seems to be the predominant genotype in Libya. Among the 25 HC`V-RNA positive Libyan 
subjects in the control and chronic liver disease groups, 22 (881/o) had this genotype. Since 
few of these subjects had travelled outside their country, it is very likely that the majority of 
these infections were acquired in Libya. By contrast, only three (50%) of the 6 
haernodialysis patients v6th HCV infection were found to have type 4. Infections lAith the 
other genotypes in this group of patients may have been acquired through transfusions with 
imported blood. Among the 16 non-Libyan patients 1Aho had been initially classified as 
having "mixed" or "undefined & genotypes, 15 were from Egypt or the Middle East (Table 
7.3) and all but one of these were found by sequence analysis to have type 4. Thus the 
present findings are keeping with, and add to, the literature (see Chapter 1, Section 1.4.3) on 
the prevalence of type 4 in North Affica and the Middle East. Although the majority of the 
genotype 4 cases appeared to have subtypes 4a or 4b, as reported by (Simmonds et al. 
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1993b) for isolates from Africa and the Middle East, it is clear that there are several other 
subtypes of genotype 4. 
Genotype 5 has been previously reported in Central and South Africa (Cha et al. 
1992; Bukh et al. 1993b; Simmonds et al. 1993a; Ohno et al. 1994) and preliminary data 
from our laboratories indicate that it is also present in East Africa (Saleh et al. 1994a), but it 
is believed that this is the first documentation of type 5 in West Africa and the Caribbean. 
Unlike type 4, relatively little sequence heterogeneity has been found within genotype 5. All 
isolates that have been analysed so far indicate that there may be only a single subtype (5a) 
and that infectionwith this variant is highly restricted to these areas. This apparent sequence 
homogeneity between type 5 isolates has been confinned in the present study. 
The present study afforded the opportunity to undertake phylogenetic analyses of 
other published sequences and, particularly, to make comparisons between the new genotypes 
(7,8 and 9) proposed by Tokita et al. (1994) (above), by construction of phylogenetic trees 
based on both the 339 bp and the partial (222 bp) sequences of Simmonds and colleagues 
(Simmonds et al. 1993a). From Fig. 8.5, it is clear that all of the proposed new genotypes 
cluster with genotype 6 and probably represent new subtypes (6a to 6d) of genotype 6, rather 
than distinct new genotypes. It is believed, therefore, that the proposed new genotypes may 
represent misclassifications. 
Finally, from the detailed sequence analyses and phylogenetic trees recently reported 
for the helicase and RNA-dependent RNA polyrnerase regions of GBVs A and B by 
Muerhoff et al. (1995), and for GBV-C by Simons et al. (1995b), the predicted amino acid 
sequence homologies between HCV and GBV range between 20% and 30%. It is thought 
that viral proteins containing NTP-binding motifs may be subunits of RNA helicases involved 
in the unwinding of double-stranded replication forms during RNA replication and in 
recombination between RNA genomes (Hodgman, 1988; Gorbalenya and Koonin, 1989; 
Wassannan and Steitz, 1991). It is interesting to speculate that these two viruses may have 
originated through a common ancestor. 
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Table 8.1 Designation and accession Number of HCV sequences used in the shxIy 
Abbreviation Accession nwhber Abbreviation Accession nwnber 
HCVI D00831 VN085 D17471 
GMI M61720 VN235 D14202 
GM2 M61721 VN405 D17472 
HCV-J D00574 VN506 D17473 
HC-J6 D00944 VN541 D17474 
HCV-BK M58335 VN569 D17476 
LIB-1 D31726 VN571 D17477 
Paki-I D16720 VN606 D17478 
Paki-2 D16721 VN655 D17479 
Q19 D16811 VN689 D17480 
Q14 D16813 VN693 D17481 
SA-K3 D16789 VN710 D17482 
SA-K14 D16792 VN711 D17483 
E-bl D10123 VN746 D17484 
T3 L16648 VN753 D17485 
Sal L16642 DK13 M84832 
SO L16645 EG-13 L08140 
HK-10 L16659 Z4 M84848 
P8 M84856 Z6 M84862 
HK2 L16634 VN004 D17470 
Z8 M84829 SA156 L23471 
4TY4 L23447 2TY4 L23446 
AGR6 L23457 AGR8 L23458 
NZLI D14305 USAGC54 L23453 
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FIgum 8.1 Growtme analysis of FUTR sequences of HCV fmm 11byan (LIB-n) com- 
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Figum 8.2 Phylogenetic twe was constnxted by the neighbour-joining mediod 
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Figum 8.3 Phylogenetic twe of the nucleotide sequences in HCV NS5-mgion for the Libyan 
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FIgum 8.5 Phylogenetic twe of GBV-C/HGV. 
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9.1 VRIAL I-IFPATTIIS IN URYA 
It seems clear from this study that the background prevalence of two of the viruses capable of 
causing chronic hepatitis, i. e. HBV and HCV, in the Libyan population must be high. The socioeconomic 
implications of this are significant. Unfortunately, economic strictures to date have dictated that 
screening for hepatitis viral infections is limited to testing for HBsAg and only by a relatively insensitive 
test (Wellcotest). In the present study, some 13.2% of the "healthy" blood donors studied had evidence 
of current infection with either HBV or HCV. Therefore, until more rigorous and comprehensive 
screening procedures are introduced, 11BV and HCV infections will continue to be spread in Libya 
through blood transfusions. Additionally, particularly against this economic background, accurate 
diagnosis in infected individuals would seem essential. Interferon therapy, although so far somewhat 
disappointing in chronic HCV infection, is effective in many cases of chronic hepatitis B (Di Bisceglie 
et al. 1990), and targeting of this expensive treatment to those individuals most likely to benefit seems 
sensible. In this regard, it is worth noting that 25 % of the Libyan patients who were considered to be 
cases of non-A, non-B hepatitis were in fact HBsAg seropositive on re-testing (Chapter 5, Section 5.3.2). 
Interestingly, the two other viruses known to be capable of causing chronic hepatitis, HDV and 
GBV, appear to be very rare in Libya. As noted in Chapters I and 5, intravenous drug use is a major 
risk factor for acquisition of these viruses, and their relative absence in Libya might be related to the low 
incidence of intravenous drug use in that country. It is unlikely, however, that this alone can account 
for the low frequency of detection in this population of GB virus, which is reportedly quite widespread 
in Egypt and elsewhere in Africa (Zuckerman, 1995). 
The finding of a high frequency of exposure to HBV in this population is not surprising, given 
that this virus is endemic in North Africa. However, the prevalence and nature of HCV infection in 
Libya has not been investigated previously and the present study has therefore concentrated on hepatitis 
C virus infection. 
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9.2 TRANSMISSION OF TIFIE ]HEPATITIS C VIRUS 
All of the Libyan subjects vvith HCV seem to have been cases of "sporadic" infection (Chapter 
5). How such infections are acquired remains a mystery. There is no evidence that the virus is capable 
of infection other than by the parenteral route. Inapparent transn-fission through close contact between 
individuals with open sores or abrasions, particularly in children during play, is one possibility. 
However,, none of the 49 subjects under the age of 20 years in the present study had evidence of 
exposure to HCV. As noted in Chapter I (Section 1.4.2), data on sexual and maternal/foetal transmission 
are conflicting but, overall, transmission via these routes appears to be low. Nonetheless, there does 
seem to be an increased incidence of exposure to the virus in households with an infected individual. 
In contrast to other flaviviruses (such as those causing yellow fever and dengue fever) that are spread 
by mosquitoes or sand flies, few epidemics of hepatitis C have been reported. If transn-fission involves 
an arthropod vector, therefore, this is unlikely to be a flying insect. The possibility that IJCV infection 
tnight be spread by a crawling insect such as a bedbug or house mite needs to be investigated. 
One possible explanation for the present findings relates to the practice of men attending barber 
shops each day to be shaved, which is widespread (almost ritualistic) in Libya. Indeed, in a recent letter 
to Lancet, (Tumminelli et al. 1995) have reported that 38% of Sicilian barbers'who shaved themselves 
regularly vvith the same non-disposable and unsterilised blades used on customers had circulating anti- 
HCV antibodies, compared with none of the 50 age- and sex-matched control subjects studied. This 
would not, however, explain the high frequency of HCV infection among the fernale Libyan subjects. 
9.3 GENOMIC VARIATION OF 11HE BEPATfIlS C VIRUS 
Sequence variation within the HCV genome undoubtedly affects screening for infection by 
detection of anti-HCV antibodies, because it leads to variability in the protein products of the virus and 
therefore in the host immune response and the specificity of the antibodies produced. The C100-3 
protein on which the first generation anti-HCV test was based was derived from HCV type I and 
identified about 90% of individuals infected with this genotype, but only one third of those with types 
2 or 3(McOrnish et al. 1993). Later generation assays incorporating peptides from the core region (c22) 
are much less prone to such false-negativity, presumably reflecting the greater degree of conservation 
in this region of the genome (Simmonds et al. 1994b). Certainly, in the present study this seems to have 
been the case, for the UBI assay used detected anti-HCV antibodies in all but three subjects with 
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circulating HCV-RNA regardless of the genotype with which they were infected. 
The present fmding that genotype 4 predominates in Libya and that, by the combination of TSP 
typing, sequencing and phylogenetic analysis, up to six distinct subtypes may exist in that country, is 
in keeping with the reported distribution of this genotype in this geographical area. However, Simmonds, 
(Simmonds, 1994; Simmonds, 1995) emphasises the extreme difficulties in assigning geographical 
distributions to the various genotypes and subtypes at the present time. On the one hand, increased 
tourist travel, general mobility of populations, and interchange of blood products for therapeutic purposes 
between countries during the past three decades has meant that genotypes that may have been restricted 
to one area are now found in quite disparate countries. For example, 40% of blood donors in Scotland 
are reportedly (Simmonds, 1994) infected with type 3 possibly via intravenous drug users following the 
"hippie" trail through South-East Asia. On the other hand there is considerable heterogeneity between 
subtypes of certain genotypes. To quote Simmonds, (1995): "although genotypes in the Middle East and 
Central Affica can be assigned as genotype 4 on the basis of sequence comparisons in the core, El and 
NS-5 regions, it is apparent that this genotype actually comprises a bewildering number of subtypes ..... 
type 4a is the most frequently found genotype in Egypt and elsewhere in the Middle East, [but] we have 
detected at least three other subtypes of type 4 in this region alone [and] El sequences from six infected 
individuals in Zaire yielded four subtypes, none of which correspond to those in the Nliddle East nor to 
many of those found in Gabon". These problems present difficulties for phylogenetic analysis to study 
the evolution of the virus. 
9.4 CIJNICAL SIGNIRCANCE OF GFNOMIC VARIAUON OFTHE IlEPATrIlS C VIRUS 
Although there is increasing evidence that the clinical profile, severity of liver disease, and 
response to anti-viral therapy may depend on the particular genotype or subtype with which the patient 
is infected (Mita et al. 1994; Dusheiko et al. 1994; Mahaney et al. 1994; Davidson et al. 1995), the 
clinical utility of determining the genotypes and subtypes of HCV in infected individuals is currently the 
subject of much debate. The available data are somewhat conflicting, and it is often difficult to compare 
results of the different studies because of major differences in their design and technical execution. One 
early report suggested that there was no significant difference in severity of liver disease between 
individuals infected with genotype I or type 2 (Takada et al. 1992). A slightly later study indicated that 
patients with type 3 had a higher rate of liver ftmction abnormalities than those with either type I or type 
2 (McCt-fish et al. 1993), while a very recent study from Italy found that asymptomatic carriers of 
genotype I had abnormal biochemical liver tests significantly more frequently than those with type 2, 
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although the incidence of histologically proven chronic hepatitis did not differ between these two groups 
(Prati et al. 1996). Several studies in Japan have suggested that infections v6th genotype 1, and 
particular subtype lb, are less susceptible to treatment vvith interferon (Pozzato et al. 1991; Takada et 
al. 1992; Kanai et al. 1992; Yoshioka et al. 1992). 
This tendency for type I patients to have more severe disease and a poorer response to anti-viral 
therapy was confirmed in a later study of 80 patients from different countries who were variously 
infected with types I to 4, but it was noted that severe disease could be found in association with all four 
types (Dusheiko et al. 1994). A study in the USA found that patients infected with type 2 had 
histologically more severe disease, but lower levels of circulating HCV-RNA and a better response to 
interferon, than those with types I or 3 (Mahaney et al. 1994). On the other hand, a more recent study 
from France (Martinot Peignoux et al. 1995), which confirmed the tendency for patients with type lb 
and/or high levels of viraemia to have a poor response to interferon, found that older age, infection via 
blood transfusion (possibly reflecting a higher viral load in the infecting inocultun), and longer duration 
of infection, were also significantly associated with a poor response. Another recent study, in French 
and Italian patients (Nousbaum et al. 1995), also confirmed that type lb, older age and longer duration 
of disease are associated with a significantly poorer response to treatment, but found no difference in 
levels of viraemia between patients with different genotypes. That study also suggested that the 
prevalence of type lb in French and Italian patients seemed to be decreasing, being found less frequently 
in younger patients (Nousbaum et al. 1995). This has implications for the study of the evolution of the 
virus. However, it is difficult to make such extrapolations from studies conducted at only me time 
point, which give only a cross-sectional "snapshot" of a particular population. An alternative explanation 
for the apparent decrease in type lb, suggested by Sallie (Sallie, 1995), is that the infecting genotype is 
related to the mode of acquisition which, in turn, may be age-related. In support of this, he Points to 
the study of Mdhaney et al. (1994) which showed no difference in frequency of different genotypes or 
subtypes between infected intravenous drug users but a seven-fold higher frequency of type lb among 
patients who had acquired their infections via blood transfusion. 
Overall, it is probably true to say that there is not yet sufficient evidence to draw defmitive 
conclusions about the influence of genotype on severity of disease and outcome. However, the present 
findings that there were no correlations between histological severity of disease and the infecting 
genotypes would suggest that the influence of the different genotypes on disease severity may be quite 
marginal and that other factors may be more important in determining outcome. What these factors may 
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be is Currently unknown. The suggestion that the mode of acquisition of the infection may be important 
(Gordon et al. 1993) is not borne out by the present finding that there was no correlation between disease 
severity and the presw-ned route of infection - which is in agreement with a very recent report by 
Chiaramonte et al. (1996). 
9.5 FU URE STUDIES 
Undoubtedly the present findings point to the need for a full epidemiological survey of, 
particularly, HCV and GBV infection in Libya. Prevention of transmission via blood transftisions, and 
accurate diagnosis in patients'"ith suspected viral hepatitis, through proper screening would seem to be 
of paramount importance - althoughAbether this will be possible in the present economic climate in that 
country is uncertain. Ultimately, the aim must be to introduce a mass vaccination program but the 
variability of the HCV genome is presenting problems for the development of effective vaccines and not 
enough is yet known about GBV to say whether it might be possible to produce a vaccine against this 
virus. Thus, the realisation of this aiiin would seem to be still a long way off. Nonetheless, attempts 
to reduce "sporadic" transmission at relatively little cost might be made if the mode of these infections 
can be identified. In this context, it would be useful to attempt to investigate whether there is cross- 
infection in barber shops, and to undertake a full entomological study of the possibility of transmission 
by household arthropods. 
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